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 ABSTRACT 
 
Follicular cell derived thyroid carcinoma comprise a heterogeneous 
group of cancers with different clinical and morphological characteristics. 
Anaplastic thyroid carcinomas (ATC) represent less than 5% of all thyroid 
cancers but are responsible for more than 50% of thyroid cancer mortality, with 
a mean survival time from diagnosis of ∼3–6 months. ATC is characterized by 
local invasion, distant metastasis, chemo and radio-resistance. We showed that 
~ 50% of ATCs up-regulated Twist1 with respect to normal thyroids as well as 
to poorly and well-differentiated thyroid carcinomas. Twist1 is a highly 
conserved basic helix-loop-helix transcription factor that plays an important 
role in the development and progression of human cancer. Knockdown of 
Twist1 by RNA interference in ATC cells reduced cell migration and invasion 
and increased sensitivity to apoptosis. The ectopic expression of Twist1 in 
papillary thyroid carcinoma cells (TPC) induced resistance to apoptosis and 
increased cell migration and invasion.  
In this dissertation, we have investigated the molecular mechanisms by 
which Twist1 exerts its biological effect in thyroid cancer cells. To this aim, 
we analyzed gene expression profiles of thyroid cancer cells ectopically 
expressing Twist1 in comparison to vector control cells. According to gene 
expression profile, the top functions enriched in TPC-Twist1 cells were: 
cellular movement, cellular growth and proliferation, cell death and survival. 
Silencing of the top ten up-regulated genes reduced viability of TPC-Twist1 
and CAL62 cells. Silencing of COL1A1, KRT7, PDZK1 induced also cell 
death. Silencing of HS6ST2, THRB, ID4, RHOB, and PDZK1IP, also impaired 
migration and invasion of TPC-Twist1 cells. Chromatin immunoprecipitation 
showed that Twist1 directly binds the promoter of the ten up-regulated genes. 
q-RT-PCR on thyroid cancer samples showed that HS6ST2, COL1A1, F2RL1, 
LEPREL1, PDZK1 and PDZK1IP1 are over-expressed in thyroid carcinoma 
samples compared to normal thyroids.  
More recently we have conducted a miRNome expression profile of 
TPC-Twist1 cells in comparison to control. We identified a set of miRNA 
potentially regulated by Twist1. We then focused on miR-584 up-regulated by 
Twist1 in TPC cells. We showed that miR-584 is up-regulated in ATCs respect 
to normal thyroids and papillary thyroid carcinomas. The ectopic expression of 
miR-584 protected TPC cells from apoptosis induced by Doxorubicin and 
Staurosporine. Finally, we showed that miR-584 targets TUSC2 (tumor 
suppressor candidate 2).  
Thus, we have identified a set of mRNA and miRNA that mediates 
Twist1 biological effects in thyroid cancer cells. Transcription factors as 
Twist1 are generally believed to be difficult to target due to nuclear 
localization and lack of a specific groove for tight binding of a small molecule 
inhibitor. Thus, downstream targets of Twist1 could be more realistic for 
therapeutic intervention. 
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1. BACKGROUND 
 
 
1.1 Thyroid tumors 
 
1.1.1 Morphological and clinical features of follicular cell derived thyroid 
tumors 
 
Thyroid cancer is a common type of endocrine malignancy and its 
incidence has been steadily increasing worldwide (Jung et al. 2014). The 
enhanced incidence is limited to the papillary type of thyroid cancer (Pellegriti 
et al. 2013) and it is believed to result from increased access to high-resolution 
imaging (particularly ultrasonography) and increased use of fine needle 
aspiration (FNA) biopsy of small nodules, as well as progressively decreasing 
stringency of histopathologic criteria applied to the diagnosis of papillary 
cancer during the past 10-15 years (Howlader et al. 2012).  
There are several histological types and subtypes of thyroid cancer with 
different cellular origins, characteristics and prognoses. The vast majority of 
thyroid tumors arise from thyroid follicular epithelial cells, whereas ~3-5% of 
cancers originate from parafollicular or C cells (Xing 2013). The follicular 
cell-derived cancers (~95% of cases) are further subdivided into well-
differentiated papillary (PTC) carcinoma and follicular carcinoma (FTC), 
poorly differentiated carcinoma (PDC) and anaplastic (undifferentiated) 
carcinoma (ATC). Less-differentiated thyroid cancers (PDC and ATC) can 
develop de novo or through a stepwise dedifferentiation of papillary and 
follicular carcinomas (Figure 1) (Pitoia et al. 2013). 
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Figure 1. Model of thyroid multi-step carcinogenesis. Scheme of step-wise dedifferentiation 
of follicular cell-derived thyroid carcinoma with underlined main histological features. 
 
 
 
PTCs comprise ~75-85% of all thyroid cancers and represent the most 
common pediatric thyroid malignancy. Most PTCs in adults occur in patients 
between 20 and 50 year of age and it is more frequent in women than men 
(Nikiforov and Nikiforova 2011). Multifocality, lymphatic or local spreading 
and lymph node metastases are frequent features of PTC whereas distant 
metastases are relatively uncommon (Omur and Baran 2014). The overall 5 
and 10-year survival rates of PTCs are ~98% and 95%, respectively (Jemal et 
al. 2010). Current treatment involves surgery and radioactive iodine (RAI) 
therapy (which exploits thyroid follicular cells’ avidity for iodine) (Gruber et 
al. 2015). 
FTC is second most common thyroid malignancy and accounts for ~10–
15% of thyroid cancer. It mostly affects 40-60 years old patients and it is rare 
in children (Kondo et al. 2006). FTCs are defined by the World Health 
Organization (WHO) as malignant epithelial tumors with evidence of follicular 
cell differentiation but lacking the diagnostic nuclear features of PTC (Najafian 
et al. 2015). Most of the tumors are encapsulated, consequently are 
characterized by absence of vascular or capsular invasion and propensity for 
metastasis via the blood stream.  
PDCs (~5% of cases), both morphologically and prognostically, occupy 
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an intermediate position between differentiated (follicular and papillary) and 
undifferentiated thyroid carcinomas (Patel et al. 2014). In addition to nodal 
metastases, patients may also present evidence of distant metastatic disease. 
Diagnostic criteria for PDC include the presence of a solid-trabecular-insular 
pattern of growth, absence of the nuclear features typical of PTC and the 
presence of at least one of these features: convoluted nuclei, high mitotic rate, 
and tumor necrosis (Volante et al. 2010) (Figure 1).  
ATC constitutes less than 5% of thyroid malignancies but it accounts for 
more than half of the deaths for thyroid cancer, with a mortality rate that is 
over 90% and a mean survival of ~3-6 months after the diagnosis (Smallridge 
2012). ATC is defined by the WHO as a highly malignant tumor completely or 
partially composed of undifferentiated cells that retain features indicative of an 
epithelial origin. It usually affects elderly people, with a mean age in the mid-
70s and shows a female predominance (Ragazzi et al. 2014). All ATCs are 
considered stage IV, indeed, ~20–50% of patients present with distant 
metastases, most often pulmonary, and another 25% develop new metastasis 
during the rapid course of the disease (Nucera et al. 2011). Benefits obtained 
from chemotherapy and radiation therapy remain only marginal and there are 
no alternative treatments yet (Deshpande et al. 2013). The histological 
categories of these tumors are sarcomatoid and epithelioid-squamoid. Common 
features to all patterns of ATC are hypercellularity, large foci of necrosis, 
marked invasiveness, and angiotropism with a tendency to infiltrate medium-
sized veins and arteries, replacing their muscular wall. ATCs with sarcomatoid 
appearance are characterized by spindle cells and giant cells and are the most 
frequent patterns seen in ATC. In fact, spindle and giant cells have been found, 
alone or in combination, in ∼50% of cases. On the contrary, ATCs with 
epithelioid-squamoid appearance are histologically less heterogeneous than 
sarcomatoid tumors. They are characterized by polygonal cells with a clearly 
epithelial appearance, growing in solid nests, intermingled by desmoplastic 
stroma. On the other hand, ATC tissues contain tumor-associated macrophages 
(TAM), which may represent up to 50% of the nucleated cells and show 
elongated thin ramified cytoplasmic extensions (Hèbrant et al. 2014). A 
relationship between the increased densities of TAM type M2 and decreased 
survival was reported in thyroid cancer patients (Caillou et al. 2011). 
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1.1.2 Genetic alterations in follicular cell derived thyroid tumors 
 
Similar to other cancer types, thyroid cancer initiation and progression 
occurs through a gradual accumulation of various genetic and epigenetic 
alterations, including activating and inactivating somatic mutation, alteration in 
gene expression patterns, microRNA (miRNA) deregulation and aberrant gene 
methylation (Nikiforov and Nikiforova 2011) (Table 1).  
 
 
 
Table 1- Types of follicular cell derived thyroid cancer and their mutational profiles (modified 
from Nikiforov and Nikiforova 2011). 
 
Characteristics PTC FTC PDC ATC 
Prevalence (%) ~75-85 ~10-15 ~5 <5 
Typical route of 
spread 
Local lymph-node 
metastases 
Hematogenous 
metastases (to bone 
and lung) 
Invasive local 
growth, lymph-node 
and hematogenous 
metastases 
Invasive local 
growth, lymph-node 
and hematogenous 
metastases 
10-year survival 
rate (%) 
~95-98 ~90-95 ~50 < 10 
Common 
mutations 
(prevalence, %) 
BRAF (> 60) 
RAS (∼ 13) 
RET/PTC (∼ 7) 
NTRK (∼ 1) 
TERT (< 9) 
IDH1 (∼ 20) 
 
RAS (∼ 30-45) 
PAX8/PPARγ  
(∼ 30-45) 
PIK3CA (∼ 5-15) 
PTEN (< 10) 
RAS (∼ 20-40) 
TP53 (∼ 20-30) 
BRAF (∼ 10-20) 
CTNNB1 (∼ 25) 
PIK3CA (∼ 5-10) 
AKT1 (∼ 5-10) 
TP53 (∼ 70-80) 
CTNNB1 (∼ 60-65) 
RAS (∼ 20-30) 
BRAF (∼ 20-40) 
PIK3CA (∼ 15-25) 
PTEN (∼ 10-20) 
AKT1 (∼ 5-10) 
IDH1 (∼ 10-30) 
ALK (∼ 10) 
 
 
 
Genetic alterations in PTC 
  
Most mutations in PTC involve members of the mitogen-activated 
protein kinase (MAPK) pathway: the tyrosine kinase receptor RET 
(REarranged during Transfection), NTRK1 (neurotrophic receptor-tyrosine 
kinase) and intracellular signal transducers BRAF and RAS (Table 1) (Kondo 
et al. 2006). These mutations are typically mutually exclusive, occur in ~70% 
of PTC cases and are associated with particular clinical, histopatological and 
biological characteristics.  
The RET proto-oncogene, which is located on chromosome 10q11.2, was 
first identified in 1985 (Takahashi et al. 1985). It encodes a tyrosine kinase 
receptor consisting of an extracellular domain with a ligand binding site, a 
transmembrane domain and an intracellular tyrosine kinase domain. RET is 
activated by interaction with a multicomponent complex that includes a soluble 
ligand family, the glial cell line-derived neurotrotrophic factors (GDNF). 
Ligand binding results in receptor dimerization leading to autophosphorylation 
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of the protein on tyrosine residues and initiation of the signaling cascade. RET-
PTC is a chromosomal rearrangement found in PTC and occurs as a 
consequence of genetic recombination between the tyrosine kinase domain of 
the RET gene located on the 3’ and 5’terminal of various partner genes 
(Santoro et al. 1994). The rearrangement results in ligand independent 
dimerization and constitutive tyrosine kinase activity of RET which leads to 
chronic stimulation of MAPK signaling. Based on the partner genes, at least 
ten different types of RET/PTC rearrangements have been identified. Of these, 
the most common types in PTC are RET/PTC1 and RET/PTC3. The partner 
genes for RET/PTC1 and RET/PTC3 are the coiled-coil domains containing 
gene 6  (CCDC6) and the nuclear receptor co-activator gene 4 (NcoA4) 
respectively (Santoro et al. 2000). RET rearrangements are found in ~10-20% 
of PTCs; in particular, RET/PTC1 is more frequently associated with classic 
PTCs and with the diffuse sclerosing variant; conversely, RET/PTC3 is more 
common in the solid variant and in PTCs associated to ionizing radiations 
(Thomas et al. 1999).  
Chromosomal rearrangements involving another neurotrophic tyrosine 
kinase receptor (NTRK1) also occur in PTC. The NTRK1 gene resides on 
chromosome 1q22 and can be fused to at least three different partner genes 
located on the same or different chromosomes (Miranda et al. 1994). The 
prevalence of NTRK rearrangements is ~3-5% of PTC (Greco et al. 2004).  
 Point mutations in H-RAS, K-RAS, and N-RAS are uncommon in 
classic papillary thyroid carcinomas with an overall frequency of less than 10% 
(Cancer Genome Atlas Research Network 2014).  
BRAF, a member of the RAF protein family (ARAF, BRAF, CRAF), is a 
serine threonine-kinase. There is a direct association between BRAF mutation 
and aggressive clinical outcomes such as invasion, metastasis and relapse of 
PTC. Several studies demonstrated a close association between BRAF 
mutation and dedifferentiation of PTC (Holderfield et al. 2014). In thyroid 
cancer, BRAF can be activated by point mutations, small in-frame deletions or 
insertions or by chromosomal rearrangement. The most common oncogenic 
mutation in BRAF is thymine to adenine transversion at position 1799 
(T1799A) resulting in the substitution of valine by glutamate at residue 600 
(V600E) (Soares et al. 2003). This mutation causes constitutive activation of 
BRAF kinase and induction of the MAPK signaling pathway. In small 
percentages of PTC, K601E point mutation and small deletions or insertion 
around codon 600 are also observed (Murugan et al. 2011). BRAF mutations 
are uncommon in radiation-induced PTCs; however, Ciampi and coworkers 
have reported a rearrangement via paracentric inversion of chromosome 7q 
resulting in AKAP9-BRAF fusion (Ciampi et al. 2005).  
Single nucleotide change in the promoter region of TERT are found in 
~9% of PTC. The change generate de novo consensus binding motifs for 
MAPK-dependent ETS (E-twenty-six) transcription factors and is strongly 
associated with an increased risk of mortality (Melo et al. 2015). 
Novel fusions, including PAX8/PPARγ, ETV6/NTRK3 and 
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RBPMS/NTRK3 rearrangements, were discovered with low frequency in 
classical PTC. These fusions are more prevalent in radiation-induced thyroid 
cancers but have lower prevalence in sporadic PTC (Ricarte-Filho et al. 2013). 
Recently, The Cancer Genome Atlas (TCGA) has deposited the analysis 
results of ~500 thyroid cancer genomes only from PTC patients. These 
analyses provide a more detailed, multidimensional genomic characterization 
of thyroid cancer genomes. The TCGA identified novel driver alterations 
including EIF1AX, PPM1D and CHEK2 in PTC. The EIF1AX gene codes for 
a protein that is required for the transfer of methionyl-tRNA molecules to 
ribosomes in order to initiate protein translation. Mutations in EIF1AX, that in 
most cases target the N-terminal domain of the protein, as occur in PTC, have 
been previously reported in other tumors (Martin et al. 2013). Newly identified 
mutations in PPM1D, CHEK2, as well as genes that encode for components of 
the DNA-damage response pathway, were enriched in samples from patients 
with high risk PTC and occurred concomitantly with MAPK driver mutations 
(Cancer Genome Atlas Research Network 2014).  
 
Genetic alterations in FTC 
 
FTCs may develop trough at least two different pathways involving RAS 
or PPARγ (peroxisome proliferation activated receptor). Mutations in RAS 
gene family have been detected in up to 50% of follicular adenomas and 
carcinomas. Nikiforova and coworkers reported that among RAS-positive 
carcinomas, N-RAS codon 61 mutation is the most common in FTC 
(Nikiforova 2003). PAX8/ PPARγ rearrangement leads to the fusion between a 
portion of the PAX8 gene, which encodes a paired domain transcription factor, 
and the PPARγ gene. The fusion results in strong over-expression of the 
chimeric PAX8/PPARγ protein. RAS mutations and PAX8/PPARγ 
rearrangements represent distinct pathogenetic pathways in the development of 
follicular thyroid carcinomas (Eberhardt et al. 2010). 
 
Genetic alterations in PDC 
 
 PDCs have genetic features intermediate between well-differentiated 
and ATC consistent with the hypothesis of a multi-step model of thyroid 
carcinogenesis (Tallini 2011) (Figure 1). Similar to well-differentiated thyroid 
carcinomas, RAS point mutations occur in ∼20-40% of PDCs (Volante et al. 
2010). Similar to ATC, PDC features in some cases mutations in exon 5-9 of 
TP53 (∼20-30%) or in PIK3CA and its downstream effector AKT or point 
mutation in exon 3 of CTNNB1 (Catenin-cadherin-associated protein Beta 1) 
(Ricarte-Filho et al. 2013). Approximately 10-20% of PDC harbor BRAF 
mutation, particularly those samples with morphological evidence of pre-
existing PTC (Begum et al. 2004). A small number of PDC express rearranged 
tyrosine kinase genes such as RET/PTC or NTRK1, however there is no 
association with unfavorable clinico-pathological features or decreased 
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survival (Santoro et al. 2006) (Table 1).  
 
Genetic alterations in ATC 
 
To date, a considerable number of genetic mutations have been identified 
in ATC (Lee et al. 2013). 
Mutations in the components of the principal oncogenic pathways (i.e. 
MAPK, PI3K, WNT) have been described to occur with high frequency in 
ATC. RAS mutations are detected in ATCs, with variable frequency ranging 
from ∼20 to 40% of cases (Ragazzi et al. 2014). RAS mutations correlate with 
aggressiveness and/or poor prognosis (Milosevic et al. 2014). In contrast, 
RET/PTC rearrangements are rarely found in ATCs (Lee et al. 2013). The 
BRAF V600E mutation occurs in ∼38% of ATC (Vanden Borre et al. 2014), 
and recent reports indicate that BRAF V600E alters ATC tumor 
microenvironment through extracellular matrix (ECM) protein such as 
thrombospondin-1 (TSP-1) and ECM receptors (ie, integrins) (Duquette et al. 
2013; Gandolfi et al. 2014). 
Gain of function mutations in the PIK3CA (phosphatidylinositol-4, 5-
bisphosphate 3-kinase, catalytic subunit alpha) gene are also common in ATC 
(Charles et al. 2014). Amplification of the PIK3CA genomic locus in 3q26.3 is 
found in ∼40% of ATC suggesting that alteration of the PI3K pathway plays a 
pivotal role in the pathogenesis of ATCs (Xing 2013). Importantly, the over-
activation of the PI3K-AKT pathway can be induced by PTEN inactivation, 
including PTEN promoter methylation, deletion, or point mutations that occur 
in ∼10–20% of ATC (Nucera et al. 2011).  
Somatic mutations in the promoter of the TERT (Telomerase Reverse 
Transcriptase) gene have been described as highly recurrent in different types 
of cancer including ATC (Shi et al. 2015). Intriguingly, TERT promoter 
mutations seem to occur prevalently in those tumors harboring mutated BRAF 
or RAS, suggesting that TERT alteration is acquired later during tumor 
development and may provide a functional advance to BRAF or RAS driven 
tumors by enabling acquisition of additional genetic defects leading to disease 
progression (Liu et al. 2014). 
WNT pathway appears also to play a relevant function in ATC 
development. Mutations in CTNNB1 gene leading to a constitutively active 
WNT-signaling have been reported in ∼25–60% of ATCs (Kunstman et al. 
2015). CTNNB1 is a major component of the E-cadherin cell-cell adhesion 
complexes and a role of this protein in the epithelial-mesenchymal transition 
process has been demonstrated (Lamouille et al. 2014). 
Although the mutation prevalence is not high, mutations in the gene for 
isocitrate dehydrogenase 1 (IDH1) have been recently identified in ATC 
(Hemerly et al. 2010) (Table 1).  
In ∼11% of ATC patients, a mutation in anaplastic lymphoma kinase 
(ALK), a tyrosine kinase receptor involved with the activation of both the 
MAPK and PI3K-AKT pathways, is observed. Specifically, two point 
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mutations have been identified (ALK L1198F and ALK G1201E) that result in 
increased tyrosine kinase activity (Murugan and Xing, 2011). Also several 
rearrangements involving ALK gene were found in ATC. The most common of 
these involves a fusion between ALK and the striatin (STRN) gene, which is 
the result of a complex rearrangement involving the short arm of chromosome 
2. STRN-ALK leads to constitutive activation of ALK kinase, which is able to 
transform cells in vitro and to induce tumor formation in nude mice. In 
addition STRN-ALK did not overlap with other known driver mutations in 
these tumors (Kelly et al. 2014). 
Recently, several novel mutations not previously described in ATC were 
observed including mTOR, NF1 or ERBB2; some of these are particularly 
intriguing because have been targeted previously by pharmaceuticals currently 
in clinical or experimental use (Kunstman et al. 2015). 
More than 50% of ATCs have been reported to carry loss of function 
mutations in the p53 gene. As well, the over-expression of p53, which may 
reflect altered function of the protein in the absence of mutation, has been 
frequently observed in ATC (Pita et al 2014).  
ATCs are characterized by a higher number of chromosomal alterations 
with respect to well-differentiated and poorly differentiated thyroid cancer. Liu 
and colleagues observed that genes coding for tyrosine kinase receptors (RTK) 
like EGFR, PDGFR, VEGFR, KIT, and MET are frequently amplified in 
thyroid cancer and in particular in the ATC histotype (Liu et al. 2008). Many 
of the genes with copy number gains are known to be proto-oncogenes so that 
they may be play an important role in ATC tumorigenesis.  
Wreesman and colleagues observed several chromosomal abnormalities 
that were common to both well-differentiated and undifferentiated thyroid 
cancer (like gain of 5p15, 5q11– 13, 19p, and 19q and loss of 8p) and that 
could represent early event in the genesis of these tumors. Furthermore, they 
found alterations like gain in 3p13-14, loss of 5q11– 31, and gain in 11q13 that 
were exclusive of the genome of ATC and that may represent late genetic 
events driving the transformation of a preexisting thyroid cancer into the 
aggressive ATC histotype (Wreesman et al. 2002). 
Intriguingly, the chromosomal regions affected by the alterations were 
extremely heterogeneous, suggesting the existence of a high-grade genetic 
inter-neoplastic diversity in ATC (Ragazzi et al. 2014). This observation 
implies that the high-grade genomic instability in ATCs is a side effect of the 
loss of restraining mechanisms of cell proliferation rather than being the cause 
of tumor progression. Indeed, a number of mitotic proteins involved in cell 
cycle checkpoints or engaged in chromosome assembly and segregation are 
deranged in ATCs (Isham et al. 2013; Pita et al. 2014). These include the three 
members of the Aurora kinase family. Aurora kinases are implicated in several 
aspects of chromosome segregation and cytokinesis. Expression of all Aurora 
kinases, in particular of Aurora A, is strongly induced in ATC cells and its 
over-expression induces centrosome amplification and increases the oncogenic 
function of RAS (Tatsuka et al. 2005). Moreover, evidences exist of a negative 
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cross-talk between Aurora A kinase and p53 (Liu et al. 2004). Inhibitors of 
Aurora kinases, alone or in combination with other drugs, showed an important 
anticancer effect in preclinical models of ATCs indicating this approach as a 
possible therapeutic strategy for ATCs treatment (Baldini et al. 2014; Granata 
et al. 2013). 
Epigenetic changes of tumor-associated genes have been found in ATC. 
Schagdarsurengin and colleagues analyzed the methylation pattern of 17 gene 
promoters in ATC, included those involved in DNA damage avoidance and 
repair (MGMT, GSTP1), apoptosis (DAPK, UCHL1), cell cycle control (p16, 
RB), and regulation of thyrocyte function and growth (TSHR). Among these 
genes, they found that TSHR, MGMT, UCHL1, p16, and DAPK were 
frequently methylated in ATC (Schagdarsurengin et al. 2006).  
PTEN methylation was found in ATC and was closely associated with 
the activating mutations in the PI3K/AKT pathway (Milosevic et al. 2014) 
(Table1). 
Additionally, Rodríguez-Rodero and colleagues observed that four 
oncogenes (INSL4, DPPA2, TCL1B and NOTCH4) are frequently regulated 
by hypomethylation in ATC (Rodríguez-Rodero et al. 2013). 
EZH2, member of the polycomb family of proteins, is a histone lysine-
methyl-transferase and is over-expressed in ATC. EZH2 is essential for the 
regulation of cell proliferation and differentiation. When EZH2 is over-
expressed, histone methylation is altered, silencing the PAX8 gene and leading 
to an aggressive phenotype (Catalano et al. 2012). 
Finally, histone deacetylation plays a role in ATC pathogenesis. Most 
ATC tumors show over-expression of histone deacetylases (HDACs). Less 
acetylation of histones leads to an altered expression of proteins involved in the 
regulation of cell cycle and proliferation (Lin et al. 2013). 
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1.1.3 Aberrant expression of miRNAs in thyroid cancers 
 
MicroRNAs (miRNA) are small (19–25 nucleotides) noncoding RNA 
molecules that typically function as negative regulators of the expression of 
protein-encoding genes (Bartel 2009). miRNAs regulate major processes as 
development, apoptosis, cell proliferation, immune response, and 
hematopoiesis; they also may act as tumor suppressor genes and oncogenes (Di 
Leva et al. 2014). Mature miRNAs regulate gene expression through 
translational inhibition (accounting for ∼16%) or mRNA degradation 
(accounting for ∼84%) by annealing to complementary sequences in mRNA 
3’untranslated regions (UTRs) (Djuranovic et al. 2011). Each miRNA is 
predicted to repress the expression of thousands of mRNAs, and in turn, each 
mRNA can be targeted by several hundred different miRNAs (Di Leva et al 
2014). The production of miRNAs follows a canonical multistep process that 
starts in the nucleus and ends in the cytoplasm and is composed of three main 
events: cropping, nuclear export, and dicing (Figure 2) (Shen and Hung 2015).  
 
 
 
 
  
Figure 2: Biogenesis of miRNA. Transcription of miRNA by RNA polymerase II yields a long primary 
transcript (pri-miRNA) that contains a cap 5’ and poly-A tail. The complex DROSHA/DGCR8 cleaves 
pri-miRNA and gives rise to an miRNA precursor (pre-miRNA) that is exported to the cytoplasm and 
further processed by DICER endonuclease. A miRNA duplex associates with the RISC complex and 
retains the mature strand of miRNA. This complex directs imperfect binding to 3’UTR region of target 
mRNA, leading to a reduction in protein levels via translation blockage and mRNA deadenylation and 
decay (modified from Di Leva 2014).   
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Recent data suggests that miRNA deregulation could be a crucial event 
in thyroid carcinogenesis.  
Deregulated expression of several miRNAs in PTC was found to 
correlate with certain genetic lesions. For example, the expression of miR-187 
is enhanced in samples of PTC leading the RET/PTC rearrangement 
(Nikiforova et al. 2008); also the up-regulation of miR-128a, -128b, -139 and -
200a strongly correlates with RET/PTC rearrangement (Cahill et al. 2006). 
miR -221 and -222 are over-expressed in BRAF-mutated and RAS-mutated 
PTC. In addition, the miRNA profile is often associated with some clinical 
features of PTC: a microarray analysis revealed up-regulation of miR-31, -
146b -155, -221 and -222 in aggressive versus non-aggressive PTCs (Yip et al. 
2011). In particular, deregulated expression of miR-146b, miR-221 and miR-
222 may be the crucial component for initiation and development of PTC. The 
putative target of these miRNAs was suspected to be c-KIT, as a tyrosine 
kinase receptor that plays an important role in cell growth and differentiation 
(Yip et al. 2011). Very few miRNAs have been found to be down-regulated in 
PTC versus normal thyroid tissue. miR-1 is one of the most consistently and 
drastically down-regulated miRNAs in PTC. Its expression is also decreased in 
tissue from FTC and ATC, irrespective of the degree of malignancy, 
suggesting a role of miR-1 down-regulation in early stages of thyroid 
carcinogenesis. miR-1 targets the chemokine receptor CXCR4 and its ligand 
CXCL12, and have a critical role in tumor metastasis (Leone et al. 2011). 
Moreover, miR-1 down-regulation contributes to the EMT by modulating 
protein levels of the zinc finger protein SNAI2 (also known as SLUG), which 
is a transcriptional repressor of E-cadherin and a known EMT inducer 
(Tominaga et al. 2013). 
Mancikova and colleagues identified miRNA expression profile specific 
for follicular thyroid tumors. FTC showed a notable over-expression of several 
members of miR-515 family, and down-regulation of miR-1247. They also 
observed the up-regulation of miR-96, -182, and -183 in both follicular 
adenomas and follicular carcinomas (Mancikova et al. 2015). Recently, the 
expression level of miR-192, -197, -328 and -346 has been reported to be 
decreased in FTC compared to normal thyroid. These miRNAs are evidently 
specifically associated with FTC (Faam et al. 2015).  
Specific miRNAs are reduced in thyroid cancer, such as the let-7 family, 
but other miRNAs, such as the miR-200 and miR- 30 families, are exclusively 
down-regulated in ATC, indicating that the latter miRNAs may play a role in 
the acquisition of more aggressive tumor characteristics.  
The miR-200 family was recently identified as a suppressor of EMT 
promoting ZEB degradation and thus suggested to interfere with metastasis by 
sustaining an epithelial character of tissues. The miR-200 family was found 
decreased in ATC and the expression of these miRNAs in mesenchymal ATC-
derived cells reduced their invasive potential and induced mesenchymal–
epithelial transition (MET) by regulating the expression of MET marker 
proteins (Braun et al. 2010). An important transcriptional activator of miR-200 
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is p53 (Hermeking et al. 2012). 
Down-regulation of the miR-30 family is observed in metastasis 
compared to the primary tumor suggesting a role in aggressive disease. The 
group of Hébrant demonstrated, by in situ hybridization, aberrant expression of 
miR-30e in ATC where miR-30 modulated vimentin expression (Hébrant et al. 
2014). Furthermore, down-regulation of miR-30 de-represses the expression of 
EZH2, an important component of the polycomb repressive complex 2 (PRC2) 
that regulates chromatin condensation and is frequently over-expressed in ATC 
(Esposito et al. 2012). Another important cellular process regulated by the 
miR-30 family is autophagy through targeting the key autophagy-promoting 
protein, Beclin1. In ATC, miR-30d restoration sensitizes cancer cells to 
cisplatin treatment by repressing Beclin1 (Zhang et al 2014) (Table 2).  
Family genes of let-7 are located on different chromosomes and are 
abundantly expressed in a normal thyroid gland. Deregulation of let-7 is 
observed in several types of cancer; in particular, in well-differentiated thyroid 
cancer (PTC and FTC), but a marked decrease in the expression of let-7 family 
is also observed in ATC (Catalano et al. 2012).  
Common miRNAs such as miR-146, -221, -222, and -17-92 are up-
regulated in aggressive ATC and in well-differentiated thyroid cancer, 
indicating that reinforced expression of these miRNAs is important in 
maintaining the oncogenic process (Table 2).  
The miR-17-92 cluster is located on chromosome 13 and transcribes a 
polycistron that yields seven different mature miRNAs. High levels of miR-17-
92 components are expressed in ATC and their inhibition leads to the recovery 
of PTEN protein levels and resulted in a pronounced apoptosis through 
activation of caspase-3 and caspase-9 (Takakura et al. 2008). Furthermore, a 
key target of miR17-5p and miR-17-3p is TIMP-3, an important inhibitor of 
metalloproteinase activation (Catalano et al. 2012).  
miR-146a and -146b are over-expressed in ATC (Pacifico et al. 2010). 
miR-146a/b are transcribed by two independent genes located on chromosomes 
5 and 10, respectively, and either regulated by the transcription factor NF-kB, 
usually over-activated in ATC. Increased plasma circulating levels of miR-
146b can be detected also in PTC before surgery and correlate with tumor 
aggressiveness and poor prognosis (Lee et al. 2013) (Table 2). 
 miR-221 and miR-222 over-expression is detected in differentiated 
(PTC and FTC) (Pallante et al. 2014) and ATC cells (Jikuzono et al. 2013) 
(Table 2) and it is associated with poor clinical-pathological features of cancer. 
miR-222 increased circulating plasma level is associated with the presence of 
the BRAF mutation and recurrent PTC (Lee et al. 2013). Both miR-221 and -
222 also influence cell proliferation by targeting the p27kip1 protein, a key 
regulator of cell cycle progression (Visone et al. 2007). Ectopic expression of 
miR-221 in cancer cells results in a robust increase in anchorage-independent 
growth in soft-agar medium (Pallante et al. 2014), pointing to a role for this 
cluster of miRNAs in the process of invasion and cell migration (Table 2).  
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Table 2. Validated targets for deregulated miRNAs in ATC. 
miRNAs Validates targets Cellular processes 
miR-200 
family 
ZEB1 ZEB2 β-Catenin EMT and proliferation 
miR-30 family Beclin1 EZH2 VIM Autophagy, Chromatin condensation 
and EMT 
miR-7 family RAS HMGA2 LIN28 Proliferation, Histone modification and 
stemness 
miR-25 family EZH2 BIM KLF4 Chromatin condensation and apoptosis 
 
 
Down-
regulated 
miRs 
 
 
miR-125 
family 
MMP1 HMGA2 LIN28A Invasion, Histone modification  and 
stemness 
miR- 221, -222 P27 RECK PTEN Cell cycle, growth, and invasion 
miR-17-92 
cluster 
P21 TIMP3 PTEN Cell growth and invasion 
 
Up-
regulated 
miRs 
 
miR -146a; 
-146b 
NF-kB THRB SMAD4 Cell differentiation, proliferation, and 
invasion 
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1.1.4 Targeted therapy for thyroid carcinomas 
 
The majority of well-differentiated thyroid carcinomas (papillary and 
follicular) are characterized by good prognosis and good response to surgery 
and radioiodine therapy. Nevertheless, ~10% of differentiated carcinomas 
recur and become resistant to all therapies.  
The majority of patients with ATC die from aggressive local regional 
disease, primarily from upper airway respiratory failure. For this reason, 
aggressive local therapy is indicated in all patients who can tolerate it. 
Although rarely possible, complete surgical resection gives the best chance of 
long-term control and improved survival. In fact, surgical de-bulking of local 
tumor, combined with external beam radiation therapy and chemotherapy as 
neoadjuvant (before surgery) or adjuvant (after surgery) therapy, may prevent 
death from local airway obstruction and as best may slight prolong survival 
(Taccaliti et al. 2012). Investigational clinical trials in phase I or in phase II 
are actually in running and they include multi-kinase inhibitor, anti-
angiogenetic drugs, histone deacetylase and mTOR inhibitors drugs. 
Tyrosine-kinase inhibitor. The last decade has seen advances in the 
understanding of the molecular basis of thyroid cancer, leading to the 
application of new pharmacological treatments with inhibitors of kinases 
(Marotta et al. 2013). The BRAF inhibitor vemurafenib (PLX4032) improves 
survival among patients with metastatic melanoma, and suppresses growth of 
BRAF-mutated human ATC in a mouse model (Rosove et al. 2013). The 
beneficial effect of BRAF inhibition in ATC with activating BRAF mutations 
has been recently reported (Salerno et al. 2010). Sorafenib and Imatinib are a 
broad-spectrum tyrosine-kinase inhibitor (TKI), that demonstrated an 
acceptable response rate in pre-treated ATC patients (Thomas et al. 2014; 
Savvides et al. 2014). Pazopanib, another TKI, similarly to Sorafenib has been 
tested also in ATC in the context of a phase II trial demonstrating minimal 
single-agent clinical activity (Bible et al. 2012).  
Anti-angiogenetic agents. A common feature of thyroid cancers is their 
markedly increased vascularization, with an elevated expression of the vascular 
endothelial growth factor (VEGF) compared with normal thyroid tissue. VEGF 
levels are correlated with stage, tumor size, extra-thyroidal invasion, and 
distant metastases (Bauer et al. 2003). On the basis of these findings, several 
drugs targeting angiogenesis have been evaluated against ATC. Combretastatin 
A4 (CA4), a vascular disrupting agent which blocks the tumor directed blood 
flow altering the neovasculature morphology, has shown to produce a trend 
toward a significant overall survival improvement in ATC patients (Sosa et al. 
2012). Axitinib, a VEGFR2 inhibitor, showed therapeutic efficacy only in one 
of two patients with ATC (Cohen et al. 2014). 
Histone deacetylase inhibitors. Histone deacetylase inhibitors are a 
promising class of antineoplastic agents that induce cell differentiation, cell 
cycle arrest, and apoptosis through hyperacetylation of histones, with the 
potential to enhance the cytotoxicity of drugs such as doxorubicin (Smith and 
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Nucera 2015). Preclinical studies have shown that valproic acid, a potent anti-
convulsant agent, is able to enhance the activity of Doxorubicin in cell lines 
derived from ATC alone or in combination with other drugs (Smith and Nucera 
2015). 
mTOR inhibitors. More recently inhibition of mTOR has been taken into 
account for clinical trials (Fury et al. 2013). Everolimus, an inhibitor of the 
mammalian target of rapamycin (mTOR), is effective in treating tumors 
harboring alterations in the mTOR pathway. Wagle and colleagues identified 
potential genomic mechanisms of exquisite sensitivity and acquired resistance 
to everolimus by performing whole-exome sequencing on the pre-treatment 
and drug-resistant tumors. Nonsense mutation in TSC2, a negative regulator of 
mTOR, results in sensitivity to mTOR inhibition in some cancer, whereas the 
mechanism of acquired resistance to everolimus was identified as a mutation in 
mTOR that causes resistance to allosteric mTOR inhibition by preventing the 
binding of the drug to the protein (Wagle et al. 2014). 
Nevertheless, the effectively right strategy of therapy may be a multi 
disciplinary approach based on a radical surgery followed by adjuvant chemo 
and target therapy and external beam radiotherapy. Early integration of all the 
available strategy is the only way to face this poor prognosis disease (Perri et 
al. 2014). 
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1.2 The transcription factor Twist1 
 
 
1.2.1 Molecular structures of the Twist1 gene and protein 
 
Little is known about the molecular events that lead from the highly 
curable differentiated tumors to the very aggressive ATC. Through, a cDNA 
microarray analysis on different thyroid tumors in comparison to normal 
thyroids, we have isolated Twist1 transcription factor as a gene up-regulated in 
ATC (Salvatore et al. 2007).  
Twist1 was first identified in Drosophila (D-Twist) as a gene involved in 
the early development of the mesoderm and during gastrulation promoting the 
N-cadherin expression (Puisieux et al. 2006). Drosophila embryos lacking the 
Twist1 gene failed to gastrulate normally, produced no mesoderm and died at 
the end of embryogenesis with a ‘twisted’ appearance. D-Twist is able to form 
homodimers and does not need to form heterodimers for DNA binding (Šošić 
et al. 2003).  
Two Twist genes exist in vertebrates, well conserved during evolution, 
Twist1 and Twist2 (formerly Dermo-1). The Twist proteins display a high 
degree of sequence similarity in their C-terminal portion, including the bHLH 
and ‘Twist-box’ domains, but are more divergent in their N-terminal portion. 
While Twist1 has a glycine-abundant region in the N-terminal side, Twist2 
does not have it (Bialek et al. 2004). Once expressed, Twist1 and Twist2 may 
function either as transcriptional activators or repressors, through both direct 
and indirect mechanisms. Both proteins have been associated with the 
differentiation of cells like muscle, cartilage and osteogenic cells. Mutations in 
Twist2 are associated with the Setleis Syndrome, an inherited developmental 
disorder characterized by bilateral temporal marks (Tukel et al. 2010). Twist1 
gene mutations cause Saethre-Chotzen syndrome (SCS), an autosomal 
dominant inheritance disease characterized by a broad spectrum of 
malformations including short stature, craniosynostoses, ptosis (El Ghouzzi et 
al. 1997). 
Human Twist1 gene maps on chromosome 7q21.2 and contains two 
exons and one intron (Wang et al. 1997). The first exon contains an ATG site 
followed by an open reading frame encoding 202 amino-acid residues. The 
open reading frame is followed by a 45-bp untranslated portion in exon 1, a 
536-bp intron and a second untranslated exon with two potential 
polyadenylation sites that are 65 and 415 bp from the 5′ end of exon 2 (Figure 
3A).  
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Figure 3. Structure of human Twist1. A. The human-Twist1 gene comprises two exons separated by a 
unique intron. B. The human-Twist1 protein is 202 amino acids presenting a basic helix-loop-helix 
(bHLH) domain. C. Interaction of dimers of Twist1 with DNA (modified from Bonaventure and El 
Ghouzzi 2003). 
 
 
 
The molecular mass calculated from the amino-acid sequence of human 
Twist1 is ∼21 kDa, with a theoretical isoelectric point of ~9.6. The protein 
contains relatively more polar amino-acid residues in the region close to the 
NH2-terminus and more non-polar residues at the COOH-terminus where the 
bHLH (basic helix–loop–helix) domain is located (Qin et al. 2012).  
Twist1 is a transcription factor that belongs to the bHLH family (Thisse 
et al. 1987). The bHLH domains of Twist1 show a very high degree of 
conservation among a broad range of species. Structurally, bHLH proteins are 
characterized by the presence of a conserved domain containing a stretch of 
basic amino acids adjacent to two amphipathic α-helices separated by an inter-
helical loop (Figure 3B). The α-helices mediate the interaction of this protein 
with a second bHLH factor, leading to the formation of a dimer that binds to 
5’-CANNTG-3’ hexanucleotide sequenze known as the E-box. The traditional 
classification categorizes the bHLH family into three subfamilies: class A, 
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class B and class C (Murre et al. 1989). The proteins in class A, which include 
E12, E47, HEB, E2-2 and are ubiquitously expressed in mammalian cells. 
Class B comprises bHLH proteins that have relative specificity in tissue 
expression and form dimers with class A molecules for binding to E-boxes. 
Class C molecules, consisting of the Myc proteins, do not form heterodimers 
with either class A or class B proteins. The Twist family, which has relative 
tissue specificity and forms heterodimers with E12 and E47, falls into class B 
(Castanon and Baylies 2002). 
Twist box, also known as ’WR motif’ (the tryptophan and arginine 
motif), is located between 20 and 55 amino acids COOH-terminal to the bHLH 
region and it is highly conserved among vertebrates (Figure 4). It has been 
demonstrated that the Twist box is required for the transactivation function of 
Twist1, and genetic mutations in the Twist box domain are associated with 
SCS of human patients (Puisieux et al. 2006). Recently it was demonstrated 
that through the Twist box, Twist1 binds and inhibits p53, suggesting that the 
Twist box is essential for inhibition exerted by Twist1 on other transcription 
factors (Piccinin et al. 2012). 
Twist1 functions as a transcription factor in the cell nucleus. There are 
two nuclear localization signal (NLS) sequences, 37RKRR40 and 
73KRGKK77, in the human Twist1 protein (Figure 3). In the nucleus, N-
terminus of Twist1 can interact with p300, cAMP-response element binding 
protein (CREB), CREB-binding protein (CBP) and p300/CBP associated factor 
(PCAF) (Figure 3), resulting in inhibition of the acetyltransferase activities of 
these histone remodeling enzymes (Hamamori et al. 1999). Since histone 
acetylation is usually coupled with transcriptional activation, the inhibition of 
p300, CBP and PCAF activities by Twist1 should repress gene expressions. 
Finally, the C-terminus of Twist1 interacts with the DNA-binding domain of 
Runx2 to repress Runx2 function (Figure 3). Runx2 is a necessary transcription 
factor for osteoblast differentiation. These findings suggest that Twist1 may 
function as transcriptional activators or repressor, through both direct and 
indirect mechanisms recruiting other transcription factors such as MEF2, 
MyoD, RUNX1-2, CEBP-a and NF-kB (Figure 3) (Puisieux et al. 2006). 
Regulation of protein stability is an important way to control Twist1 
function. The most characterized post-translational modification of Twist1 its 
phosphorylation on serine68 (S68) by p38, JNK and ERK1/2 MAPKs; and this 
phosphorylation prevents Twist1 protein from ubiquitination-mediated 
degradation (Hong et al. 2011). In addition, p62 (autophagy adaptor protein) 
has been shown to bind Twist1 protein and inhibit its degradation; p62-
dependent Twist1 stabilization, following autophagy inhibition, promotes 
tumor cell growth and metastasis (Qiang et al. 2014). Conversely, a recent 
study has shown that the ectopic expression of death effector domaincontaining 
DNA-binding protein (DEDD) in metastatic breast cancer cells induces 
autophagy and increases degradation of Snail and Twist1 through the 
autophagy-lysosome degradation system (Lv et al. 2012). Twist1 stability is 
also regulated at the post-trascriptional level through phosphorylation on Ser42 
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by AKT. AKT phosphorylation of Twist1 Ser42 has also been shown to confer 
cell death resistance to DNA damage through inhibition of a p53-dependent 
pathway (Xue et al. 2012). 
Among the bHLH proteins, Twist1 proteins are unique in their ability to 
form functional homo- and heterodimers. Twist1 can heterodimerize with 
different transcription factors. Partner choice could also be regulated by the 
phosphorylation state of specific threonine (Thr 125) and serine (Ser 127) 
residues (TQS motif) that are conserved in the first α-helix of the HLH domain 
of Twist1 protein. The phosphorylation state is determined by protein kinase A 
(PKA) and C (PKC) (Firulli et al. 2003). Gajula et al. for the first time 
described also the requirement of the PI3K-AKT-mTOR pathway for 
phosphorylation of TQS motif, which is required for the pro-metastatic 
functions of Twist1 in prostate cancer cells (Gajula et al. 2015). 
 
 
 
Figure 3 Molecular structure of the human Twist1 protein. The number of amino-acid residues for 
each structural domain is indicated. The regions that interact with other proteins are also indicated by 
solid lines. NLS1 and NLS2, nuclear localization signal sequences 1 and 2; bHLH, basic helix-loop-helix 
domain; WR, the tryptophan (W) and arginine (R) motif; CBP, cAMP-response element binding protein 
(CREB)-binding protein; PCAF, p300/CBP-associated factor, Runx2, Runt-related transcription factor; 
E12/E47, a bHLH transcription factor that forms dimer with Twist1; MyoD, a bHLH transcription factor 
that regulates muscle differentiation (modified from Qin 2012). 
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1.2.2 Physiological functions of Twist1 protein  
 
Twist1 was originally identified in Drosophila as a zygotic 
developmental gene crucial for the establishment of the ventral furrow, a 
prerequisite for the development of all mesoderm-derived internal organs 
(Thisse et al. 1987).  
In mice, Twist1 haploinsufficiency produces viable offspring but leads to 
abnormal craniofacial structures and polydactyly in the hind limb, a phenotype 
reminiscent to the dominantly inherited SCS in humans where Twist1 is 
mutated (Bourgeois et al. 1998). Twist1-/- mice undergo normal gastrulation 
but die at E10.5-11. Twist1, therefore, acts after mesoderm specification in 
vertebrates, but remains essential in mesoderm differentiation including 
muscle, cartilage and osteogenic cell lineages. Twist1-/- mice also present a 
significant increase in apoptotic cells, especially in the developing sclerotome 
(Chen and Behringer 1995). This cell death could reflect Twist1 anti-apoptotic 
properties as Twist1 proteins also behave as key regulators of the p53 onco-
suppressive protein and as major effectors of the NF-kB survival pathway 
(Maestro et al. 1999). The lethality of the Twist1 knockout mouse led to the 
development of a Cre-mediated conditional knockout mouse to help study the 
regulatory functions of Twist1 post-neural crest cell migration (Bildsoe et al. 
2009). 
The expression profile of Twist1 during human embryogenesis is 
lacking. After birth, Twist1 is expressed in the adult stem cells of the 
mesenchyme (Qin et al. 2011). Ectopic expression of Twist1 in human bone 
marrow-derived mesenchymal stromal/stem cells (MSC) was found to 
maintain an immature stromal phenotype, to inhibit their osteo-chondrogenic 
potential and conversely to increase their adipocyte potential, strengthening 
their role in cell fate determination (Patterson et al. 2011). Twist1 expression 
was originally defined as being restricted to mesoderm-derived tissues 
including placenta, heart and skeletal muscles (Wang et al. 1997), presumably 
in precursor cells. Recently, the protein was found to be additionally expressed 
in brown fat and to be essential for its function in adaptative thermogenesis, a 
process that consists of metabolizing fat as heat (Dobrian et al. 2012). Twist1 
behaves as a negative regulator of the PGC1-a transcription factor, the key 
regulator of the entire program of thermogenesis, by scaffolding together 
PGC1-a with a class II histone deacetylase to silent its target genes. Twist1 
depletion is sufficient to provide a remarkable obesity-resistant phenotype, 
elevated oxygen consumption and mitochondrial biogenesis linking for the first 
time Twist1 to cell metabolism (Patterson et al. 2011). Twist1 expression was 
not observed in human epithelial cells, although its mRNA was detected in 
both fetal and adult human skin fibroblasts (Wang et al. 1997). 
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1.2.3 Twist1 expression in cancers 
 
Twist1 plays an important role in development and progression of 
different types of cancer (Wushou et al. 2015).  
Up-regulation of Twist1 expression is frequently reported in breast 
cancer and indicates advanced tumor stage and poor overall survival (Lim et al. 
2015). Moreover, Twist1 is also responsible for the hormone resistance in 
breast cancer cells (Vesuna et al. 2012). In particular, Twist1 is responsible for 
the loss of estrogen receptor (ER) activity, which contributes to the generation 
of hormone-resistant. Studies showed that the hyper-methylation of specific 
genes is a common feature of breast carcinomas and Twist1 is one of these 
genes (Dumont et al. 2008).  
Twist1 over-expression is associated with another gynecological cancer, 
i.e. epithelial ovarian cancer. In epithelial ovarian carcinomas Twist1 
expression was significantly increased in response to the chemotherapy and 
was associated with increased migration of the cells (Du et al. 2014).  
Twist1 is a critical regulator of prostate cancer cell growth and is a 
prognostic marker of high-grade prostate cancer (Raatikainen et al. 2015). 
High expression of Twist1 is closely associated with more aggressive 
behaviors of hepatocellular carcinoma (HCC) (Zhang et al. 2015). Different 
studies have reported that the over-expression of Twist1 is also associated with 
gastric carcinoma, colon-rectal carcinoma and esophageal squamous carcinoma 
(Qin et al. 2012). Co-expression of Twist1 with hypoxia-inducible factor-1 
alpha (HIF1-α) and Snail is an important prognostic predictor in patients with 
non-small cell lung cancer and it is associated with mesenchymal phenotype 
(Liu et al. 2015).  
 
 
 
  29 
1.2.4 Mechanisms of Twist1 reactivation in human cancers 
 
The mechanisms leading to the aberrant reactivation of Twist1 appear to 
be various and complex. Up-regulation of Twist1 or its promoter methylation 
is reported in brain cancer, head and neck cancer (Ou et al. 2008). Like 
carcinomas, Twist1 is also over-expressed in chronic myeloid leukemia (CML) 
patients and in other hematological malignancies (Merindol et al. 2014). 
Twist1 is activated by a variety of signal transduction pathway, including 
AKT, STAT3, MAPK, RAS and WNT signaling. It was demonstrated that 
STAT3 bind to Twist1 promoter activating the transcription. The activity of 
STAT3 depends of its phosphorylation state (Zhao et al. 2015). Co-expression 
of Tyr705 p-STAT3 and Twist1 within the nucleus was observed in late-state 
tumors (Cheng et al. 2008). The epidermal growth factor (EGF) is able to 
increase the RNA and protein levels of Twist1 in EGFR- expressing cells via 
STAT3 activation (Cho et al. 2014). 
Stress conditions seem to control both the physiological and aberrant 
expression of Twist1. Hypoxic conditions are similarly defined as potent 
inducers of Twist1 expression in cancer cells thereby promoting cell 
dissemination to less hostile environment. Consistently, up-regulation of 
Twist1 by HIF1α during hypoxic conditions has significant implications in 
tumor invasion and angiogenesis (Du et al. 2015; Yang et al. 2008). 
Other results indicated that over-expression of Sox12, a member of SYR-
related HMG box (SOX) family proteins, induced invasion and metastasis by 
trans-activating Twist1 expression in hepatocellular carcinoma (HCC). Co-
expression of Sox12 and Twist1 were significantly correlated with loss of 
tumor encapsulation, microvascular invasion and a higher tumor-nodule-
metastasis and indicated poor prognosis in human HCC (Huang et al. 2015).  
It was reported that also YB1 (Y box-binding protein I) is able to 
modulate Twist1 expression. The DNA/RNA binding protein YB1 was found 
to suppress cap-dependent initiation of growth promoting mRNAs and 
enhances the cap-independent translation initiation of EMT-inducing mRNA 
including Twist1, thereby promoting growth arrest and cell dissemination 
(Evdokimova et al. 2009). 
Recent data support that hyper-methylation of Twist1 promoter may 
represent an alternative mechanism for its regulation and influence the EMT in 
colorectal cancer (Galván et al. 2015).  
Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma is highly 
metastatic compared to other head and neck tumors. A study showed that the 
principal EBV oncoprotein, latent membrane protein 1 (LMP1), up-regulates 
Twist1 to induce EMT, suggesting the contribution of Twist1 induction by the 
human viral oncoprotein LMP1 to the highly metastatic nature of 
nasopharyngeal carcinoma (Horikawa et al. 2007).  
Moreover, it was describes that Twist1 form a negative loop with inflammatory 
cytokines, as Twist1 are transcriptionally induced by NF-kB and in turn bind to 
the TNFα (Tumor Necrosis Factor α) and IL1β promoters blocking NF-kB 
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transcriptional activity (Šošić et al. 2003). In a recent paper it was also 
demonstrated that HMGA2 (high mobility group A2) protein in association 
with Smad complex directly associate with A:T rich sequences and promote 
transcription from the Twist1 promoter (Tan et al. 2012). 
miRNAs are endogenous small non-coding RNA that regulate gene 
expression post-transcriptionally by modulating mRNA translation or stability. 
The mammalian Twist1 3’UTRs are highly conserved and contain a number of 
potential regulatory elements including miRNA target sites. Recently, it was 
reported that Twist1 is regulated by miR- 145a-5p, miR-151-5p and miR-337-
3p. All of the miRNAs shown to repress Twist1 expression are involved both 
in embryonic development and cancer (Nairismägi et al. 2013). 
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1.3.5 Downstream effects of Twist1 in human cancers 
 
Twist1 plays an important role in several processes involved in cancer 
progression i.e. cromosomal instability, angiogenesis, invadopodia formation, 
extravasation and metastasis. Twist1 also protects cancer cell from apoptotic 
cell death. In addiction, Twist1 is responsible for the stemness of cancer cells 
and the generation of drug resistance. 
 
Epithelial- to-mesenchymal transition 
 
A crucial mechanism by which tumor cells enhance their invasive 
capacity is the dissolution of intercellular adhesions and the acquisition of a 
more motile mesenchymal phenotype as part of an epithelial- to-mesenchymal 
transition (EMT) (Hanahan and Weinberg 2011). EMT is a critical mechanism 
of migration and invasion during development and in the case of cancer cells is 
a mechanism of increased invasion, metastasis, and resistance to 
chemotherapy. A hallmark of EMT is the functional loss of the protein E-
cadherin encoded by the CDH1 gene (De Craene and Berx 2013). Twist1 has 
been identified as a master regulator of EMT (Ansieau et al. 2010).  
In accordance with its important role in EMT, it was demonstrated that 
Twist1 directly down-regulates the epithelial marker E-cadherin and on the 
other hand up-regulates the mesenchymal marker N-cadherin (Vesuna et al. 
2008). In particular, there is a positive correlation among ZEB1, ZEB2 (E-
cadherin repressors) and Twist1 expression, suggesting the collaboration 
between these proteins to increase the E-cadherin suppression (Neves et al. 
2010). Moreover, it has been demonstrated that Twist1 can interact with 
MTA2, RbAp46, Mi-2 and HDAC2, all these proteins bind to the NuRD 
complex and are necessary to repress E-Cadherin expression and promote 
cancer cell EMT and metastasis. Twist1 can interact with RAS or ErbB2 
proteins to induce EMT (Ansieau et al. 2008). Recent data demonstrated that 
miR-520d-5p promotes a decrease of Twist1, resulting in restoration of E-
Cadherin expression, which in turn results in reduced cellular motility and 
invasiveness (Tsukerman et al. 2014).  
Recent data support an oncogenic feed-forward loop in which 
cytoplasmic p27 promotes EMT and tumor metastasis via STAT3-mediated 
Twist1 up-regulation in breast and bladder models (Zhao et al. 2015). 
In addition, Twist1 activated the integrin α5 promoter by interacting with 
and activating the transcription factor AP-1 (Nam et al. 2015). Integrin α5, a 
fibronectin receptor, is an important mesenchymal marker; its up-regulation is 
required for EMT induction in transformed mammary epithelial cells and in 
melanoma cells (Qian et al. 2005). Recently, the group of Wang reported that 
SOX5 promotes EMT and cell invasion via regulation of Twist1 expression in 
hepatocellular carcinoma (Wang et al. 2015). SOX5 is one member of the SOX 
family of transcription factors that play important roles in the regulation of 
embryonic development in various types of cancers (Schanze et al. 2013). 
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Suppression of apoptosis 
 
Various studies have shown that Twist1 protein negatively regulate the 
p53 pathway at many steps, including p53 stabilization, post-translational 
modifications, DNA binding and trans-activation potential (Pinho et al. 2011).  
Mechanistic investigations revealed that Twist1 exerts its negative effect 
on p53 protein by reducing the expression of the p14ARF tumor suppressor. 
Moreover, Twist1 binds to the C-terminal of p53 through the Twist box and 
facilitates its MDM2-mediated degradation (Piccinin et al. 2012). In addition to 
interfering with p53, Twist1 is positively associated with anti-apoptotic protein 
Bcl-2. Twist1 and Bcl-2 are usually co-expressed in cancer patients in hypoxic 
condition (Zhao et al. 2012). Other results indicated that Twist1 and T-bet 
induce expression of miR-148a. miR-148a regulates expression of the pro-
apoptotic gene Bim, resulting in a decreased Bim/Bcl2 ratio and, thus, leading 
to inhibition of apoptosis (Haftmann et al. 2015). 
 
Stemness of cancer cells  
Recent studies show that the stem cell properties induced by EMT was 
one of reasons for the dismal outcome of ATC (Jung et al. 2015). Beside the 
role of Twist1 in inducing EMT, it was demonstrated that its over-expression 
can promote the formation of cancer stem cells (CSCs) phenotype in breast 
cancer cells, which have the ability of self-renew and resistance to the 
chemotherapy. Notably, Twist1 directly up-regulates Bmi1, a polycomb-group 
protein that maintains stem cell self-renewal and is frequently over-expressed 
in human cancers (Wu et al. 2011). Anticancer molecule, sulforaphane (SNF), 
can eliminate CSC characteristics in pancreatic CSCs and inhibition of Twist1 
expression is one of the mechanisms behind this property of SFN (Srivastava et 
al. 2011). Recent data show that SATB1 (Special AT-rich sequence-binding 
protein1) participates in the maintenance of breast cancer stem cells through 
regulation of the Notch signaling pathway, which promotes up-regulation of 
Twist1 (Sun et al. 2014). Twist1 directly represses CD24 expression through 
the E-box element to increase CD44+/CD24-low cancer stem-like cell population 
in breast cancer cells (Venusa et al. 2009).  
Interestingly, recent data provide that persistent activity of Twist1 
inhibits stem-cell-like properties and the outgrowth of disseminated cancer 
cells into macroscopic metastases, while transient Twist1 activation primes a 
subset of mammary epithelial cells with stem-cell-like properties, which only 
emerge and stably persist following Twist1 deactivation promoting all steps of 
the metastatic cascade (Schmidt et al. 2015). 
 
Angiogenesis 
 
Angiogenesis is the physiological process involved in the growth of new 
blood vessels from preexisting vessels, which is a critical event for cancer 
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metastasis. Twist1 has demonstrated its ability to develop angiogenesis and this 
effect may be through the induction of VEGF-C and VEGFR-3 expression in 
supraglottis carcinomas and in hepatocellular carcinoma (Lu et al. 2011). 
Recent data show that Twist1 recruits stromal macrophages through 
CCL2 induction to promote angiogenesis and tumor progression (Low-
Marchelli et al. 2013).  
Moreover, Twist1 directly activated the cell adhesion protein periostin 
(POSTN), involved in cancer metastasis (Oshima et al. 2002). Twist1 induces 
also PDGFRα (Platelet-derived Growth Factor Receptor α) expression, which 
in turn activates Src, to promote invadopodia formation. Invadopodia are 
specialized membrane protrusions for extracellular matrix degradation (Eckert 
et al. 2011). In addition, Twist1 can promote cancer cell invasion and 
metastasis also by repressing the expression of TIMP1 a key inhibitor of 
MMPs (metalloproteinase) (Okamura et al. 2009). 
 
Inflammation 
 
In addition to its role in embryogenesis, Twist1 has been found to be a 
key regulator in the development of hematopoietic cells and in inflammatory 
processes (Merindol et al. 2014). Šošić et al. first observed that Twist1 
regulates cytokine signaling by establishing a negative feedback loop that 
represses the NF-kB-dependent cytokine pathway (Šošić et al. 2003). Sharif et 
al. then reported the interaction between Type I interferons (IFNs), Twist1, 
NF-kB. IFNs are pleiotropic cytokines and have immune regulatory functions 
by controlling the production of pro-inflammatory cytokines. They found that 
IFNs suppressed the production of TNFα through the regulation of the 
expression of the receptor tyrosine kinase Axl and downstream induction of 
Twist1 (Sharif et al. 2006). Moreover, Twist1 negatively regulates NF-kB-
dependent cytokine production through the regulation of miR-199a, which 
subsequently inhibits IKKβ and therefore NF-kB activity (Yin et al. 2010). 
Moreover, Twist1 also plays an important role in regulating the function and 
differentiation of immune cells, particularly T helper 1 (Th1) cells (Niesner et 
al. 2008). Pham et al. showed that Twist1 decreased IFN-γ production in Th1 
cells by impairing the activity of the Th1 transcription factor network T-bet, 
STAT4, and Runx3. In a subsequent study, they showed that Twist1 was a key 
component of a STAT3-induced feedback loop that controls IL6 signaling 
(Pham et al. 2013). 
 
Drug resistance    
Chemoresistance is a major limitation on the successful treatment of all 
types of cancers. Emerging evidence suggests that Twist1 can cause drug 
resistance or decrease sensitivity to chemotherapy agents. In details, Twist1 is 
responsible for the generation of resistance against chemotherapeutic drug 
Taxol, once considered one of the most effective anticancer drugs against 
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many types of human cancers including bladder, ovarian and prostate cancer; 
in Cisplatin and Doxorubicin-resistant tumor cells, Twist1 is over-expressed 
and by targeting YB-1, acts synergistically enhancing cell growth, invasion, 
motility and drug resistance (Shiota et al. 2008). Moreover, Twist1 up-
regulation, likely induced by NF-kB, was associated with an impaired 
chemotherapeutic-induced programmed cell death (Pham et al. 2007). Finally, 
Twist1 suppression increases etoposide drug response in mouse fibroblast 
(Hosono et al. 2007). 
 
 
 
 
Figure 5: Twist1 signaling. The interaction of Twist1 with different proteins and mechanisms by which 
could acts to promote several cellular reactions as apoptosis, proliferation, EMT, invasion, migration, 
metastasis, drug resistance and stem-cells development is shown (modified from Je, 2013). 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2. AIMS OF THE STUDY 
 
 
The aim of this study was to identify transcriptional targets that mediate Twist1 
biological effects in thyroid cancer cells. 
The specific aims were as follow: 
 
1. Identification of mRNA targets of Twist1 in thyroid cancer cells and 
analysis of the functional consequences of silencing of top up-regulated 
genes on cell proliferation, survival, migration and invasion. 
 
2. Identification of miRNA targets of Twist1 in thyroid cancer cells. In 
particular, we focused on miR-584 induced by Twist1. We investigated 
the role of miR-584 ectopic expression (in TPC negative cells) and of 
miR-584 knockdown (in TPC-Twist1 cells) on cell proliferation, 
migration, invasion and resistance to apoptosis. 
 
Besides Twist1 studies, another project developed during my PhD program 
regarded also the identification of Anterior gradient protein 2 (AGR2), as a 
novel marker of PTC. We showed that AGR2 is up-regulated in PTC and is 
involved in thyroid cancer cells survival, migration and invasion and in 
protection from endoplasmatic reticulum stress (attached manuscript II). 
 
  36 
3. MATERIALS AND METHODS 
 
 
3.1 Reagents 
 
Staurosporine and Doxorubicin were obtained from Sigma-Aldrich (St. 
Louis, MO). 
 
 
3.2 Cell lines 
 
The human papillary thyroid cancer cells, TPC-1 (named TPC) were 
obtained from M. Nagao (Carcinogenesis Division, National Cancer Center 
Research Institute, Tokyo, Japan). The TPC cell line was identified on the basis 
of the unique presence of the RET/PTC1 rearrangement. CAL62 was 
purchased from DSMZ (Deutsche Sammlung von Mikroorganismen und 
Zellkulturen GmbH, Germany). CAL62 cells were DNA profiled by short 
tandem repeats analysis in 2009 and shown to be unique and identical with 
those reported in Schweppe et al (Schweppe et al. 2008). The TPC-Twist1 cell 
lines (mp1, mp2, and Cl2) and the CAL62 shTwist1 cells were generated and 
characterized as described in Salerno et al, 2011 (Salerno et al. 2011). The 
thyroid cancer cell lines were grown in DMEM (Dulbecco's Modified Eagle 
Medium, Invitrogen) containing 10% FBS (fetal bovine serum), L-glutamine 
and penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA). 
 
 
3.3 Tissue samples 
 
Tumors and normal thyroid tissue samples for immunohistochemical 
analysis, RNA extraction and quantitative RT-PCR were retrieved from the 
files of the Department of Surgery, University of Pisa (Italy). Case selection 
was based on the histological findings and on the availability of adequate 
material for RNA extraction. PDC were defined as malignant tumors of 
follicular cells displaying predominant solid/trabecular/insular growth patterns, 
high grade features such as mitoses (more than three to five mitoses x10 high 
power field) and/or necrosis and convoluted nuclei, with or without concurrent 
differentiated components of the follicular or papillary type. ATC were defined 
as tumors displaying admixtures of spindle, pleomorphic giant, and epithelioid 
cells; high mitotic activity; extensive coagulative necrosis with irregular 
borders; and infiltration of vascular walls often accompanied by obliteration of 
the vascular lumina. Processing of samples and of patient information 
proceeded in agreement with review board-approved protocols.   
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3.4 Immunohistochemistry 
 
Formalin-fixed and paraffin-embedded 3- to 5 µm-thick tumor sections 
were deparaffinized, placed in a solution of absolute methanol and 0.3% 
hydrogen peroxide for 30 min, and treated with blocking serum for 20 min. 
The slides of tumor sections were incubated with a rabbit polyclonal antibody 
against TUSC2 (Proteintech, Chicago, USA) and processed according to 
standard procedures. Cases were scored as positive when unequivocal brown 
staining was observed in the nuclei of tumor cells. Immunoreactivity was 
expressed as the percentage of positively stained cells and scored in four 
intensity categories (-, no staining; +, low/weak; ++ moderate; +++, high/ 
intense).   
 
 
3.5 Microarray analysis 
 
 Total RNA from TPC-Twist1 cells (Twist1 mp1, Twist1 mp2, Twist1 
Cl2) and pcDNA control cells was transcribed into cDNA using Superscript 
RT (Invitrogen, Carlsbad, CA, USA), in the presence of T7-oligo (dT) 24 
primer, deoxyribonucleoside triphosphates (dNTPs), and T7 RNA polymerase 
promoter (Invitrogen, Carlsbad, CA, USA). An in vitro transcription reaction 
was then performed to generate biotinylated cRNA which, after fragmentation, 
was used in a hybridization assay on Affymetrix U133 plus 2.0 GeneChip 
microarrays, according to manufacturer's protocol (GeneChip 3' ivt Express 
Kit, Affymetrix). Normalization was performed by global scaling and analysis 
of differential expression was performed by Microarray Suite software 5.0 
(Affymetrix).  
miRNome array was performed using the TaqMan LDA cards. The 
TaqMan Array Human MicroRNA Card Set v3.0 consist of two card set 
containing a total of 384 TaqMan MicroRNA Assays per card.  
Both screening were conducted at Aarhus Biotechnology (Aarhus, 
Denmark). The final results were imported into Microsoft Excel (Microsoft).    
 
 
3.6 Network and gene ontology analysis 
 
For functional analysis, the set of input genes (158 up-regulated and 221 
down-regulated genes) were uploaded into the Ingenuity Pathway Analysis 
(IPA) online tool (Ingenuity System Inc, www.ingenuity.com). IPA is a system 
that transforms large data sets into a group of relevant networks biological 
processes, and pathways, containing direct or indirect relationships between 
genes based on known interactions in the literature and in the experimental 
studies. IPA computes a score for each biological process according to the fit 
of the user's set of significant genes. The score indicates the likelihood of the 
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genes in a biological process from the Ingenuity knowledge base being found 
together due to random chance.  
 
 
3.7 RNA extraction, cDNA synthesis, and quantitative real-time PCR 
 
RNA was isolated using the mirVanaTM miRNA Isolation Kit (Ambion, 
Austin, TX, USA) according to the manufacturer’s instructions. The purity and 
quantity of RNA were assessed using the NanoDrop spectrophotometer 
(Thermo Scientific, Wilmington, DE, USA). The quality of the RNAs was 
verified by the 2100 Bioanalyzer (Agilent Techonologies, Waldbronn, 
Germany). Only samples with RNA integrity number (RIN) value > 7 were 
used for further analysis.  
miRNA expression levels were measured using specific primers and 
probes (Thermo Scientific, Waltham, MA, USA). Briefly, for miRNA 
detection, 10 ng of total RNA were reverse transcribed using a miRNA 
Reverse Transcription Kit (Thermo Scientific, Waltham, MA, USA), followed 
by amplification using a TaqMan Universal Master Mix II (Thermo Scientific, 
Waltham, MA, USA). U6 snRNA was used as an endogenous control.  
mRNA expression levels were measured by quantitative PCR assay, 
using the Universal ProbeLibray Set, Human (Roche, Basel, Switzerland). PCR 
reactions were performed in triplicate and fold changes were calculated with 
the formula: 2-(sample 1 ΔCt - sample 2 ΔCt), where ΔCt is the difference between the 
amplification fluorescent thresholds of the mRNA of interest and the mRNA of 
RNA polymerase 2 used as an internal reference. The primers used were 
reported the attached manuscript II. 
mRNA expression levels of TUSC2 and β-Actin were measured by 
quantitative PCR assay, using specific primers and probes and TaqMan 
Universal PCR Master Mix (Thermo Scientific, Waltham, MA, USA). 
 
 
3.8 RNA silencing  
TPC-Twist1 and CAL62 cells were transfected with the specific small 
interfering RNAs (siRNAs) (QIAGEN) in 6-well plates in triplicate. siRNA 
and the protocol of transfection are described in the attached manuscript I. 
 
 
3.9 Cell Proliferation Assays 
 
5x104 cells were plated in a 6-well. Cells were kept in DMEM 
supplemented with 10% fetal bovine serum. The day after plating, compounds 
were added. To estimate IC50 value, cells were counted after 24 or 48 hours 
with TC10TM Automated Cell Counter (Biorad, Richmond, VA, USA).  
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3.10 Transwell and Collagen Cell Migration Assay, Collagen Cell Invasion 
Assay, Transendothelial Cell Migration Assay 
 
The procedures to perform these experiments are described in detail in 
the attached manuscript I.  
 
 
3.11 Chromatin immunoprecipitation assay 
 
Chromatin samples were processed for chromatin immunoprecipitation 
(ChIP) as reported in detail in the attached manuscript I. All quantitative ChIP 
data were derived from at least three independent experiments, and for each 
experiment, q-RT-PCR was performed in triplicate. The GAPDH promoter 
amplicon was used as a negative control. 
 
 
3.12 miR-584 transfection 
 
The miR-584 precursor construct expressing pre-miR-584, pEP-has-miR-
584 and the corresponding empty vector were purchased at Cell Biolabs (San 
Diego, USA).  
For miRNA inhibition, hsa-miR-584 inhibitor and control vector were 
purchased at GeneCopoeia (Nivelles, Belgium).  
The day of transfection, 1x105 cells were incubated with 50 nmol/ml of 
plasmid (pEP-has-miR-584 or hsa-miR-584 inhibitor) or with their respective 
control and transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, 
USA) according to the manufacturer’s instructions. Mass population was 
selected in Puromicyn (1 mg/ml) 48h after transfection and analyzed for miR-
584 expression. 
 
 
3.13 Wound Closure Assay and Matrigel Invasion assay 
 
A wound was induced on the confluent monolayer cells by scraping a 
gap using a micropipette tip after 48h of transfection with specific siRNA. 
Photographs were taken at 10 X magnification using phase-contrast 
microscopy immediately after wound incision and 24h later. Pixel densities in 
the wound areas was measured using the Cella software (Olympus Biosystem 
Gmb) and expressed as percentage of wound closure where 100 % is the value 
obtained at 24h for control cells.  
Cell invasion was examined using a reconstituted extracellular matrix 
(Matrigel, BD Biosciences, San Jose, CA). The cell suspension (1 x 105 cells 
per well) was resuspended in serum free culture medium (100 μl) and loaded 
onto the upper chamber of transwell cell culture chambers on a prehydrated 
polycarbonate membrane filter of 8-μm pore size (Costar, Cambridge, MA) 
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coated with 35 μg of Matrigel (BD Biosciences, San Jose, CA). The lower 
chamber was filled with 2.5% medium (500 µl). After 24-h incubation at 37°C, 
non-migrating cells on the upper side of the filter were wiped-off. Invading 
cells were stained and quantified at OD 570 nm after color extraction, in 
triplicate. 
  
3.14 Protein studies 
 
Immunoblotting was carried out according to standard procedures. 
TUSC2 (1538-1AP) antibody was from Proteintech (Chicago, IL, USA), 
monoclonal anti-α-Tubulin antibody was from Sigma-Aldrich (St. Louis, MO); 
Secondary anti-mouse and anti-rabbit antibodies coupled to horseradish 
peroxidase were from Santa Cruz Biotechnology. 
 
 
3.15 Luciferase Assay 
 
TPC miR-584 cells were seeded into a 96-well plate (103 cells per well) 
and cultured for 24 hours. The pLightswitch 3’UTR reporter gene plasmid 
(pLightswitch-TUSC2-3’UTR or pLightswitch-Empty-3’UTR) were 
transfected into the cells using the FuGENE Transfection Reagent (Roche, 
Basel, Switzerland) according to the manufacturer's protocol. Luciferase 
activity was measured 24 hours after transfection using the LightSwitch 
Luciferase Assay reagent (SwitchGear Genomics, CA) according to the 
manufacturer's protocol. 
The primers used to generate the mutant pLuc TUSC2-3’UTR del were: 
TUSC2-3’UTR del forward 5’- GGGACTGTTCACCACCTTGT- 3’ 
TUSC2-3’UTR del reverse 5’- CCCAAGCCATTTCCCACATT-3’. 
 
 
3.16 Statistical analysis 
 
Data are presented as mean ± SD. Two-tailed paired Student’s t test (normal 
distributions and equal variances) was used for statistical analysis. Differences 
were significant when P < 0.05. Statistical analyses were carried out using the 
GraphPad InStat software program version 3.1a (San Diego, CA). 
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4. RESULTS 
 
 
4.1 Identification of mRNA targets of Twist1 
 
4.1.1 mRNA expression profile of TPC-Twist1 cells 
 
We used cDNA microarrays to characterize the gene expression profile 
of ATC compared with PTC and normal thyroid tissue samples. Among the 
genes differentially expressed in undifferentiated vs differentiated samples, we 
isolated the transcription factor Twist1 as a gene up-regulated in ATC cells 
(Salvatore et al. 2007). We showed that ∼50% of ATCs up-regulated Twist1, 
both at mRNA and protein level, compared to normal thyroids as well as to 
well-differentiated and poorly-differentiated thyroid carcinoma. Silencing of 
Twist1, by RNA interference, impaired cell migration and invasion in the ATC 
cell lines CAL62 and increased sensitivity to apoptosis. On the contrary, 
ectopic expression of Twist1 in the papillary thyroid cancer cells (TPC) 
induced resistance to apoptosis and increased cell migration and invasion 
(Salerno et al. 2011).  
Despite the growing literature on the role of Twist1 in cancer 
progression, through which target genes Twist1 exerts its functions remains 
elusive. In this dissertation we aim to identify transcriptional targets of Twist1. 
Thus, we analyzed gene expression profiles of TPC-Twist1 in 
comparison with control cells (TPC-pcDNA). Total RNA extracted from three 
TPC-Twist1 stable transfectants  (mp1, mp2, and Cl2) and vector control cells 
was analyzed using human Genome U133 Plus 2.0 Array GeneChips 
(Affymetrix) containing > 47 000 gene transcripts. We sorted only the genes 
that were changed in all three Twist1 transfectants compared with vector 
control cells. We found 158 genes up-regulated and 221 down-regulated by ∼  
1.5-fold in TPC-Twist1 cells compared with control cells (data are described in 
detail in the attached manuscript I). Consistent with the role of Twist1 in ATC, 
the top three molecular and cellular bio functions enriched in TPC-Twist1 cells 
were: i) cellular movement, ii) cellular growth and proliferation, iii) cell death 
and survival. In details 53.6% of the genes (203 of 379) belonged to cellular 
movement, cellular growth and proliferation, and cell death and survival, 
17.6% (67 of 379) belonged to other top categories involved mainly to cancer 
(cellular assembly and organization; cellular function and maintenance), and 
28.7% (109 of 379) were not classified (Figure 6). There wasn’t any difference 
in the distribution in the different groups among up-regulated and down-
regulated genes (data not shown). 
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Figure 6. Graphic representation of Twist1 target genes classified by Ingenuity Pathways 
Analysis. The number of the genes is reported on y axis. 
 
 
 
We performed q-RT-PCR of the top 16 up-regulated genes in the cell 
lines used in the screening in comparison with vector control cells. As shown 
in Figure 7, q-RT-PCR confirmed the microarray screening, albeit with some 
variability in the different Twist1 clones.  
 
  43 
 
Figure 7. Expression levels of Twist1 targets in TPC transfected cells. q-RT-PCR of the 
indicated genes in TPC-Twist1 cells in comparison to vector control cells (pcDNA mp). Values 
represent the average of triplicate experiments ± standard deviations. Asterisks indicate p < 
0.001 (***). 
 
 
 
To confirm that Twist1 transcriptionally regulates the identified genes, 
we studied whether silencing of Twist1 affected their expression levels. Thus, 
we performed q-RT-PCR of the top up-regulated genes in the CAL62 (ATC) 
cell line stably transfected with shTwist1 plasmid. The CAL62 cell line 
presents a high endogenous level of Twist1 (Salerno et al. 2011), and in 
CAL62-shTwist1 cells, Twist1 mRNA was down-regulated ∼2-fold (Salerno et 
al. 2011). Transfection of CAL62 with a Twist1 short hairpin RNA blunted 
expression of up-regulated genes with respect to the control cell (data not 
shown, see attached manuscript I).  
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4.1.2 Silencing of Twist1-upregulated genes in TPC-Twist1 and in CAL62 
cells impairs cell viability   
 
Ten of the top up-regulated genes (∼70%) belong to the categories 
cellular movement, cellular growth and proliferation and cell death and 
survival. Focusing on these genes (Table 3), TPC-Twist1 and CAL62 cells 
were transiently transfected with siRNAs for HS6ST2, COL1A1, KRT7, 
F2RL1, LEPREL1, THRB, ID4, RHOB, PDZK1, PDZK1IP1, or a scrambled 
siRNA and examined at 48 and 72 hours after transfection for cell viability 
using a trypan blue assay. 
 
 
 
Table 3. List of top 10 up-regulated genes by Twist1 in TPC cells.  
Gene Fold change Molecular and Cellular Bio function 
HS6ST2 10.28 Cellular growth and proliferation 
COL1A1 7.22 Cellular growth and proliferation, cell death and survival, 
cellular movement 
KRT7 5.56 Cellular growth and proliferation, cellular movement 
F2RL1 5.31 Cellular growth and proliferation, cell death and survival, 
cellular movement 
LEPREL1 4.99 Cellular growth and proliferation 
THRB 4.88 Cellular growth and proliferation, cellular movement 
ID4 4.33 Cellular growth and proliferation cell death and survival 
RHOB 4.13 Cellular growth and proliferation cell death and survival, 
cellular movement 
PDZK1 3.99 Cellular growth and proliferation cell death and survival 
PDZK1IP1 2.90 Cellular growth and proliferation 
  
 
 
As shown in Figure 8, transient silencing of all 10 genes decreased cell 
number in TPC-Twist1 (Figure 8A) and in CAL62 (Figure 8B) cells at 
different time points. Silencing of COL1A1, KRT7, and PDZK1 also increased 
the cell death rate (in particular at 72 hours after transfection).  
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Figure 8. Silencing of the top up-regulated genes impairs cell viability. TPC-Twist1 and 
CAL62 cell lines were transfected with the indicated siRNAs or scrambled siRNA; after 48 
and 72 hours, cells were collected by trypsinization, stained for 10 minutes with trypan blue, 
and counted; black bars represent the viable cells, and white bars represent the dead cells. 
 
 
 
As a control, transfection of the 10 siRNAs efficiently down-regulated 
the specific genes, albeit with some variability (data not shown, see attached 
manuscript I).   
 
 
 
4.1.3 Silencing of HS6ST2, THRB, ID4, RHOB, and PDZK1IP1 in TPC-
Twist1 and in CAL62 cells impairs cell migration and invasion  
 
Twist1 increases the migration ability of TPC cells, whereas Twist1 
knockdown in CAL62 cells decreases cell migration (Salerno et al. 2011). We 
selected HS6ST2, THRB, ID4, RHOB and PDZK1IP1 because silencing of 
these genes affected the cell viability to a lower extent than silencing of other 
target genes and, thus there were a sufficient number of surviving cells 
available for further analysis (Figures 8A and B). A scraped wound was 
introduced on the confluent monolayer of TPC-Twist1 and CAL62 cells 
transfected with specific siRNAs or scrambled siRNA, and the cell migration 
into the wound was monitored after 24 hours. TPC-Twist1 and CAL62 cells 
transfected with the scrambled control efficiently migrated into the wound; by 
contrast, cells transfected with HS6ST2, THRB, ID4, RHOB, and PDZK1IP1 
siRNAs displayed reduced migrating ability. This phenomenon was 
particularly evident with siRNA of RHOB or PDZK1IP1 (Figure 9A). 
To better characterize this effect, we performed a Transwell migration 
assay. As shown in Figure 9B silencing of HS6ST2, THRB, ID4, RHOB, and 
PDZK1IP1 reduced the number of migrated cells in the Transwell. 
Twist1 increased (∼ 2-fold) the ability of TPC cells to migrate into 
Collagen I matrix whereas Twist1 knockdown in CAL62 cells decreased cell 
migration into Collagen I matrix (data not shown, see attached manuscript I). 
Thus, we asked whether silencing of HS6ST2, THRB, ID4, RHOB and 
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PDZK1IP1 affected this ability. As shown in Figure 9C, TPC-Twist1 and 
CAL62 cells transfected with HS6ST2, THRB, ID4, RHOB and PDZK1IP1 
siRNA presented a decreased ability to migrate into Collagen I matrix 
compared with siRNA scrambled transfected cells 
 
 
 
 
Figure 9. Silencing of the indicated genes reduces the migration ability of TPC-Twist1 
and CAL62 cells. A. Cells were transfected with specific siRNAs, and 48 hours after 
transfection, scratch wounds were inflicted on the confluent cell monolayer. After 24 hours, 
cells were photographed. Wound closure was measured by calculating pixel densities in the 
wound area and expressed as percentage of wound closure of triplicate areas ±SDs. B. TPC-
Twist and CAL62 cells were transfected with specific siRNAs or scrambled control, and 48 
hours after transfection, cells were seeded in the upper chambers of Transwells, allowed to 
migrate. Migration ability is expressed as absorbance at OD 570 nm. Values represent the 
average of triplicate experiments ±SDs. C. TPC-Twist1 and CAL62 transfected cells were 
seeded onto the insert coated with Collagen I, left to migrate. Migration ability in Collagen I is 
expressed as absorbance at OD 570 nm. Values represent the average of triplicate experiments 
±SDs.   
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We evaluated cell invasion in Collagen I matrix. Silencing of HS6ST2, 
THRB, ID4, RHOB and PDZK1IP1 reduced this ability compared with cells 
transfected with scrambled siRNA (Figure 10A). We, then, evaluated cell 
invasion in Matrigel matrix. Twist1 increased the invasion ability of TPC cells 
∼5-fold in Matrigel, whereas Twist1 knockdown in CAL62 cells decreased cell 
invasion in Matrigel (Salerno et al. 2011). TPC-Twist1 and CAL62 cells 
transfected with HS6ST2, THRB, ID4, RHOB and PDZK1IP1 siRNA 
presented a reduced ability to invade Matrigel compared with siRNA 
scrambled transfected cells. In particular, the silencing of RHOB and 
PDZK1IP1 induced a reduction of ∼86% and ∼84% in TPC-Twist1 and of ∼ 
59% and ∼ 56% in CAL62 cells respectively, of invasion ability assessed by 
counting the number of invaded cells in 3 different fields (Figure 10B). 
Finally, we studied the cell ability to penetrate into the endothelium by a 
trans-endothelial cell migration assay. TPC-Twist1 cells presented an increased 
ability to migrate through endothelial cells compared with control cells, 
whereas CAL62 shTwist1 presented a reduced ability to migrate through 
endothelial cells compared with control (data not shown, see attached 
manuscript I). As shown in Figure 10C, TPC-Twist1 and CAL62 cells 
transfected with HS6ST2, THRB, ID4, RHOB, and PDZK1IP1 siRNA 
presented a decrease in the trans-endothelial cell migration ability compared 
with cells transfected with scrambled siRNA. 
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Figure 10. Silencing of the indicated genes reduces the invasion ability of TPC-Twist1 and 
CAL62 cells. A. TPC-Twist1 and CAL62 transfected cells were seeded in the upper chamber 
of Transwells coated with Collagen I matrix and incubated for 24 hours (TPC-Twist1) or 48 
hours (CAL62). The invasive ability in Collagen I is expressed as absorbance at OD 570 nm. 
B. TPC-Twist1 and CAL62 transfected cells were seeded in the upper chambers of Transwells 
coated with Matrigel and incubated; the upper surface of the filter was wiped clean and cells on 
the lower surface were stained and counted. The invasive ability in Matrigel matrix is 
expressed as number of invaded cells. C. TPC-Twist1 and CAL62 transfected cells were 
seeded on a confluent monolayer of endothelial human umbilical vein endothelial cells 
(HUVECs) and left to migrate. Migration ability through HUVECs is expressed as absorbance 
at OD 570 nm. Values represent the average of triplicate experiments ±SDs. 
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4.1.4 Twist1 directly binds the promoter of target genes 
 
To formally prove that the identified genes are direct Twist1 targets, we 
verified whether Twist1 binds to their promoters. Consensus binding sites for 
Twist1 are represented by an E-box (5’-CANNTG-3’) sequence motif (Qin et 
al. 2012). In the promoter of all 10 up-regulated genes, we found several E-box 
sequences (Figure 11). 
 
 
 
 
Figure 11. Twist1 directly binds the promoter of the indicated genes. Schematic 
representation of the E-box consensus sequences (CANNTG) in the promoter regions of the 
top ten up-regulated genes. In black are reported the E-box amplified in ChIP assay. 
 
 
 
Thus, DNA-chromatin complexes from TPC-pcDNA and TPC-Twist1 
were subjected to immunoprecipitation (IP) with Twist1 antibody or with 
control antibody (IgG1). As shown in Figure 12, promoter regions of all 10 up-
regulated genes were significantly enriched by Twist1 IP in TPC-Twist1 cells 
compared with TPC-pcDNA cells. Conversely, no amplification was observed 
with anti-IgG precipitates and when primers for the GAPDH promoter were 
used. This corroborates the notion that the top up-regulated genes are direct 
Twist1 targets. 
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Figure 12. Twist1 directly binds the promoter of target genes. ChIP assay followed by q-
RT-PCR was performed on TPC-Twist1 and TPC-pcDNA cells. Equal amounts of proteins 
were subjected to IP with anti-Twist1 antibody or IgG1 antibody, as indicated. The GAPDH 
promoter amplicon was used as a negative control. Columns represent the average of 3 
independent experiments ±SDs. 
 
 
 
4.1.5 Twist1 target genes are over-expressed in PTC, PDC, and ATC 
samples   
 
Finally, to assess the role of the identified Twist1 targets in thyroid 
carcinogenesis we performed a q-RT-PCR on a set of normal thyroid (n = 9), 
PTC (n = 9), PDC (n = 8), and ATC (n = 12) samples. As shown in Figure 13, 
HS6ST2, COL1A1, F2RL1, LEPREL1, PDZK1, and PDZK1IP1 are 
differentially over-expressed in PTC, PDC, and ATC samples. The expression 
levels of KRT7, THRB, ID4, and RHOB were not significantly altered in 
thyroid carcinomas compared with normal thyroid samples (not shown). To 
verify these data at the protein level, we performed immunohistochemistry 
studies for leprecan-like 1 (LEPREL1) in a panel of normal thyroid (n = 27), 
PTC (n = 19), and ATC (n = 40) samples. LEPREL1 is over-expressed in 26% 
of PTC (5 of 19) and in 67% of ATC (27 of 40) samples in comparison with 
normal thyroids (attached manuscript I). 
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 Figure 13. Expression of Twist1 targets in thyroid tissue samples. q-RT-PCR of the 
indicated genes in normal thyroids (NT) (n = 9), PTC (n = 9), PDC (n = 8), and ATC (n = 12) 
snap-frozen tissues. The expression levels of genes in each sample were measured by 
comparing its fluorescence threshold with the average fluorescence threshold of the NT 
samples. The average results of triplicate samples are plotted ± SDs.
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 4.2 Identification of Twist1 target miRNAs 
 
 
4.2.1 miRNome profiles of TPC-Twist1 cells 
 
Recently, deregulation of miRNAs has been implicated in tumorigenesis 
and cancer progression. Deregulation of miRNA expression is also detected in 
thyroid cancer (Fuziwara et al. 2014). Twist1 regulated miRNA are poorly 
characterized thus to further dissect the molecular mechanisms through which 
Twist1 exerts its biological effects in thyroid cancers cells we aimed to identify 
Twist1 regulated miRNAs. We screened the miRNome profiles of TPC-Twist1 
cells (mp1, mp2 and Cl2) in comparison to control (TPC pcDNA). Fifty-one 
miRNAs (14 up-regulated and 37 down-regulated) were differentially 
expressed in all the three TPC-Twist1 cells clones by more than 2 fold 
compared to vector control (Tables 4 and 5). 
 
 
Table 4. miRNAs up-regulated in TPC-Twist1 cells. 
 pcDNA Twist1 mp1 Twist1 mp2 Twist1 Cl2 
miRNA  Ct Ct Fold Change Ct 
Fold 
Change Ct 
Fold 
Change 
hsa-mir-597 38.4 32.1 81.4 31.9 92.9 32.0 89.3 
hsa-mir-29b-2* 38.8 32.9 61.6 32.6 74.7 32.5 78.1 
hsa-mir-145 35.4 30.8 24.2 32.3 8.4 31.3 17.2 
hsa-mir-584 38.5 35.1 10.1 31.6 116.9 32.4 68.2 
hsa-mir-30c-2* 35.9 32.6 10.0 32.3 12 29.6 78.5 
hsa-mir-519b-3p 38.2 35.2 7.9 36.4 3.3 34.9 9.8 
hsa-mir-133a 37.1 34.2 7.2 35 4.1 37.2 1.1 
hsa-mir-101 37 34.3 6.6 34.7 4.9 34.1 7.5 
hsa-mir-501-5p 35.2 32.8 5.2 30.9 19 32.7 5.6 
hsa-mir-650 35.3 33.5 3.6 34.5 1.8 34 2.5 
hsa-mir-639 35.8 34.3 2.8 33.8 3.9 33.7 4.3 
hsa-mir-190b 33.6 32.1 2.7 32.4 2.2 31.5 4.4 
hsa-mir-500 31.4 30 2.7 30.3 2.2 29.4 3.9 
hsa-mir-99a* 32.5 31.4 2.1 29.3 9 30.6 3.6 
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Table 5. miRNAs down-regulated in TPC-Twist1 cells. 
 pcDNA Twist1 mp1 Twist1 mp2 Twist1 Cl2 
miRNA Ct Ct Fold Change Ct 
Fold 
Change Ct 
Fold 
Change 
hsa-mir-326 33.6 38 21.3 37.5 14.6 und  
hsa-mir-124 34.2 38 14.2 34.7 1.4 36.1 3.7 
hsa-mir-604 35.8 39.5 12.3 und  36.2 1.2 
hsa-mir-222* 34.6 38 10.5 35.6 2 38.9 19.8 
hsa-mir-190 33.5 36.9 10.1 34.3 1.7 34.3 1.8 
hsa-mir-519a 31.2 34.3 9.2 31.2 1 32.2 2.1 
hsa-mir-770-5p 35.6 38.8 9.2 37.2 3.1 37.6 3.9 
hsa-mir-576-3p 33.4 36.1 6.6 33.8 1.3 33.8 1.4 
hsa-mir-202 32.4 34.9 5.5 33.6 2.4 34.1 3.2 
hsa-mir-301b 33.1 35.5 5.3 33.2 1 34.1 2 
hsa-mir-449a 36.0 33.6 5.3 35.1 2 34.7 2.6 
hsa-mir-551b* 31.5 33.8 4.9 32.9 2.8 34.6 8.6 
hsa-mir-15b*  28.9 31.2 4.9 30.1 2.3 29.9 2.1 
hsa-mir-30d* 33.2 35.4 4.6 37.0 14.1 33.9 1.6 
hsa-mir-20a* 32.0 34.1 4.2 32.0 1.0 35.4 10.4 
hsa-mir-572 31.3 33.3 4.0 32.5 2.3 31.1 1.2 
hsa-mir-148b* 32.0 33.9 3.7 34.0 3.9 32.6 1.5 
hsa-mir-363 35.7 37.6 3.7 38.9 9.0 Und  
hsa-mir-200c 29.4 31.3 3.6 30.4 2.0 32.8 10.1 
hsa-mir-100* 30.5 32.3 3.6 31.8 2.4 33.2 6.6 
hsa-mir-301a 30.8 32.7 3.6 31.4 1.5 34.9 17.3 
hsa-mir-331-5p 31.8 33.6 3.5 33.7 3.8 33.2 2.6 
hsa-mir-215 29.5 31.2 3.5 30.2 1.7 33.1 12.8 
hsa-mir-639 34.2 36.0 3.4 34.1 1.1 33.3 1.9 
hsa-mir-206 31.7 33.4 3.3 32.6 1.9 31.9 1.2 
hsa-mir-572 31.0 32.7 3.2 31.4 1.3 31.6 1.6 
hsa-mir-622 33.3 34.8 3.0 34.3 2.0 35.9 6.4 
hsa-mir-432* 29.1 30.6 2.7 29.8 1.6 30.5 2.6 
hsa-mir-505 31.4 32.8 2.7 31.6 1.2 32.8 2.7 
hsa-mir-26a-1* 31.0 32.4 2.7 31.4 1.3 31.0 1.0 
hsa-mir-888 37.0 38.3 2.5 37.8 1.8 38.5 2.9 
hsa-mir-135b 26.0 27.2 2.3 25.8 1.1 28.2 4.5 
hsa-mir-194 27.6 28.7 2.3 28.3 1.6 29.6 4.1 
hsa-mir-636 31.6 32.7 2.2 31.7 1.1 32.2 1.6 
hsa-mir-340 29.6 30.7 2.1 31.0 2.5 30.7 2.1 
hsa-mir-218 30.4 31.4 2.1 30.7 1.3 32.4 4.1 
hsa-mir-184 31.9 32.9 2.1 33.7 3.6 36.4 22.8 
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Initially, we verified the microarray results by q-RT-PCR of the 10 top (5 
up and 5 down) changed miRNAs in TPC-Twist1 cells in comparison to 
control. We confirmed ∼80% of the deregulated miRNAs (Figure 14). The 
expression of miR-124 and miR-190 did not change in TPC-Twist1 cells 
respect to control cells (data not shown). 
 
 
 
  
 
Figure 14. Relative expression levels of the indicated miRNAs in TPC-Twist1 cells. 
Quantitative-RT-PCR of the indicated miRNAs in TPC-Twist1 cells in comparison to vector 
control cells. Samples were normalized using U6 snRNA measurement. Average results of three 
independent experiments were reported and expressed as fold change compared to control cells 
± SD. 
 
 
 
4.2.2 miR-584 is up-regulated in ATC samples  
 
We then focused on miR-584 because it was one of the most up-
regulated in TPC-Twist1 cells respect to the control cells and because its role 
in cancer is poorly studied.  
We measured miR-584 by q-RT-PCR on total RNA extracted from 7 
normal thyroid (NT), 6 papillary thyroid carcinoma (PTC), and 5 anaplastic 
thyroid carcinoma (ATC) tissues samples. As illustrated in Figure 15, all ATC 
samples showed a significant higher expression of miR-584 compared to 
normal thyroid and PTC samples, with a fold change values ranging from 2 to 
7 fold.  
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Figure 15. Expression of miR-584 in thyroid tissue samples. Quantitative RT-PCR analysis 
of miR-584 in normal thyroid (NT), PTC, and ATC snap-frozen tissue samples. The level of 
miR-584 in each sample was measured by comparing its fluorescence threshold with the 
average fluorescence threshold of the NT samples. The average results of triplicate samples are 
plotted. 
 
 
 
4.2.3 Ectopic expression of miR-584 protects TPC cells from apoptosis  
 
We previously showed that Twist1 sustains the invasive and motile 
phenotype of ATC cells (Salerno et al. 2011). Therefore, we investigated 
whether miR-584 could be, at least partially, responsible for these effects.  
To these aim, TPC cells, which have low endogenous level of miR-584, 
were stably transfected with the precursor of miR-584 or with the empty vector 
(null) as control. Quantitive-RT-PCR confirmed that miR-584 was increased in 
a selected mass population of TPC-transfected cells compared to control cells 
(Figure 16). 
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Figure 16. miR-584 expression level was measured by q-RT-PCR in TPC cells after stable 
transfection. Results are reported as fold change in comparison with the control. Values 
represent the average of triplicate experiments ± SDs. 
 
 
 
We performed a wound-closure assay, by introducing a scraped wound 
on a confluent monolayer of TPC miR-584 or control cells and cell migration 
into the wound was monitored after 12 and 24 hours. As shown in Figure 17A, 
miR-584 over-expression did not affect the motility rate of TPC cells, indeed 
after 24 hours both cell lines equally closed the wound. Moreover, we 
performed a Matrigel invasion assay, TPC miR-584 and control cells were 
seeded into the top chamber of Transwells and their ability to invade into the 
matrix were evaluated after 24 hours. No difference in cell invasion ability was 
observed in TPC miR-584 cells compared with control (Figure 17B). Finally, 
we asked whether miR-584 forced expression affects cell proliferation rate. 
TPC cells, with or without miR-584, were seeded at a density of 5x104 cells 
and counted every 24 hours for 96 hours. Four days after plating, TPC miR-
584 cells were 8.6 x 105 while TPC miR-null were 8.4 x 105. Thus miR-584 
forced expression did not affect cellular proliferation (Figure 17C). 
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Figure 17. Effects of miR-584 expression in TPC cells on cell migration, invasion and 
proliferation. A. Scratch wounds were inflicted at confluent cell monolayer and after 12 and 
24h cells were photographed. B. TPC miR-584 and TPC miR-null were seeded in upper 
chamber of Transwells and allowed to migrate for 24h; migration ability was expressed as 
absorbance at OD 570 nm. C. TPC miR-584 and TPC miR-null cells were plated and counted 
at different time points. Values represent the average of triplicate experiments. Values 
represent the average of triplicate experiments ± standard deviations. 
 
  58 
Then, we investigated whether over-expression of miR-584 affects 
sensitivity to apoptosis, since Twist1 is an anti-apoptotic factor. 
To this purpose, we used two different inducers of apoptosis Doxorubicin 
and Staurosporine. TPC miR-584 and control cells were treated with different 
doses of Doxorubicin (ranging from 10 nM to 3000 nM) or Staurosporine 
(ranging from 20 nM to 1500 nM) and counted after 48 and 24 hours, 
respectively. The growth-inhibitory concentration 50% (IC50) of Doxorubicin 
in TPC miR-null cells was 8.9 nM while in TPC miR-584 cells was 48 nM 
(Figure 18A). Similarly, miR-584 expression induced a reduction of sensitivity 
to Staurosporine in TPC cells, with an IC50 of 123 nM in TPC miR-null cells 
and of 334 nM in TPC miR-584 cells (Figure 18B).  
 
 
 
 
Figure 18. IC50 of Doxorubicin (A) and Staurosporine (B) in TPC cells transfected with or 
without miR-584. A. TPC-transfected cells were treated with increasing concentrations of 
Doxorubicin and counted 48 hours after treatment. B) TPC-transfected cells were treated with 
increasing concentrations of Staurosporine and counted 24 hours after treatment. Average of 
three independent experiments ± SD were represented. IC50 values were calculated with Prism 
software. 
 
 
 
4.2.4 Silencing of miR-584 in TPC-Twist1 cells induces apoptosis  
 
Furthermore, we silenced miR-584 in TPC-Twist1 cells by using a vector 
containing an Anti-miR-584, a chemically modified single-stranded nucleic 
acid, designed to specifically bind and inhibit endogenous miRNAs molecules. 
After antibiotic selection, cells were screened by q-RT-PCR for miR-584 
expression. A mass population (TPC-Twist1 Anti-miR-584) with a miR-584 
knockdown of ∼50% was used for further study (Figure 19). 
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Figure 19. Silencing of miR-584 TPC-Twist1 cells. q-RT-PCR of miR-584 in TPC-Twist1 
cells transfected with Anti-miR-584 or a empty vector (Anti-null) are shown. The expression 
levels of miR-584 were normalized to those of U6 snRNA. Values represent the average of 
triplicate experiments ± SDs. 
 
 
Initially, we evaluated in these cell lines proliferation, migration and 
invasion. As shown in Figures 20A, B and C, silencing of miR-584 did not 
affect cell proliferation, invasion and migration in TPC-Twist1 Anti-miR-584 
cell in comparison to control cells.  
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Figure 20. Effects of miR-584 silencing in TPC-Twist1 cells on cell migration, invasion 
and proliferation. A. A scratch wounds were inflicted at confluent cell monolayer and after 12 
and 24h cells were photographed. B. TPC-Twist1 Anti-miR-584 and control cells were seeded 
in upper chamber of transwells and allowed to migrate for 24h; migration ability was expressed 
as absorbance at OD 570 nm. Values represent the average of triplicate experiments ± standard 
deviations. C. TPC-Twist1 Anti-miR-584 and TPC-Twist1 Anti-miR-null cells were plated and 
counted at different time points. Values represent the average of triplicate experiments. 
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Then, we treated TPC-Twist1 Anti-miR-584 and control cells with 
different doses of Doxorubicin and Staurosporine (Figures 21A and B). The 
IC50 for Doxorubicin was 4.9 nM in TPC-Twist1 Anti-miR-584, whereas in 
TPC-Twist1 transfected with control was 14.2 nM. Similarly, Staurosporine 
showed an IC50 of 101.8 nM and 23.2 nM in TPC-Twist1 Anti-miR-584  and in 
TPC-Twist1 Anti-null respectively (Figure 21). All together, these data 
suggested that miR-584 contributes in Twist1 induced resistance to apoptosis. 
 
 
 
 
Figure 21. The sensitivity to apoptosis is increased in TPC-Twist1 cells after miR-584 
silencing. A-B. The cells were treated with increasing doses of Doxorubicin or Staurosporine 
and counted after 48 and 24 hours, respectively. The 50% growth-inhibitory concentration 
(IC50) is shown: values represent the average of three independent experiments ± SD. 
 
 
 
4.2.5 miR-584 targets TUSC2  
 
We then searched putative targets of miR-584 by using five different 
bioinformatics programs (Targetscan, Pictar, DianaLab, miRDB and Miranda). 
Among the ∼200 targets predicted by all five programs, TUSC2 (tumor 
suppressor candidate 2, also named FUS1) was of particular interest because of 
its involvement in apoptosis and chemosensitivity (Li et al. 2014; Deng et al. 
2008) in according with our observed effects of miR-584 in TPC cells and with 
the role of Twist1.  
The 3’UTR of TUSC2 is highly conserved across different species, 
strongly suggesting that it plays an important role in regulating TUSC2 
expression. In the 3’UTR of TUSC2 there is sequence of complementarity with 
miR-584 (Figure 22). 
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Figure 22. Predicted duplex formation between human TUSC2-3’UTR and miR-584. 
 
 
 
We further evaluated the expression of TUSC2, both at mRNA and 
protein level, in TPC transfected with miR-584 and control. As shown in 
Figure 23A, TUSC2 protein level was decreased of  ∼2-fold in TPC miR-584 
cells respect to control cells. Further, TUSC2 mRNA decreased upon miR-584 
over-expression (Figure 23B) suggesting that miR-584 could act both by 
reducing translation and by accelerating mRNA degradation of TUSC2. 
 
 
 
 
Figure 23. miR-584 suppresses TUSC2 in TPC cells. A. Immunoblotting of TUSC2 and α-
Tubulin in TPC miR-584 or control cells. B. q-RT-PCR of TUSC2 in TPC cells transfected 
with miR-584 or empty vector; data were normalized to the level of RNAPol mRNA and 
assuming that the value of TPC transfected with a empty vector is equal to 1. 
 
 
 
We also evaluated the expression of TUSC2 in TPC-Twist1 cells 
transfected with Anti-miR-584 or control by q-RT-PCR and Western blot. As 
shown in Figures 24, A and B, TUSC2 was increased, both at mRNA and 
protein level in miR-584 silenced cells. 
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Figure 24. Silencing of miR-584 induced an increased of TUSC2 expression in TPC 
Twist1 cells. A. Immunoblotting of TUSC2 and α-Tubulin in TPC miR-584 and in TPC-
Twist1 Anti miR-584 or control cells, respectively. B. q-RT-PCR of TUSC2 in TPC-Twist1 
Anti miR-584 and in control cells ; data were normalized to the level of RNAPol mRNA. 
 
 
 
To further verify whether TUSC2 is a direct target of miR-584, we 
generated a vector containing a synthetic luciferase reporter gene fused with 
the 3’UTR sequence of TUSC2, driven by a constitutive promoter. A mutant 
version of this plasmid, where the 8 nucleotides of 3’UTR of TUSC2 
complementary to miR-584 were deleted, was also generated and used as 
control (Figure 25A). TPC miR-584 and TPC miR-null cells were transiently 
transfected with the plasmids and luciferase activity was measured 24 hours 
after transfection. miR-584 over-expression induced a significant reduction in 
luciferase activity compared with control cells. No change of luciferase activity 
was observed in TPC miR-584 cells, transfected with the deletion mutant 
reporter plasmids. These data demonstrates that miR-584 binds to the 3’UTR 
sequence of TUSC2 mRNA, damping its expression (Figure 25B). 
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Figure 25. TUSC2 is a direct target of miR-584. A. Sequence of miR-584 binding site 
deleted within the TUSC2 3’UTR. B. Luciferase activity of wild-type (TUSC2-3’UTR) or 
delete (TUSC2-3’UTR del) TUSC2-3’UTR reporter gene in TPC cells stably transfected with 
miR-584, or empty vector. Luciferase activity was normalized on that a co-transfected β-actin-
reporter. 
 
 
 
4.2.6 TUSC2 is down-regulated in human thyroid tumors 
 
Finally, we evaluated by immunohistochemistry the expression level of 
TUSC2 protein in a panel of human thyroid carcinoma tissues, including 37 
normal thyroids (NT), 20 PTCs, 9 PDCs and 40 ATCs. As reported in Table 6, 
all normal thyroids examined showed TUSC2 positivity, with ∼60% of samples  
showing strong TUSC2 staining (+++). On the contrary TUSC2 was 
undetectable in all PDC and ATC samples. An intermediated positivity of 
staining was seen in PTC, suggesting a correlation between TUSC2 down-
regulation and tumor progression (Table 6). A representative image of TUSC2 
staining is shown in Figure 26. 
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Table 6: TUSC2 expression in thyroid samples (n = 106). 
TUSC2 
NT 
(N = 37) 
PTC 
(N = 20) 
PDC 
(N = 9) 
ATC 
(N = 40) 
+++ 22 (59.5%) - - - 
++ 11 (29.8%) 1 (5%) - - 
+ 4 (10.8%) 4 (20%) - 1 (2.5%) 
Negative - 15 (75%) 9 (100%) 39 (97.5%) 
+: ≥ 5 – ≤ 25% of positive cells; ++: > 25 – <60% of positive cells; +++: ≥ 60% of positive 
cells. Percentage of positive samples respect to each group was reported in parenthesis. 
 
 
 
 
Figure 26. Expression of TUSC2 in thyroid tissue samples. Immunohistochemical analysis 
of TUSC2 protein expression in normal and malignant thyroid tissues. Representative 
histological sections from NT (20 X magnification), classical PTC (20 X magnification), PDC 
(20 X magnification), and ATC (20 X and magnification) stained with an anti-TUSC2 antibody 
are shown.  
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5. DISCUSSION 
 
 
Anaplastic thyroid cancer (ATC) is the most lethal histotype of thyroid 
cancer, responsible for more than one-third of thyroid cancer-related deaths. 
The fast-growing nature of this type of cancer and its refractoriness to 
radioiodine treatment limit the efficacy of therapeutic interventions.  
Previously, we have demonstrated that Twist1 transcription factor is up-
regulated, both at mRNA and protein level, in approximately 50% of ATC. 
Twist1 plays a pleiotropic role in determining the ATC phenotype affecting 
cell migration, invasion and resistance to apoptosis (Salerno et al. 2011). 
This dissertation is focused on unraveling the molecular mechanisms 
responsible for Twist1 biological effects in thyroid cancer cells. To achieve 
this goal, we have analyzed mRNA and miRNA expression profile of TPC 
cells over-expressing Twist1 protein.  
mRNA signature in TPC-Twist1 cells was enriched for genes involved in 
invasion, migration and apoptosis consistent with the role of Twist1 in 
anaplastic thyroid cancer cells. We focused on the up-regulated genes because 
more is known about the role of Twist1 as transcriptional activator. The top up-
regulated genes by more than 4-fold studied were: HS6ST2, COL1A1, KRT7, 
F2RL1, LEPREL1, THRB, ID4, RHOB, PDZK1, and PDZK1IP1.  
Chromatin immunoprecipitation provides evidence that these genes are 
direct transcriptional targets of Twist1. Herein, we also demonstrated that 
HS6ST2, COL1A1, F2RL1, LEPREL1, PDZK1, and PDZK1IP1 are over-
expressed in ATC. Moreover, immunohistochemistry analysis showed that 
LEPREL1 was over-expressed in 67% of ATC and in 26% of PTC cases. In the 
same dataset, Twist1 was over-expressed in 62% of ATC and in 0% of PTC 
samples. Interestingly, many of the identified Twist1 targets are over-expressed 
also in PTC where Twist1 is negative (Figure 13). It is possible that other 
factors regulate the identified target genes in Twist1 negative samples. 
Furthermore, we have performed a gene expression profile in TPC-Twist1 cells 
that, although express high levels of Twist1, are a cell line and thus could be 
not representative of thyroid cancer complexity.  
Heparan sulfate 6-O-sulfotransferase 2 (HS6ST2) is an enzyme that 
attaches sulfate groups to glucosamine residues in heparan sulfate. Heparan 
sulfate proteoglycans are ubiquitous components of the cell surface, 
extracellular matrix, and basement membranes and interact with various 
ligands to influence cell growth, differentiation, adhesion, and migration (Song 
et al. 2011). Importantly, it was recently reported that the specific inhibition of 
HS6ST2 by heparin and a high-molecular-weight Escherichia coli K5-derived 
heparin-like polysaccharide (K5-NSOS) efficiently reduced osteolytic lesion 
area and metastatic tumor burden in a mouse model of breast cancer bone 
metastasis (Pollari et al. 2012).  
LEPREL1 encodes a member of the prolyl 3-hydroxylase subfamily of 2-
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oxo-glutarate-dependent dioxygenases. These enzymes play a critical role in 
collagen chain assembly, stability, and cross-linking by catalyzing post-
translational 3-hydroxylation of proline residues (Fernandes et al. 2011). 
Hypoxia-inducible factor 1 activates the transcription of collagen prolyl 
hydroxylases (Gilkes et al. 2013). Of note, Twist1 is a downstream target of 
hypoxia-inducible factor 1 (Yang et al. 2008). Noteworthy, an ethyl 3,4-
dihydroxybenzoate, a prolyl hydroxylase inhibitor, decreased tumor fibrosis 
and metastasis in a mouse model of breast cancer (Gilkes et al. 2013). During 
cancer progression, increased deposition of collagens can occur within and 
near the primary tumors, and it is associated with a poor outcome due to 
increased local invasion and distant metastasis (Conklin et al. 2011). 
Straightened and aligned collagen fibers in tumor samples are predictive of 
patient mortality, presumably because collagen fibers provide directional cues 
that dictate cell morphology and promote cell migration as well as induce 
stiffness, which promotes tissue tension to enhance cancer progression 
(Provenzano et al. 2006).  
Indeed, in TPC-Twist1 cells, we found up-regulated COL1A1 (7.2±1.4), 
COL4A1 (2.0±0.05), COL18A1 (1.7±0.1), COL4A2 (1.5±0.2) (data are 
described in the manuscript I). These results are in agreement with Hébrant and 
colleagues (Hébrant et al. 2012) who demonstrated that one of the clusters that 
differentiated ATC vs PTC is composed of genes involved in calcification and 
fibrosis processes. 
PDZK1IP1, also known as membrane-associated protein 17 (MAP17), is 
a small 17-kDa non-glycosylated membrane protein over-expressed in a great 
variety of human carcinomas. Immunohistochemical analysis of PDZK1IP1 
shows that over-expression of the protein strongly correlates with tumor 
progression (Birrane et al. 2013). The increased malignant cell behavior 
induced by PDZK1IP1 is associated with an increase in reactive oxygen 
species production, and the treatment of PDZK1IP1-expressing cells with 
antioxidants resulted in a reduction in the tumorigenic properties of these cells 
(Cancero et al. 2012; Birrane et al. 2013). 
Coagulation factor II (thrombin) receptor-like 1 (F2RL1), also known as 
protease-activated receptor 2 (PAR2), is a member of the large family of 7-
transmembrane- region receptors that couple to guanosine nucleotide- binding 
proteins and is a key signaling component for proteases in vascular biology and 
tumor progression (Schaffner et al. 2012). PAR2 is involved in tissue factor 
(TF) signaling pathway and plays a crucial role in tumor growth. TF forms a 
catalytic enzyme complex with coagulation factor VIIa, and selective 
inhibition of TF-factor VIIa-PAR2 signaling using a monoclonal antibody was 
shown to reduce breast tumor growth. Consistent with the hypothesis that 
F2RL1 mediated signaling contributes to tumor growth in breast cancer, mice 
lacking F2RL1 exhibited reduced tumor growth in a model of spontaneous 
mammary tumors (Versteeg et al. 2008).  
Thus, we have identified a set of novel direct transcriptional targets of 
Twist1. The identified targets could be important to mediate Twist1 biological 
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effects also in other malignancies such as breast and prostate carcinoma and 
sarcoma where Twist1 is over-expressed (Ansieau et al. 2010). All the genes 
identified are potential targets for cancer therapy. Indeed, HS6ST2 and 
LEPREL1 are enzymes, whereas PDZK1IP1 and F2RL1 are membrane 
proteins and thus targetable by small molecules or monoclonal antibodies 
respectively (Imai et al. 2006).   
Recently, deregulation of microRNAs (miRNAs), a class of small 
endogenous RNAs that regulated the protein expression, has been implicated in 
tumorigenesis and cancer progression. A large body of evidence shows that 
human tumors are characterized by a global miRNA down-regulation, hence 
their oncogenic targets are over-expressed enhancing tumor proliferation, 
invasion and metastasis, what makes this cancers perfect targets for the use of 
specific miRNA mimetics as therapeutics tools. On the contrary, in human 
cancer some specific miRNAs are up-regulated with oncogenic potential 
(oncomiRs) and, thus, they are possible therapeutic targets for inhibition. To 
date, oncogenic miRNAs can be inhibited by using antisense oligonucleotides, 
antagomirs, sponges or locked nucleic acid (LNA) constructs (Garzon et al. 
2010).  
By analyzing the miRNome of human thyroid carcinomas it has been 
shown up-regulation of miRNAs, such as miR-146b, miR-221, and miR-222, 
in ATC and also in differentiated thyroid cancer (papillary and follicular), 
indicating that these miRNAs’ over-expression is essential in maintaining 
tumorigenesis. However, specific miRNAs are down-regulated in ATC, such 
as those of the miR-200 and miR-30 families, which are important negative 
regulators of cell migration, invasion, and epithelial-to-mesenchymal transition 
(EMT) (Braun et al. 2010; Visone et al.  2007). 
To unravel miRNA regulated by Twist1, we have explored miRNA 
expression profile of TPC-Twist1 protein, using a miRNACHIP microarray. 
We found 51 miRNAs changed (14 up-regulated, Table 4, and 37 down-
regulated, Table 5) by more than 2 fold in TPC-Twist1 cells in comparison to 
control. 
We searched in our array miRNA that were previously reported to be 
deregulated in ATC samples. TPC-Twist1 cells down-regulated with respect to 
control miR-148b (Table 5). The paper of Braun and the paper of Visone, 
reported a down-regulation of this miRNA in ATC samples in comparison to 
normal thyroid. Interestingly, miR-148b is also down-regulated in aggressive 
breast and lung tumors, in which it is a major coordinator of malignancy 
influencing invasion, survival to anoikis, extravasation, metastasis formation, 
and chemotherapy response (Cimino et al. 2013).  
In addition, also miR-301a and miR-301b, down-regulated in several 
microarray of ATC samples (Braun et al. 2010), were decreased in our array 
(Table 5). 
We found a significant decrease in miR-200c in TPC-Twist1 cells 
compared to control (Table 5). miR-200 family is involved in EMT and tumor 
invasion and was found to be down-regulated in ATC but not in PTC and FTC. 
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Restoration of miR-200 family members in ATC cells reduced their invasive 
potential and inhibited EMT (Braun et al. 2010).  
miR-15b targets directly the expression of BMI1; interestingly, BMI1 
cooperates with Twist1 in repressing E-cadherin and promoting EMT. miR-
15b was down-regulated in TPC-Twist1 cells respect to control cells (Table 5). 
Despite the general reduction of miRNA expression levels in cancers, 
several miRNAs are up-regulated; some of them play oncogenic role (Di Leva 
et al. 2014). Among Twist1 induced miRNAs, miR-584 was found to be one of 
the most up-regulated, showing a ~ 6-fold increase in TPC-Twist1 cells with 
respect to the control cells. The human miR-584 is located within the 
chromosome 5q32. miR-584 promoter displays 13 consensus binding sites for 
Twist1 (E-boxes), therefore we are currently performing chromatin 
immunoprecipitation to formally prove that Twist1 direct regulates its 
expression.  
Quantitative-RT-PCR was performed to evaluate the expression of miR-
584 in a panel of normal thyroid, PTC and ATC samples. All undifferentiated 
samples showed a statistically significant higher expression of miR-584 
compared to normal thyroid and PTC samples, suggesting that Twist1 over-
expression could induce miR-584 expression also in vivo.  
To address miR-584 role in thyroid cell biology, we have conducted 
functional experiments by ectopic transfection of miR-584 in well-
differentiated thyroid carcinoma cells (TPC) and by silencing miR-584, 
through the transfection of Anti-miR-584 plasmid, in TPC-Twist1 cells. 
We determined the effects of miR-584 on sensitivity of TPC cells to 
apoptosis induced by two different agents Doxorubicin and Staurosporine. 
Doxorubicin elicits its anti-neoplastic activity by binding to DNA and 
distrusting template functions or by inhibition of topoisomerase II activities, 
Staurosporine is an inhibitor of protein kinase. Here we showed that miR-584 
is involved in resistance to induced apoptosis in thyroid carcinoma cells. On 
the other hand miR-584 forced expression or silencing did not affect cell 
proliferation, migration and invasion. 
The biological functions of miRNAs are highly dependent on cellular 
context, which may be due to the differential expression of their targets 
mRNAs. Accordingly, some miRNAs are oncogenic and up-regulated in one 
cancer type but are tumor suppressive and down-regulated in another cancer 
type, consequently, miRNA functions across different contexts and tissues (Di 
Leva et al. 2014). Consistently miR-584 was found to be down-regulated in 
other types of neoplasm such as glioma where could suppress cell growth 
(Wang et al. 2014). Moreover, down-regulation of miR-584 is required for 
TGF-β-induced cell migration of breast cancer cells (Fils-Aimé et al. 2013).  
In agreement with our findings, miR-584 was found up-regulated in a 
microarray screening of different malignant thyroid tissues compared to benign 
lesions (Vriens et al. 2011). 
miRNAs generally bind to target mRNA through their 3’untranslated 
regions (UTRs) and recruit the RNA-induced silencing complex, which 
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mediates the inhibition of translation and the degradation of the respective 
mRNA. To identify targets of miR-584 we used several computational 
algorithms based on conservation criteria such as Targetscan, Pictar, DianaLab, 
miRDB and Miranda. Among targets predicted by all five computational 
methods, TUSC2 was of particular interest because its role in carcinogenesis. 
Tumor suppressor candidate 2 (TUSC2), also known as FUS1, is a tumor 
suppressor gene located on human chromosome 3p21.3, a region in which 
deficient gene expression is frequently seen in lung cancer (Lerman et al. 
2000). Indeed, a reduction or complete loss of TUSC2 expression was found in 
82% of non–small-cell lung cancer cell lines and in 100% of small-cell lung 
cancer cell lines studied and was associated with significantly worse overall 
survival (Deng et al. 2008). Genes in the 3p21.3 region are associated with cell 
differentiation, cell proliferation, ion exchange and transportation, apoptosis, 
and cell death (Ji et al. 2005). Over-expression of TUSC2 significantly inhibits 
tumor growth and progression in mouse models and TUSC2 knockout mice 
show an increased frequency of spontaneous cancers (Ivanova et al. 2007).     
The 3’UTR of TUSC2 is highly conserved, strongly suggesting that it 
plays an important role in regulating TUSC2 expression (Du et al. 2009). Here, 
we show that miR-584 directly interacts with the 3’-untranslated region 
(3’UTR) of TUSC2, leading to down-regulation of protein expression. In fact, 
deletion of this site renders the reporter construct insensitive to miR-584 
expression. 
 We are currently verifying if TUSC2 revert the biological effects 
induced by miR-584 to further prove that TUSC2 is a miR-584 target. 
In this dissertation, we demonstrated that TUSC2 was down-regulated 
not only in ATC but also in PTC and PDC samples where Twist1 and miR-584 
are not expressed. These suggest that other mechanism could modulate the 
expression of TUSC2 in PTC and PDC samples. Notably, loss or reduced 
TUSC2 expression could be caused by various mechanisms. For example, 
allelic loss of the 3p21.3 chromosomal region containing TUSC2 is the major 
cause of loss or reduction of TUSC2 expression in lung cancer (Prudkin et al. 
2008). One mechanism regulating TUSC2 expression and function has already 
been shown by Uno et al. who showed that loss of myristoylation of TUSC2 
protein causes it to be rapidly degraded and removes its ability to suppress 
tumor growth (Uno et al. 2004).     
Preclinical studies in human lung cancer cell lines identified the intrinsic 
apoptosis pathway as a mediator of cell death following forced expression of 
TUSC2 (Ji et al. 2008; Deng et al. 2007). To translate these finding into 
clinical applications for molecular cancer therapy, a novel TUSC2-expressing 
nanoparticle has been developed for treating patients with lung cancer. 
Nanoparticles have been reported to deliver drugs and siRNA to tumors in 
humans. Lu and coworkers first showed, in phase I of clinical trial, the ability 
of systemic administration of genes via this DC nanoparticle vector to 
efficiently deliver therapeutic tumor suppressor genes, to suppress metastasis 
growth and to prolong survival. In particular, they observed major changes in 
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gene expression in the intrinsic pro-apoptotic pathway in the tumor following 
DC-TUSC2 treatment (Lu et al. 2012). Thus, the low level of side effects after 
repeated DC administrations is very encouraging suggesting that DC-TUSC2 
may be combined with small molecule targeted drugs at an effective dose. 
They observed major changes in gene expression in the intrinsic pro-apoptotic 
pathway in the tumor following DC-TUSC2 treatment. 
Benefits obtained from chemotherapy and radiation therapy of ATC 
remains only marginal and there are no alternative treatments yet, therefore 
new therapeutic approaches are needed. To date several approaches are 
suggested: silencing of one or more miRNA up-regulated in tumor cells (i.e. 
miR-584), may be an interesting approach to treat the ATC patients, but, of 
course, it raises the question of cell specificity.  
Here we showed that miR-584 enables thyroid cancer cells to acquire 
resistance to chemotherapeutics induced apoptosis. Further experiments are on 
going in our laboratory to characterize the molecular mechanisms of resistance 
to apoptosis induced by miR-584.  
 Over-expression of miR-584 inhibits synthesis of the TUSC2 protein by 
targeting the 3’UTR of TUSC2. Importantly, TUSC2 is progressively down-
regulated in PTC, PDC and ATC tissues suggesting that TUSC2 is also likely 
to be involved in thyroid cancer progression, with implications for TUSC2 
targeting as a rational therapeutic strategy in ATC. 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6. CONCLUSIONS 
 
Anaplastic thyroid carcinoma (ATC) is the least common but the most lethal 
type of thyroid cancers. We previously showed that Twist1 transcription factor 
plays a pleiotropic role in determining malignant features of the anaplastic 
phenotype. In this dissertation, we aimed to identify transcriptional targets of 
Twist1 because they could be more realistic for therapeutic intervention. Here, 
we have identified a set of mRNA and miRNA regulated by Twist1, which 
mediates the biological effects of Twist1 in thyroid carcinoma cells. Consistent 
with the biological functions of Twist1 in ATC, mRNA targets of Twist1 
affected cellular movement, cellular growth and proliferation and cell death 
and survival. Further, we identified a set of miRNA potentially regulated by 
Twist1. We focused on miR-584 and showed that is up-regulated in ATCs 
respect to normal thyroids as well as to poorly and well differentiated thyroid 
carcinomas. The ectopic expression of miR-584 enables thyroid cancer cells to 
acquire resistance to apoptosis. Finally, we have identified among the putative 
mRNA targets of miR-584, TUSC2 tumor suppressor. 
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Context: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human tumors. Twist1
is a basic helix-loop-helix transcription factor involved in cancer development andprogression.We
showed that Twist1 affects thyroid cancer cell survival and motility.
Objective: We aimed to identify Twist1 targets in thyroid cancer cells.
Design: Transcriptional targets of Twist1 were identified by gene expression profiling the TPC-
Twist1 cells in comparison with control cells. Functional studies were performed by silencing in
TPC-Twist1 and in CAL62 cells the top 10 upregulated genes and by evaluating cell proliferation,
survival, migration, and invasion. Chromatin immunoprecipitation was performed to verify direct
binding of Twist1 to target genes. Quantitative RT-PCR was applied to study the expression level
of Twist1 target genes in human thyroid carcinoma samples.
Results: According to the gene expression profile, the top functions enriched in TPC-Twist1 cells
were cellular movement, cellular growth and proliferation, and cell death and survival. Silencing
of the top 10 upregulated genes reduced viability of TPC-Twist1 and of CAL62 cells. Silencing of
COL1A1, KRT7, and PDZK1 also induced cell death. Silencing of HS6ST2, THRB, ID4, RHOB, and
PDZK1IP also impaired migration and invasion of TPC-Twist1 and of CAL62 cells. Chromatin im-
munoprecipitation showed that Twist1 directly binds the promoter of the top 10 upregulated
genes. Quantitative RT-PCR showed that HS6ST2, COL1A1, F2RL1, LEPREL1, PDZK1, and PDZK1IP1
are overexpressed in thyroid carcinoma samples compared with normal thyroids.
Conclusions:We identified a set of genes that mediates Twist1 biological effects in thyroid cancer
cells. (J Clin Endocrinol Metab 99: E1617–E1626, 2014)
Anaplastic thyroid carcinoma (ATC) is one of themostlethal human malignancies. Ninety percent of pa-
tients with ATC die within 6 months of diagnosis (1, 2).
ATC usually presents as a rapidly expanding tumor mass
in the neck, causing hoarseness, breathing difficulties, and
dysphagia (3, 4). Current treatments for ATC are aggres-
sive and include surgery, chemotherapy, and radiation
therapy.However, ATC is resistant to all types of therapy,
and disease prognosis has remained unchanged (5–7).
ATCmay derive de novo or from preexisting papillary
thyroid carcinoma (PTC) or follicular thyroid carcinoma.
Many patients do indeed have a history of preexisting
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well-differentiated thyroid carcinoma or nodular goiters
(8–10). Little is known about the molecular events that
lead from the highly curable differentiated tumors to
ATCs. The main differences between the 2 tumor types
bear on themuch stronger epithelial tomesenchymal tran-
sition (EMT), dedifferentiation, fibrosis, and glycolytic
phenotypes shown by the ATC (11). Through a microar-
ray analysis on different thyroid tumors in comparison
with normal thyroids, we have isolated Twist1 transcrip-
tion factor as a gene upregulated in ATC (12, 13).
Twist1 is a highly conserved transcription factor that
belongs to the family of basic helix-loop-helix proteins.
Twist1 overexpression is associated with many types of
aggressive tumors and correlates with poor prognosis and
high grade/stage of the tumor (reviewed in Refs. 14 and
15). Twist1 has been identified as a master regulator of
epithelial tomesenchymal transition, a criticalmechanism
used by cancer cells to increase invasion, metastasis, and
resistance to chemotherapy (16–18). We showed that ap-
proximately 50% of ATCs upregulated Twist1 with re-
spect to normal thyroids as well as to poorly and well-
differentiated thyroid carcinoma. Silencing of Twist1, by
RNA interference, in ATC cells (CAL62) reduced cell mi-
gration and invasion and increased sensitivity to apopto-
sis. The ectopic expression of Twist1 in papillary thyroid
cancer cells (TPC-1) induced resistance to apoptosis and
increased cell migration and invasion (13).
Here, we aimed to identify a set of genes that mediates
Twist1 biological effects in thyroid cancer cells.
Materials and Methods
Cell lines
Thehumanpapillary thyroid cancer cell lineTPC-1 (hereafter
named TPC), was obtained fromM. Nagao (Carcinogenesis Di-
vision, National Cancer Center Research Institute, Tokyo, Ja-
pan). The TPC cell line was authenticated based on the unique
presence of the RET/PTC1 rearrangement. The human anaplas-
tic thyroid cancer cell line CAL62 was purchased from DSMZ
(Deutsche Sammlung von Mikroorganismen und Zellkulturen
GmbH).CAL62 cellswereDNAprofiled by short tandem repeat
analysis in 2009 and shown to be unique and identicalwith those
reported in Schweppe et al (19). The TPC-Twist1 cell lines (mp1,
mp2, andCl2) and theCAL62 shTwist1 cellswere generated and
characterized as described in Salerno et al, 2011 (13). TPC and
CAL62 cells were grown in DMEM (Dulbecco’sModified Eagle
Medium) supplemented with 10% FBS (fetal bovine serum), L-
glutamine and penicillin/streptomycin (Invitrogen, Carlsbad,
CA). Normal human umbilical vein endothelial cells (HUVEC)
werepurchased fromLonza (Lonza, Switzerland) andcultured in
EBM-2 (Endothelial Cell BasalMedium)medium supplemented
with SingleQuot growth supplements (Lonza) up to passage 7.
Microarray analysis, network and gene ontology
analysis, RNA extraction, cDNA synthesis, and
quantitative real-time PCR, immunohistochemistry,
migration and invasion assay, and
transendothelial cell migration assay
These studies were performed according to standard proce-
dures. A description is available in Supplemental Methods.
RNA silencing
All functional experiments described hereafter have been per-
formed in TPC-Twist1 mp1 (TPC-Twist1) and in CAL62 cells.
TPC-Twist1 and CAL62 cells were transfected with the specific
small interfering RNAs (siRNAs) (QIAGEN) in 6-well plates in
triplicate. For each transfection, 5 L of 100M siRNA was
mixedwith 20L ofHiPerFect Transfection reagent (QIAGEN)
and 300 L of Optimemmedium (Invitrogen). After 10 minutes
of incubation, the transfection mix was delivered to each well
and incubated at 37°C for 72 hours. The following specific siR-
NAs (QIAGEN) were used: siRNA HS6ST2 (SI04269020),
siRNA COL1A1 (SI04434773), siRNA KRT7 (SI04339776),
siRNA F2RL1 (SI04435088), siRNA LEPREL1 (SI04265184),
siRNATHRB (SI03027535), siRNA ID4 (SI00445389), siRNA
RHOB (SI00058912), siRNA PDZK1 (SI04314723), siRNA
PDZK1IP1 (SI04164587), and AllStars negative control
siRNA (SI03650318).
Trypan blue assay
Cells were collected by trypsinization after 48 and 72 hours
of transfection, stained for 10 minutes with 0.4% trypan blue
(Sigma-Aldrich) according to manufacturer’s instructions, and
counted in triplicate with TC10 automated cell counter
(Bio-Rad).
Wound closure assay
A wound was inflicted on the confluent monolayer cells by
scraping a gap using a micropipette tip 48 hours after transfec-
tion with specific siRNAs. Photographs were taken at10mag-
nification using phase-contrast microscopy immediately after
wound incision and 24 hours later. Pixel densities in the wound
areas were measured using the Cella software (Olympus Biosys-
tem GmbH) and expressed as percentage of wound closure,
where 100% is the value obtained at 24 hours for control cells.
Chromatin immunoprecipitation assay
Chromatin samples were processed for chromatin immuno-
precipitation (ChIP) as reported elsewhere (20). Briefly, TPC-
pcDNA and TPC-Twist1 cell lysates were sonicated on ice in a
cold room, 30 times for 30 seconds each atmaximum settings, to
obtain fragments between 0.3 and 1.0 kb. Samples were sub-
jected to IP with anti-Twist1 antibody (Twist2C1a, sc-81417;
SantaCruzBiotechnology, Inc) or control antibody (mouse IgG1
isotype control, clone G3A1, no. 5415; Cell Signaling). For
quantitative RT-PCR (qRT-PCR), 2 of 30 L immunoprecipi-
tated DNAwas used. Input DNA values were used to normalize
the values from quantitative ChIP samples. Percent input was
calculated as 2Ct  3, where Ct is cycle threshold and Ct is
the difference between Ctinput and CtcIP. All quantitative ChIP
data were derived from at least 3 independent experiments, and
for each experiment, qRT-PCRwas performed in triplicate. The
GAPDH promoter ampliconwas used as a negative control. The
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sequences of the primers, covering E-box regions, used in ChIP
assays are listed in Supplemental Table 1.
Tissue samples
Tumors and normal thyroid tissue samples for RNA extrac-
tion and qRT-PCR were retrieved from the files of the Depart-
ment of Surgery, University of Pisa (Italy). The institutional re-
view boards approved the study protocols. Informed consent
was obtained from each subject. Samples were classified accord-
ing to the diagnostic criteria required for the identification of
PTC, poorly differentiated thyroid carcinoma (PDC), and ATC
(21).
Statistical analysis
Data are presented as mean  SD. Two-tailed paired Stu-
dent’s t test (normal distributions and equal variances) was used
for statistical analysis. Differences were significant when P 
.05. Statistical analyses were carried out using the GraphPad
InStat software program version 3.1a.
Results
Identification of Twist1 target genes
We analyzed gene expression profiles of TPC-Twist1
cells in comparison with control cells (TPC-pcDNA). To-
talRNAextracted from3TPC-Twist1 stable transfectants
(Twist1 mp1, Twist1 mp2, and Twist1 Cl2) and vector
control cells was analyzed using human Genome U133
Plus 2.0 Array GeneChips (Affymetrix) containing
47 000 gene transcripts. We sorted only the genes that
were changed in all 3 Twist1 transfectants comparedwith
vector control cells. We found 158 genes upregulated
(Supplemental Table 2) and 221 downregulated (Supple-
mental Table 3) by 1.5-fold in TPC-Twist1 cells com-
pared with control cells. Ingenuity Pathways Analysis (In-
genuity Systems, www.ingenuity.com) was used to
classifyTwist1 target genes.Consistentwith thebiological
functions of Twist1 in ATC, the top 3 categories enriched
in TPC-Twist1 cells compared with vector control were
cellular movement, cellular growth and proliferation, and
cell death and survival (Supplemental Figure 1).Other top
categorieswere cancer, reproductive systemdisease, tissue
development, and tumormorphology. In details 53.6%of
the genes (203 of 379) belonged to cellular movement,
cellular growth and proliferation, and cell death and sur-
vival, 17.6% (67 of 379) belonged to other top categories
(mainly to cancer), and 28.7% (109 of 379) were not clas-
sified (Supplemental Figure 2). Here we focused on the
genes that were upregulated by 4-fold; PDZK1IP1, al-
thoughupregulated3-fold,was also studied because it is
the interacting protein of PDZ domain containing 1
(PDZK1) (22, 23) (Supplemental Table 4).
Expression levels of upregulated genes are
affected by Twist1 level
We performed qRT-PCR of the top 16 upregulated
genes in the cell lines used in the screening in comparison
withvector control cells.As shown inSupplemental Figure
3, qRT-PCR confirmed the microarray screening, albeit
with some variability in the different Twist1 clones. We
failed to efficiently detect the expression ofMXRA8 and
GFRA1; thus, these genes were excluded from further
study. To confirm that Twist1 transcriptionally regulates
the identified genes, we studied whether silencing of
Twist1 affected their expression levels. Thus, we per-
formed qRT-PCR of the top 14 upregulated genes in the
CAL62 (ATC) cell line stably transfected with shTwist1
plasmid. The CAL62 cell line presents a high endogenous
level of Twist1 (13), and inCAL62-shTwist1 cells, Twist1
mRNA was downregulated 2-fold (13). As shown in
Supplemental Figure 4, transfection of CAL62 with a
Twist1 short hairpin RNA blunted expression of upregu-
lated genes with respect to the control cell.
Silencing of Twist1-upregulated genes in TPC-
Twist1 and in CAL62 cells impairs cell viability
Ten of the top 14 upregulated genes (70%) belong to
the categories cellularmovement, cellular growthandpro-
liferation, and cell death and survival. Focusing on these
genes (Table 1), TPC-Twist1 and CAL62 cells were tran-
siently transfected with siRNAs for HS6ST2, COL1A1,
KRT7,F2RL1,LEPREL1,THRB, ID4,RHOB,PDZK1,
Table 1. List of Top 10 Upregulated Genes
Gene Fold Change Molecular and Cellular Biofunction
HS6ST2 10.28 Cellular growth and proliferation
COL1A1 7.22 Cellular growth and proliferation, cell death and survival, cellular movement
KRT7 5.56 Cellular growth and proliferation, cellular movement
F2RL1 5.31 Cellular growth and proliferation, cell death and survival, cellular movement
LEPREL1 4.99 Cellular growth and proliferation
THRB 4.88 Cellular growth and proliferation, cellular movement
ID4 4.33 Cellular growth and proliferation, cell death and survival
RHOB 4.13 Cellular growth and proliferation, cell death and Survival, cellular movement
PDZK1 3.99 Cellular growth and proliferation, cell death and survival
PDZK1IP1 2.90 Cellular growth and proliferation
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PDZK1IP1, or a scrambled siRNA and examined at 48
and 72 hours after transfection for cell viability using a
trypanblue assay.As shown in Figure 1,A andB, transient
silencing of all 10 genes decreased cell number in TPC-
Twist1 (Figure 1A) and in CAL62 (Figure 1B) cells at dif-
ferent time points (P  .001). Silencing of COL1A1,
KRT7, and PDZK1 also increased the cell death rate (in
particular at 72 hours after transfection). As a control,
transfection of the 10 siRNAs efficiently downregulated
the specific genes, albeit with some variability (Figure 1, C
and D).
Silencing of HS6ST2, THRB, ID4, RHOB, and
PDZK1IP1 in TPC-Twist1 and in CAL62 cells impairs
cell migration
Twist1 increases the migration ability of TPC cells,
whereas Twist1 knockdown in CAL62 cells decreases cell
migration (13). We selected HS6ST2, THRB, ID4,
RHOB, and PDZK1IP1 because silencing of these genes
affected the cell viability to a lesser lower extent than si-
lencing of other target genes and, thus there were a suffi-
cient number of surviving cells available for further anal-
ysis (Figure 1, A and B). A scraped woundwas introduced
on the confluent monolayer of TPC-Twist1 and CAL62
cells transfected with specific siRNAs or scrambled
siRNA, and the cell migration into the wound was mon-
itored after 24 hours. TPC-Twist1 and CAL62 cells trans-
fectedwith the scrambled control efficientlymigrated into
the wound; by contrast, cells transfected with HS6ST2,
THRB, ID4, RHOB, and PDZK1IP1 siRNAs displayed
reduced migrating ability. This phenomenon was partic-
ularly evident with siRNA of RHOB or PDZK1IP1 (Fig-
ure 2A).
To better characterize this effect, we performed a
Transwell migration assay. As shown in Figure 2, B–D,
silencing of HS6ST2, THRB, ID4, RHOB, and
PDZK1IP1 reduced the number of migrated cells in the
Transwell.
Twist1 increased (2-fold) the ability of TPC cells to
migrate into collagen I matrix (Supplemental Figure 5, A
and B), whereas Twist1 knockdown in CAL62 cells de-
creased cell migration into collagen I matrix (Supplemen-
tal Figure 5, C andD) (P .001). Thus, we askedwhether
Figure 1. Silencing of the top 10 upregulated genes impairs cell viability. A and B, TPC-Twist1 (A) and CAL62 (B) cells were transfected with the
indicated siRNAs or scrambled siRNA; after 48 and 72 hours, cells were collected by trypsinization, stained for 10 minutes with trypan blue, and
counted; black bars represent the viable cells, and white bars represent the dead cells. C and D, mRNA expression levels of the indicated genes
were measured by qRT-PCR in TPC-Twist1 (C) and in CAL62 (D) cells. Results are reported as fold change in comparison with the scrambled
control. Values represent the average of triplicate experiments  SDs.
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Figure 2. Silencing of the indicated genes reduces the migration ability of TPC-Twist1 and CAL62 cells. A, Cells were transfected with specific
siRNAs, and 48 hours after transfection, scratch wounds were inflicted on the confluent cell monolayer. After 24 hours, cells were photographed.
Wound closure was measured by calculating pixel densities in the wound area and expressed as percentage of wound closure of triplicate areas 
SDs. B–D, TPC-Twist and CAL62 cells were transfected with specific siRNAs or scrambled control, and 48 hours after transfection, cells were
seeded in the upper chambers of Transwells, allowed to migrate, and photographed (C, TPC-Twist1; D, CAL62). Migration ability is expressed as
absorbance at OD 570 nm (B). Values represent the average of triplicate experiments  SDs. E–G, TPC-Twist1 and CAL62 transfected cells were
seeded onto the insert coated with collagen I, left to migrate, stained, and photographed (F, TPC-Twist1; G, CAL62). Migration ability in collagen I
is expressed as absorbance at OD 570 nm (E). Values represent the average of triplicate experiments  SDs.
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silencing of HS6ST2, THRB, ID4, RHOB, and
PDZK1IP1 affected this ability. As shown in Figure 2,
E–G, TPC-Twist1 and CAL62 cells transfected with
HS6ST2, THRB, ID4, RHOB, and PDZK1IP1 siRNA
presented a decreased ability to migrate into Collagen I
matrix compared with siRNA scrambled transfected cells
(P  .001).
Silencing of HS6ST2, THRB, ID4, RHOB, and
PDZK1IP1 in TPC-Twist1 and in CAL62 cells impairs
cell invasion
We evaluated cell invasion in collagen I matrix. As
shown in Supplemental Figure 6, A and B, Twist1 in-
creased the ability of TPC cells to invade the collagen I
matrix, whereas Twist1 knockdown in CAL62 cells de-
creased cell migration into collagen I matrix (Supplemen-
tal Figure 6, C and D) (P  .001). Silencing of HS6ST2,
THRB, ID4,RHOB, and PDZK1IP1 reduced this ability
compared with cells transfected with scrambled siRNA
(Figure 3, A–C).We then evaluated cell invasion inMatri-
gel matrix. Twist1 increased the invasion ability of TPC
cells5-fold in Matrigel, whereas Twist1 knockdown in
CAL62cells decreased cell invasion inMatrigel (13).TPC-
Twist1andCAL62cells transfectedwithHS6ST2,THRB,
ID4,RHOB, and PDZK1IP1 siRNApresented a reduced
ability to invade Matrigel compared with siRNA scram-
bled transfected cells. Inparticular, the silencingofRHOB
andPDZK1IP1 induced a reduction of86%and84%
in TPC-Twist1 and of59% and56% in CAL62 cells,
Figure 3. Silencing of the indicated genes reduces the invasion ability of TPC-Twist1 and CAL62 cells. A–C, TPC-Twist1 and CAL62 transfected
cells were seeded in the upper chamber of Transwells coated with collagen I matrix and incubated for 24 hours (B, TPC-Twist1) or 48 hours (C,
CAL62). The invasive ability in collagen I is expressed as absorbance at OD 570 nm (A). D–F, TPC-Twist1 and CAL62 transfected cells were seeded
in the upper chambers of Transwells coated with Matrigel and incubated; the upper surface of the filter was wiped clean and cells on the lower
surface were stained, photographed (E, TPC-Twist1; F, CAL62), and counted. The invasive ability in Matrigel matrix is expressed as number of
invaded cells (D). G–I, TPC-Twist1 and CAL62 transfected cells were seeded on a confluent monolayer of endothelial human umbilical vein
endothelial cells (HUVECs) and left to migrate. Cells were then stained and photographed (H, TPC-Twist1; I, CAL62). Values represent the average
of triplicate experiments  SDs. Migration ability through HUVECs is expressed as absorbance at OD 570 nm (G).
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respectively, of invasion ability assessed by counting the
numberof invaded cells in3different fields (Figure3,D–F)
(P  .001).
Finally, we studied the cell ability to penetrate into the
endothelium (24, 25) by a transendothelial cell migration
assay. As shown in Supplemental Figure 7, A and B, TPC-
Twist1 cells presented an increased ability to migrate
through endothelial cells comparedwith control cells (P
.001), whereasCAL62 shTwist1 presented a reduced abil-
ity to migrate through endothelial cells compared with
control (Supplemental Figure 7, C and D) (P  .001). As
shown in Figure 3, G–I, TPC-Twist1 and CAL62 cells
transfected with HS6ST2, THRB, ID4, RHOB, and
PDZK1IP1 siRNA presented a decrease in the transen-
dothelial cell migration ability compared with cells trans-
fected with scrambled siRNA.
Twist1 directly binds the promoter of target genes
To formally prove that the identified genes are direct
Twist1 targets, we verified whether Twist1 binds to their
promoters. Consensus binding sites for Twist1 are repre-
sented by an E-box (5	-CANNTG-3	) sequencemotif (14,
15). In the promoter of all 10 upregulated genes, we found
several E-box sequences (Supplemental Figure 8). Thus,
DNA-chromatin complexes from TPC-pcDNA and TPC-
Twist1 were subjected to IP with Twist1 antibody or with
control antibody (IgG1). As shown in Figure 4, promoter
regions of all 10 upregulated genes were significantly en-
riched by Twist1 IP in TPC-Twist1 cells compared with
TPC-pcDNA cells (P  .001). Conversely, no amplifica-
tion was observed with anti-IgG precipitates and when
primers for the GAPDH promoter were used. This cor-
roborates the notion that the top upregulated genes are
direct Twist1 targets.
Twist1 target genes are overexpressed in PTC,
PDC, and ATC samples
To assess the role of the identified Twist1 targets in
thyroid carcinogenesis we performed a qRT-PCR on a set
of normal thyroid (n
 9), PTC (n
 9), PDC (n
 8), and
ATC (n 
 12) samples. As shown in Figure 5, HS6ST2,
COL1A1, F2RL1, LEPREL1, PDZK1, and PDZK1IP1
are differentially overexpressed in PTC, PDC, and ATC
samples. The expression level of KRT7, THRB, ID4, and
RHOBwasnot significantly altered in thyroid carcinomas
compared with normal thyroid samples (not shown).
To verify these data at the protein level, we performed
immunohistochemistry studies for leprecan-like 1 (LEP-
REL1) in a panel of normal thyroid (n 
 27), PTC (n 

19), andATC(n
40) samples.As shown inSupplemental
Figure 4. Twist1 directly binds the promoter of target genes. ChIP assay followed by qRT-PCR was performed on TPC-Twist1 and TPC-pcDNA
cells. Equal amounts of proteins were subjected to IP with anti-Twist1 antibody or IgG1 antibody, as indicated. The GAPDH promoter amplicon
was used as a negative control. Columns represent the average of 3 independent experiments  SDs.
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Table 6 and Supplemental Figure 9, LEPREL1 is overex-
pressed in 26% of PTC (5 of 19) and 67% of ATC (27 of
40) samples in comparison with normal thyroids.
Discussion
Thyroid cancer includes well-differentiated carcinomas
with a good prognosis and undifferentiated carcinomas
(ATC) that represent one of the most aggressive human
cancers and present a dismal prognosis. The molecular
players sustaining such aggressive behavior are largely un-
known. We have previously demonstrated that Twist1 is
upregulated in ATC and that silencing of Twist1 in ATC
cells reduces cell migration and invasion and increases
sensitivity to apoptosis (13).
Twist1 is a transcription factor capableof directlybind-
ing E-box consensus sites (5	-CANNTG-3	) to exert tran-
scriptional effects (14, 15). Despite the growing literature
on the role ofTwist1 in cancer progression, throughwhich
target genes Twist1 exerts its functions remains elusive.
Here, we provide evidence that HS6ST2, COL1A1,
KRT7,F2RL1,LEPREL1,THRB, ID4,RHOB,PDZK1,
and PDZK1IP1 are direct transcriptional targets of
Twist1 with COL1A1, KRT7, and PDZK1mostly medi-
ating Twist1 prosurvival properties, whereas HS6ST2,
THRB, ID4, RHOB, and PDZK1IP are mainly involved
in Twist1 promotile effects. Furthermore, we showed that
HS6ST2, COL1A1, F2RL1, LEPREL1, PDZK1, and
PDZK1IP1 were differentially overexpressed in PTC,
PDC, and ATC samples.
Figure 5. Twist1 targets are upregulated in thyroid carcinoma samples, as shown by qRT-PCR of the indicated genes in normal thyroids (NT) (n 

9), PTC (n 
 9), PDC (n 
 8), and ATC (n 
 12) snap-frozen tissues. The expression levels of genes in each sample were measured by comparing
its fluorescence threshold with the average fluorescence threshold of the NT samples. The average results of triplicate samples are plotted  SDs.
E1624 Di Maro et al Twist1 Targets in Thyroid Cancer Cells J Clin Endocrinol Metab, September 2014, 99(9):E1617–E1626
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 13 March 2015. at 01:58 For personal use only. No other uses without permission. . All rights reserved.
Heparan sulfate 6-O-sulfotransferase 2 (HS6ST2) is an
enzyme that attaches sulfate groups to glucosamine resi-
dues in heparan sulfate. Heparan sulfate proteoglycans
are ubiquitous components of the cell surface, extracellu-
lar matrix, and basement membranes and interact with
various ligands to influence cell growth, differentiation,
adhesion, and migration (26, 27). Importantly, it was re-
cently reported that the specific inhibition of HS6ST2 by
heparin and a high-molecular-weightEscherichia coliK5-
derived heparin-like polysaccharide (K5-NSOS) effi-
ciently reducedosteolytic lesionareaandmetastatic tumor
burden in amousemodel of breast cancer bonemetastasis
(26).
LEPREL1 encodes a member of the prolyl 3-hydrox-
ylase subfamily of 2-oxo-glutarate-dependent dioxyge-
nases (28). These enzymes play a critical role in collagen
chain assembly, stability, and cross-linking by catalyzing
posttranslational 3-hydroxylation of proline residues
(29). Hypoxia-inducible factor 1 activates the transcrip-
tion of collagen prolyl hydroxylases (30). Of note, Twist1
is a downstream target of hypoxia-inducible factor 1 (31).
Noteworthy, an ethyl 3,4-dihydroxybenzoate, aprolyl hy-
droxylase inhibitor, decreased tumor fibrosis and metas-
tasis in amousemodel of breast cancer (30).During cancer
progression, increased deposition of collagens can occur
within and near the primary tumors, and it is associated
with a poor outcome due to increased local invasion and
distant metastasis (32). Straightened and aligned collagen
fibers in tumor samples are predictive of patientmortality,
presumably because collagen fibers provide directional
cues that dictate cell morphology and promote cell migra-
tion as well as induce stiffness, which promotes tissue ten-
sion to enhance cancer progression (33). Indeed, in TPC-
Twist1 cells, we found upregulatedCOL1A1 (7.2 1.4),
COL4A1 (2.0 0.05), COL18A1 (1.7 0.1), COL4A2
(1.5  0.2) (Supplemental Table 2). These results are in
agreement with Hébrant and colleagues (11) who dem-
onstrated that one of the clusters that differentiated ATC
vs PTC is composed of genes involved in calcification and
fibrosis processes.
PDZK1IP1, also known as membrane-associated pro-
tein17 (MAP17), is a small 17-kDanonglycosylatedmem-
brane protein overexpressed in a great variety of human
carcinomas (22). Immunohistochemical analysis of
PDZK1IP1 shows that overexpression of the protein
strongly correlates with tumor progression (22, 23). The
increased malignant cell behavior induced by PDZK1IP1
is associated with an increase in reactive oxygen species
production, and the treatment of PDZK1IP1-expressing
cells with antioxidants resulted in a reduction in the tu-
morigenic properties of these cells (22, 23).
Coagulation factor II (thrombin) receptor-like 1
(F2RL1), also known as protease-activated receptor 2
(PAR2), is a member of the large family of 7-transmem-
brane-region receptors that couple to guanosine nucle-
otide-binding proteins and is a key signaling component
for proteases in vascular biology and tumor progression
(34). PAR2 is involved in tissue factor (TF) signaling path-
way and plays a crucial role in tumor growth. TF forms a
catalytic enzyme complex with coagulation factor VIIa,
and selective inhibition of TF-factor VIIa-PAR2 signaling
using a monoclonal antibody was shown to reduce breast
tumor growth (35). Consistent with the hypothesis that
F2RL1mediated signaling contributes to tumor growth in
breast cancer, mice lacking F2RL1 exhibited reduced tu-
mor growth in a model of spontaneous mammary tumors
(36).
Here, we showed by immunohistochemistry that LEP-
REL1 was overexpressed in 67% of ATC and in 26% of
PTC cases. In the same dataset, Twist1was overexpressed
in 62% of ATC and in 0% of PTC samples. Similarly,
many identified Twist1 targets were overexpressed also in
PTCwhere Twist1 is negative (Figure 5). It is possible that
other factors regulate the identified target genes in Twist1
negative samples. Furthermore,we have performed a gene
expression profile in TPC-Twist1 cells that, although they
express high levels of Twist1, are a cell line and thus could
be not representative of thyroid cancer complexity.
In conclusion, here we have identified a set of novel
direct targets of Twist1. The identified targets could be
important to mediate Twist1 biological effects also in
other malignancies such as breast and prostate carcinoma
and sarcoma where Twist1 is overexpressed (14, 15, 37).
All the genes identified are novel transcriptional targets of
Twist1 and are potential targets for cancer therapy. In-
deed, HS6ST2 and LEPREL1 are enzymes, whereas
PDZK1IP1 and F2RL1 are membrane proteins and thus
targetable by small molecules or monoclonal antibodies
respectively (38).
Identification of genes downstream transcription fac-
tors, ie, Twist1, could be important for clinical translation
of basic research. Directly inhibiting the transcription fac-
tors is currently difficult, as targeting large binding inter-
faces is not amenable to small-molecule inhibition. Twist1
is generally believed to be difficult to target due to its
nuclear localization and lack of a specific groove for tight
binding of a small molecule inhibitor. In particular the
absenceof a clear ligand-bindingdomain inTwist1 creates
ahurdle towarddeveloping inhibitors that can suppress its
function. Thus, downstream targets of Twist1 could be
more realistic for therapeutic intervention.
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Supplemental Methods 
 
Microarray analysis  
300 ng of purified total RNA from TPC-Twist1 cells (Twist1 mp1, Twist1 mp2, Twist1 Cl2) and 
TPC-pcDNA control cells were transcribed into cDNA using Superscript RT (Invitrogen, 
Carlsbad, CA, USA), in the presence of T7-oligo (dT) 24 primer, deoxyribonucleoside 
triphosphates (dNTPs), and T7 RNA polymerase promoter (Invitrogen). An in vitro transcription 
reaction was then performed to generate biotinylated cRNA which, after fragmentation, was used 
in a hybridization assay on Affymetrix U133 plus 2.0 GeneChip microarrays, according to 
manufacturer's protocol (GeneChip 3' ivt Express Kit, Affymetrix). The screening was conducted 
at Aarhus Biotechnology (Aarhus, Denmark). Normalization was performed by global scaling 
and analysis of differential expression was performed by Microarray Suite software 5.0 
(Affymetrix). The final results were imported into Microsoft Excel (Microsoft).  
 
Network and gene ontology analysis 
The set of input genes (158 up-regulated and 221 down-regulated genes) was uploaded into the 
Ingenuity Pathway Analysis (IPA) online tool (Ingenuity System Inc, www.ingenuity.com). IPA 
is a system that transforms large data sets into relevant networks biological processes, and 
pathways, containing direct or indirect relationships between genes based on known interactions 
in the literature. IPA computes a score for each biological process according to the fit of the user's  
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set of significant genes. The score indicates the likelihood of the genes in a biological process to 
cluster together not due to random chance. 
 
RNA extraction, cDNA synthesis, and quantitative real-time PCR 
Total RNA was isolated with the RNeasy Kit (Qiagen, Crawley, West Sussex, UK). The quality 
and concentration of the RNA was verified by the NanoDrop (Thermo Scientific, Waltham, MA, 
USA) and by the 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany); only samples 
with RNA integrity number value above 7 were used for further analysis. One µg of total RNA 
from each sample was reverse-transcribed with the QuantiTect® Reverse Transcription (Qiagen) 
according to manufacturer’s instructions. The expression level of each gene was measured by 
quantitative PCR assay, using the Universal ProbeLibray Set, Human (Roche, Basel, 
Switzerland). PCR reactions were performed in triplicate and fold changes were calculated with 
the formula: 2-(sample 1 ΔCt - sample 2 ΔCt), where ΔCt is the difference between the amplification 
fluorescent thresholds of the mRNA of interest and the mRNA of RNA polymerase 2 used as an 
internal reference. The primers used are listed in Supplemental Table 5.  
 
Migration and Invasion Assay 
The migration ability was evaluated with Transwell and Collagen I assay. The TPC-Twist1 (1 × 
105) and CAL62 cells (5 × 104) transfected with specific siRNAs, were resuspended respectively 
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in serum free and 2.5% serum culture medium and loaded onto the upper well of prehydrated 
polycarbonate membrane filter of 8 μm pore size (Costar, Cambridge, MA) or on a membrane 
coated with Collagen I at the bottom side (CytoSelected 24-Well Cell Haptotaxis Assay, Cell 
Biolabs, San Diego, CA). Medium (500 μl) that contained 2.5% serum (TPC-Twist1) or 10% 
serum (CAL62) was added to the lower well and cells were allowed to migrate for 24h (TPC-
Twist1) or for 48h (CAL62) at 37°C. Migrated cells were stained with crystal violet and 
quantified at OD 570 nm (Model 550 Microplate Reader, Biorad, Hercules, CA, USA). 
The invasion ability was evaluated with Matrigel and Collagen I invasion assay. The TPC-Twist1 
(1 × 105) and CAL62 cells (5 × 104) transfected with specific siRNAs, were resuspended 
respectively in serum free and 2.5% serum culture medium and loaded onto the upper well of 
prehydrated polycarbonate membrane filter of 8 μm pore size coated with 35 μg of reconstituted 
extracellular matrix (Matrigel, BD Biosciences, San Jose, CA) or on a membrane coated with 
Collagen I at the upper side (CytoSelected 24-Well Cell Invasion assay, Collagen I, 
Colorimetric Format, Cell Biolabs). Medium (500 μl) that contained 2.5% serum (TPC-Twist1) 
or 10% serum (CAL62) was added to the lower well and cells were allowed to migrate for 24h 
(TPC-Twist1) or for 48h at 37°C (CAL62). Invaded cells in Matrigel were fixed with 10% 
glutaraldehyde solution (Sigma-Aldrich, St. Louis, MO, USA) for 30 minutes, mounted on glass 
slides and stained with Hoechst (Sigma). Cell invasion in Matrigel was quantified by counting the 
number of stained nuclei in five individual fields in triplicate. Invaded cells in Collagen I were 
stained with crystal violet and quantified at OD 570 nm (Model 550 Microplate Reader, Biorad, 
Hercules, CA, USA). 
 
Transendothelial Cell Migration Assay 
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QCM Tumor Cell Transendothelial Migration Assay was used to analyze the ability of tumor 
cells to invade the endothelium (Millipore, Billerica, MA, USA). HUVEC (1 x 105 cells) were 
grown to confluence for 48h on cell culture inserts coated with fibronectin and then treated with  
20 ng/ml of TNFα for 18h. The TPC-Twist1 (1 × 105 silenced cells suspension) and CAL62 (5 × 
104 silenced cells suspension) were resuspended in serum free and in 2.5% serum culture medium 
(250 μl) respectively, added on the endothelial layer and left to migrate for 24h (TPC-Twist1) or 
for 48h (CAL62) at 37°C. Media (500 μl) that contained 2.5% serum (TPC-Twist1) or 10% 
serum (CAL62) was added to the lower well. Migrated cells were stained with Cell Stain Solution 
(Millipore) and color intensity was measured by OD 570 nm according to the assay instruction. 
 
Immunohistochemistry 
The study group included 86 patients who underwent total thyroidectomy at the Department of 
Surgery of the University of Pisa (Pisa, Italy) from 2010 to 2014.  
Hematoxylin-eosin stained sections of 86 patients from the archives of the section of Pathology of 
University of Pisa were re-evaluated independently by two pathologists (C.U., F.B.). A diagnostic 
concordance rate of 98% was achieved between the two investigators. 
The study group included 40 anaplastic thyroid carcinoma, 19 papillary thyroid carcinoma of 
classic variant. As control 27 normal tissues from controlateral dissection of adenomas or 
uninodular goiters were evaluated. Immunohistochemical analysis of Twist1, LEPREL1 
expression was performed on formalin-ﬁxed, parafﬁn-embedded (FFPE) tumor sections using 
mouse monoclonal anti-human of Twist1 (Twist 2C1a) (Santa Cruz Biotechnology, Inc. Dallas, 
Texas) and a rabbit polyclonal anti-human LEPREL1 (HPA007890, Sigma-Aldrich S.r.l. Milan, 
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Italy). Antibodies were optimized for automated slide stainer and sections were stained using the 
Benchmarck IHC automated slide stainer (Ventana Medical Systems, Tucson, Az). Staining 
>10% of tumor cells was considered positive for LEPREL1 and for Twist1.  
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Supplemental Table 1: List of the primers used in the ChIP. 
 
Gene Forward Primer Reverse Primer 
HS6ST2 5’-ggggtagagaagggcgtaaa-3’ 5’-cgacttgctatcggagacg-3’ 
COL1A1 5’-atgtttctcaccctgcacct-3’ 5’-gaatcaaatgccttcctcca-3’ 
KRT7 5’-atgtgtgccattgtgtagcc-3’ 5’-ctctgggctctgctgtgct-3’ 
F2RL1 5’-gccattccatgtcttctttcc-3’ 5’-gtagaggcaggtgggcaac-3’ 
LEPREL1 5’-gtgttaggcgtctggctgtt-3’ 5’-agaacctttggaggcaggag-3’ 
THRB 5’-cttgcagacatcagcagcat-3’ 5’-atccaaccatcttcccatga-3’ 
ID4 5’-tatggtttcggcaaatgtga-3’ 5’-tgttcaagaaggcacgttca-3’ 
RHOB 5’-ctgtccggtaacttcctcca-3’ 5’-ggagctggctgtctggag-3’ 
PDZK1 5’-caaaataacacctggaagctca-3’ 5’-caccctcaccaactcctctg-3’ 
PDZK1IP1 5’-cccagcattagagtcccaga-3’ 5’-agcctggcctatttcctgtt-3’ 
GAPDH 5’-cccaaagtcctcctgtttca-3’ 5’-gtcttgaggcctgagctac-3’ 
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Gene Title Gene Symbol Fold Change SD
Chromosomal 
Loca9on
Cellular 
Growth and 
Prolifera9on
Cell Death 
and 
Survival
Cellular 
Movement
Other 
func9ons
Not 
Classiﬁed
heparan sulfate 6‐O‐
sulfotransferase 2 HS6ST2 10,28173122 0,351188458 chrXq26.2 X
collagen, type I, alpha 1 COL1A1 7,222289403 1,410673598 chr17q21.33 X X X
GDNF family receptor 
alpha 1 GFRA1 6,919557528 0,608276253 chr10q26 X X X
keraPn 7 KRT7 5,567294029 0,8326664 chr12q12‐q13 X X
vang‐like 2 (van gogh, 
Drosophila) VANGL2 5,480655757 0,305505046 chr1q22‐q23 X
matrix‐remodelling 
associated 8  MXRA8 5,415015976 0,577350269 chr1p36.33 X
plakophilin 2 PKP2 5,339337988 0,873689495 chr12p11 X
coagulaPon factor II 
(thrombin) receptor‐like 
1 F2RL1 5,312989839 0,953939201 chr5q13 X X X
leprecan‐like 1 LEPREL1 4,994543441 0,472581563 chr3q28 X
thyroid hormone 
receptor, beta 
(erythroblasPc leukemia 
viral (v‐erb‐a) oncogene 
homolog 2, avian) THRB 4,883874803 0,871779789 chr3p24.2 X X
zinc ﬁnger, BED‐type 
containing 2 ZBED2 4,597610544 0,655743852 chr3q13.13 X
ADAM metallopepPdase 
with thrombospondin 
type 1 moPf, 5 
(aggrecanase‐2) ADAMTS5 4,369317144 0,850490055 chr21q21.3 X
inhibitor of DNA binding 
4, dominant negaPve 
helix‐loop‐helix protein ID4 4,336721203 0,264575131 chr6p22‐p21 X X
ras homolog gene family, 
member B RHOB 4,135412309 0,611010093 chr2p24 X X X
PDZ domain containing 1 PDZK1 3,993886633 0,550757055 chr1q21 X X
Supplementary Table2: Genes upregulated by Twist1 by ≥1.5 fold
netrin 4 NTN4 3,979515052 0,75055535 chr12q22‐q23 X X X
papilin, proteoglycan‐like 
sulfated glycoprotein PAPLN 3,94748841 0,702376917 chr14q24.2 X
cytochrome P450, family 
24, subfamily A, 
polypepPde 1 CYP24A1 3,895790353 0,971253486 chr20q13 X
ﬁlaggrin FLG 3,72986228 0,692820323 chr1q21.3 X
NUAK family, SNF1‐like 
kinase, 2 NUAK2 3,644961964 0,519615242 chr1q32.1 X X
coiled‐coil domain 
containing 80 CCDC80 3,585786458 0,86216781 chr3q13.2 X
transforming growth 
factor, beta‐induced, 
68kDa TGFBI 3,504545129 0,2 chr5q31 X X X
Suppression of 
tumorigenicity 7 like ST7L 3,453420992 0,871779789 chr1p13.2 X
prostaglandin I2 
(prostacyclin) synthase PTGIS 3,43195669 0,776745347 chr20q13.13 X
transgelin TAGLN 3,405866218 1,006644591 chr11q23.2 X
mal, T‐cell diﬀerenPaPon 
protein 2 MAL2 3,381182308 0,519615242 chr8q23 X
EGF‐like repeats and 
discoidin I‐like domains 3 EDIL3 3,288688661 0,635085296 chr5q14 X X
tumor‐associated calcium 
signal transducer 1 TACSTD1 3,241226113 0,953939201 chr2p21 X X
death‐associated protein 
kinase 1 DAPK1 3,211787362 0,6244998 chr9q34.1 X
LIM and cysteine‐rich 
domains 1 LMCD1 3,202603619 0,461880215 chr3p26‐p24 X
WAS protein family, 
member 3 WASF3 3,116089412 0,585946528 chr13q12 X
microphthalmia‐
associated transcripPon 
factor MITF 2,945811369 0,854400375 chr3p14.2‐p14.1 X X X
phospholipase C, beta 4 PLCB4 2,936408568 0,793725393 chr20p12 X
ADAM metallopepPdase 
with thrombospondin 
type 1 moPf, 1 ADAMTS1 2,930214545 0,781024968 chr21q21.2 X X X
chromosome 10 open 
reading frame 65 HOGA1 2,924178087 0,611010093 chr10q24.1 X
PDZK1 interacPng protein 
1 PDZK1IP1 2,901835211 0,577350269 chr1p33 X
inositol(myo)‐1(or 4)‐
monophosphatase 2 IMPA2 2,835027268 0,550757055 chr18p11.2 X
doublecorPn domain 
containing 2 DCDC2 2,765568919 0,642910051 chr6p22.1 X
Cbp/p300‐interacPng 
transacPvator, with 
Glu/Asp‐rich carboxy‐
terminal domain, 2 CITED2 2,717517969 0,86216781 chr6q23.3 X X X
homolog of rat pragma of 
Rnd2 PRAGMIN 2,645044724 0,56862407 chr8p23.1 X
myosin, light chain kinase MYLK 2,580367042 0,642910051 chr3q21 X X X
thrombospondin 1 THBS1 2,470516694 0,4163332 chr15q15 X X X
Kv channel interacPng 
protein 1 KCNIP1 2,446433025 0,608276253 chr5q35.1 X
argininosuccinate 
synthetase 1 ASS1 2,429964151 0,702376917 chr9q34.1 X
O‐6‐methylguanine‐DNA 
methyltransferase MGMT 2,419540831 0,4163332 chr10q26 X X
endothelial PAS domain 
protein 1 EPAS1 2,36398258 0,435889894 chr2p21‐p16 X X X
syncoilin, intermediate 
ﬁlament 1 SYNC1 2,361554172 0,585946528 chr1p34.3‐p33 X
alpha‐kinase 2 ALPK2 2,336479509 0,513160144 chr18q21.31 X
ring ﬁnger 144B RNF144B 2,28151547 0,503322296 chr6p22.3 X
apolipoprotein L domain 
containing 1 APOLD1 2,267236721 0,702376917 chr12p13.1 X
ribokinase RBKS 2,2545217 0,404145188 chr2p23.3 X
cystaPn E/M CST6 2,2545217 0,404145188 chr11q13 X X
SRY (sex determining 
region Y)‐box 4 SOX4 2,247681135 0,556776436 chr6p22.3 X X
GLIS family zinc ﬁnger 3 GLIS3 2,246526787 0,529150262 chr9p24.2 X
ATPase, class II, type 9A ATP9A 2,246526787 0,529150262 chr20q13.2 X
melanoma cell adhesion 
molecule MCAM 2,24373728 0,519615242 chr11q23.3 X X X
RAB40B, member RAS 
oncogene family RAB40B 2,237691725 0,351188458 chr17q25.3 X
growth arrest‐speciﬁc 6 GAS6 2,216209577 0,251661148 chr13q34 X X X
shroom family member 3 SHROOM3 2,205673738 0,435889894 chr4q21.1 X
transducin‐like enhancer 
of split 4 (E(sp1) 
homolog, Drosophila) TLE4 2,204871835 0,550757055 chr9q21.31 X
secreted phosphoprotein 
1 (osteoponPn, bone 
sialoprotein I, early T‐
lymphocyte acPvaPon 1) SPP1 2,173953455 0,642910051 chr4q21‐q25 X
immediate early 
response 5‐like IER5L 2,168360602 0,264575131 chr9q34.11 X
tubulin, alpha 1a TUBA1A 2,148548898 0,550757055 chr12q12‐q14.3 X X
uncoupling protein 2 
(mitochondrial, proton 
carrier) UCP2 2,103543126 0,404145188 chr11q13 X X X
collagen, type IV, alpha 1 COL4A1 2,09569795 0,057735027 chr13q34 X X X
small nuclear RNA 
acPvaPng complex, 
polypepPde 1, 43kDa SNAPC1 2,093480906 0,519615242 chr14q22 X
odz, odd Oz/ten‐m 
homolog 2 (Drosophila) ODZ2 2,057218164 0,550757055 chr5q34‐q35.1 X X
UDP‐glucose ceramide 
glucosyltransferase UGCG 2,057218164 0,550757055 chr9q31 X
prickle homolog 1 
(Drosophila) PRICKLE1 2,051577463 0,4 chr12q12 X
suppressor of cytokine 
signaling 2 SOCS2 2,004667006 0,550757055 chr12q X X X
interleukin 11 IL11 2,003204303 0,1
chr19q13.3‐
q13.4 X X X
tufelin 1 TUFT1 1,962675136 0,404145188 chr1q21 X
mixed lineage kinase 4 KIAA1804 1,95883413 0,404145188 chr1q42 X
enabled homolog 
(Drosophila) ENAH 1,95855963 0,115470054 chr1q42.12 X
PRKC, apoptosis, WT1, 
regulator PAWR 1,95571516 0,529150262 chr12q21 X X
PHD ﬁnger protein 17 PHF17 1,951719066 0,37859389 chr4q26‐q27 X
family with sequence 
similarity 83, member H FAM83H 1,942631582 0,321455025 chr8q24.3 X
arresPn domain 
containing 3 ARRDC3 1,941529905 0,5 chr5q14.3 X X
Bardet‐Biedl syndrome 
10 BBS10 1,931443504 0,458257569 chr12q21.2 X
keraPn 80 KRT80 1,914189457 0,4 chr12q13.13 X
transmembrane, prostate 
androgen induced RNA TMEPAI 1,90636884 0,360555128
chr20q13.31‐
q13.33 X X
progesterone receptor 
membrane component 2 PGRMC2 1,903870091 0,360555128 chr4q26 X
myosin, light chain 9, 
regulatory MYL9 1,900435804 0,346410162 chr20q11.23 X
phospholipase C, epsilon 
1 PLCE1 1,887667543 0,264575131 chr10q23 X X
transducin‐like enhancer 
of split 1 (E(sp1) 
homolog, Drosophila) TLE1 1,872534505 0,404145188 chr9q21.32 X
ﬁbroblast growth factor 2 
(basic) FGF2 1,867503395 0,37859389 chr4q26‐q27 X X X
RNA binding moPf, single 
stranded interacPng 
protein RBMS3 1,861009508 0,513160144 chr3p24‐p23 X
glutaminase GLS 1,859225418 0,351188458 chr2q32‐q34 X
Zinc ﬁnger protein 84 ZNF84 1,851404801 0,305505046 chr12q24.33 X
zinc ﬁnger protein 91 ZNF91 1,841776492 0,251661148 chr19p13.1‐p12 X
Rho guanine nucleoPde 
exchange factor (GEF) 5 ARHGEF5 1,836384281 0,2081666 chr7q33‐q35 X
RegulaPng synapPc 
membrane exocytosis 2 RIMS2 1,833669061 0,4163332 chr8q22.3 X
heterogeneous nuclear 
ribonucleoprotein A3 HNRPA3 1,831240653 0,404145188 chr2q31.2 X
GLI‐Kruppel family 
member GLI2 GLI2 1,827656868 0,404145188 chr2q14 X X X
LIM domain and acPn 
binding 1 LIMA1 1,817570466 0,351188458 chr12q13 X
transmembrane emp24 
domain traﬃcking 
protein 2 TMED2 1,812539356 0,321455025 chr12q24.31 X
FOS‐like anPgen 2 FOSL2 1,80210051 0,458257569 chr2p23.3 X X X
hepaPPs A virus cellular 
receptor 1 HAVCR1 1,800121539 0,251661148 chr5q33.2 X
KIAA0802 KIAA0802 1,798202369 0,458257569 chr18p11.22 X
par‐3 parPPoning 
defecPve 3 homolog (C. 
elegans) PARD3 1,797518837 0,230940108
chr10p11.22‐
p11.21 X
SMAD family member 7 SMAD7 1,778705022 0,360555128 chr18q21.1 X X X
kalirin, RhoGEF kinase KALRN 1,778705022 0,360555128 chr3q21.1‐q21.2 X
eukaryoPc translaPon 
elongaPon factor 1 alpha 
1 EEF1A1 1,776276614 0,346410162 chr6q14.1 X X
Cysteine rich 
transmembrane BMP 
regulator 1 (chordin‐like) CRIM1 1,776276614 0,346410162 chr2p21 X X
protease, serine, 23 PRSS23 1,776276614 0,346410162 chr11q14.1 X
unc‐51‐like kinase 2 (C. 
elegans) ULK2 1,765837768 0,472581563 chr17p11.2 X
angiomoPn like 2 AMOTL2 1,763571984 0,461880215 chr3q21‐q22 X
collagen, type XVIII, alpha 
1 COL18A1 1,743890634 0,1 chr21q22.3 X X X
placenta‐speciﬁc 8 PLAC8 1,743714804 0,404145188 chr4q21.22 X X
heat shock 22kDa protein 
8 HSPB8 1,724993353 0,288675135 chr12q24.23 X X
guanine nucleoPde 
binding protein (G 
protein), gamma 4 GNG4 1,71843823 0,251661148 chr1q42.3 X
UDP‐N‐acetyl‐alpha‐D‐
galactosamine:polypepP
de N‐
acetylgalactosaminyltrans
ferase 4 (GalNAc‐T4) GALNT4 1,708607945 0,404145188 chr12q21.3‐q22 X
WW and C2 domain 
containing 1 WWC1 1,707627892 0,152752523 chr5q35.1 X
heterogeneous nuclear 
ribonucleoprotein R HNRNPR 1,702235682 0,057735027 chr1p36.12 X
F11 receptor F11R 1,699070132 0,37859389 chr1q21.2‐q21.3 X X
galecPn‐related protein HSPC159 1,69585321 0,351188458 chr2p14 X
Fucosyltransferase 1 
(galactoside 2‐alpha‐L‐
fucosyltransferase, H 
blood group) FUT1 1,69585321 0,351188458 chr19q13.3 X
thioredoxin reductase 2 TXNRD2 1,68141923 0,458257569 chr22q11.21 X X X
KIT ligand KITLG 1,68141923 0,458257569 chr12q22 X
dual speciﬁcity 
phosphatase 16 DUSP16 1,677144378 0,230940108 chr12p13 X
RAB11 family interacPng 
protein 1 (class I) RAB11FIP1 1,677144378 0,230940108 chr8p11.22 X
inhibitor of DNA binding 
1, dominant negaPve 
helix‐loop‐helix protein ID1 1,677039394 0,435889894 chr20q11 X X X
family with sequence 
similarity 115, member A FAM115A 1,677039394 0,435889894 chr7q35 X X X
cylindromatosis (turban 
tumor syndrome) CYLD 1,673793557 0,2081666 chr16q12.1 X X X
B‐cell CLL/lymphoma 2 BCL2 1,673793557 0,2081666
chr18q21.33|18
q21.3 X X X
cleavage and 
polyadenylaPon speciﬁc 
factor 6, 68kDa CPSF6 1,673793557 0,2081666 chr12q15 X
tumor necrosis factor, 
alpha‐induced protein 2 TNFAIP2 1,66639871 0,4 chr14q32 X
prenylcysteine oxidase 1 PCYOX1 1,657324683 0,346410162 chr2p13.3 X
NUAK family, SNF1‐like 
kinase, 1 NUAK1 1,648004234 0,3 chr12q23.3 X X
armadillo repeat 
containing, X‐linked 3 ARMCX3 1,648004234 0,3
chrXq21.33‐
q22.2 X X
pleiomorphic adenoma 
gene‐like 1 PLAGL1 1,645470844 0,461880215 chr6q24‐q25 X X
zinc ﬁnger protein 395 ZNF395 1,643310043 0,264575131 chr8p21.1 X
vesicle‐associated 
membrane protein 3 
(cellubrevin) VAMP3 1,643310043 0,264575131 chr1p36.23 X
mitochondrial ribosomal 
protein L30 MRPL30 1,632499705 0,173205081 chr2q11.2 X
zinc ﬁnger protein 260 ZNF260 1,630135968 0,404145188 chr19q13.12 X
myristoylated alanine‐
rich protein kinase C 
substrate MARCKS 1,627107495 0,1 chr6q22.2 X
Ribosomal protein L37 RPL37 1,624504793 1,05367E‐08 chr5p13 X
phosphoribosyl 
pyrophosphate 
synthetase 1 PRPS1 1,611741492 0,305505046 chrXq21.32‐q24 X
nephroblastoma 
overexpressed gene NOV 1,600570055 0,230940108 chr8q24.1 X X X
ROD1 regulator of 
diﬀerenPaPon 1 (S. 
pombe) ROD1 1,598665371 0,2081666 chr9q32 X
programmed cell death 6 
interacPng protein PDCD6IP 1,598665371 0,2081666 chr3p22.3 X
CDC14 cell division cycle 
14 homolog B (S. 
cerevisiae) CDC14B 1,598665371 0,2081666 chr9q22.33 X
nucleosome assembly 
protein 1‐like 1 NAP1L1 1,596301634 0,4163332 chr12q21.2 X
zinc ﬁnger protein 558 ZNF558 1,593273161 0,152752523 chr19p13.2 X
lysophosphaPdylcholine 
acyltransferase 2 LPCAT2 1,582286993 0,351188458 chr16q12.2 X
glucosamine (N‐acetyl)‐6‐
sulfatase (Sanﬁlippo 
disease IIID) GNS 1,56709682 0,251661148 chr12q14 X
arginine vasopressin‐
induced 1 AVPI1 1,56170461 0,2081666 chr10q24.2 X
KIAA1600 KIAA1600 1,557010418 0,152752523 chr10q25.3 X
deleted in liver cancer 1 DLC1 1,554407716 0,115470054 chr8p22 X X X
mex‐3 homolog D (C. 
elegans) MEX3D 1,548452659 0,360555128 chr19p13.3 X
dopey family member 2 DOPEY2 1,533262485 0,264575131 chr21q22.2 X
ubiquiPn‐conjugaPng 
enzyme E2H (UBC8 
homolog, yeast) UBE2H 1,532250111 0,264575131 chr7q32 X
cysteine‐rich, angiogenic 
inducer, 61 CYR61 1,525441868 0,2 chr1p31‐p22 X X X
collagen, type IV, alpha 2 COL4A2 1,525441868 0,2 chr13q34 X X X
protein‐L‐isoaspartate (D‐
aspartate) O‐
methyltransferase 
domain containing 1 PCMTD1 1,518144974 0,1 chr8q11.23 X
keraPn 81 KRT81 1,518144974 0,1 chr12q13 X
acPn binding LIM protein 
1 ABLIM1 1,501693935 0,288675135 chr10q25 X
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peroxisomal biogenesis factor 5‐like PEX5L ‐32,00209 3,2470499 chr3q26.33 X
NADPH oxidase, EF‐hand calcium binding 
domain 5 NOX5 ‐25,62318 2,8219379 chr15q23 X
hydroxysteroid (11‐beta) dehydrogenase 
1 HSD11B1 ‐24,56294 2,2143472 chr1q32‐q41 X
protocadherin 7 PCDH7 ‐23,26581 2,5716402 chr4p15 X
interleukin 13 receptor, alpha 2 IL13RA2 ‐23,05602 2,6539279 chrXq13.1‐q28 X X
granzyme A (granzyme 1, cytotoxic T‐
lymphocyte‐associated serine esterase 3) GZMA ‐19,47463 1,3650397 chr5q11‐q12 X
Rho GTPase ac[va[ng protein 9 ARHGAP9 ‐15,03306 1,8556221 chr12q14 X
interleukin 1, beta IL1B ‐13,13285 2,1079216 chr2q14 X X X
hematopoie[c cell‐speciﬁc Lyn substrate 
1 HCLS1 ‐12,83846 2,0256686 chr3q13 X X X
G protein‐coupled receptor 65 GPR65 ‐11,24875 1,4422205 chr14q31‐q32.1 X
FAT tumor suppressor homolog 3 
(Drosophila) FAT3 ‐9,696294 2,0231988 chr11q14.3 X
solute carrier family 22 (organic ca[on 
transporter), member 18 an[sense SLC22A18AS ‐9,626603 1,6441817 chr11p15.5 X
BCL2‐related protein A1 BCL2A1 ‐9,266626 1,6623277 chr15q24.3 X X
linker for ac[va[on of T cells family, 
member 2 LAT2 ‐8,215016 1,40119 chr7q11.23 X
serpin pep[dase inhibitor, clade D 
(heparin cofactor), member 1 SERPIND1 ‐8,148235 1,6072751
chr22q11.2|22q
11.21 X
heat shock 70kDa protein 1A HSPA1A ‐7,849436 1,473092 chr6p21.3 X X X
myeloma overexpressed gene (in a subset 
of t(11;14) posi[ve mul[ple myelomas) MYEOV ‐7,781161 0,6806859 chr11q13 X
gap junc[on protein, beta 2, 26kDa GJB2 ‐7,678659 1,7039171 chr13q11‐q12 X X X
protease, serine, 3 (mesotrypsin) PRSS3 ‐7,638278 1,2583057 chr9p11.2 X
growth hormone receptor GHR ‐7,380771 1,0066446 chr5p13‐p12 X X
interleukin 1, alpha IL1A ‐7,078349 1,106044 chr2q14 X X X
synaptotagmin‐like 3 SYTL3 ‐6,859925 1,473092 chr6q25.3 X
vanin 1 VNN1 ‐6,5932 0,9165151 chr6q23‐q24 X
SLAIN mo[f family, member 1 SLAIN1 ‐6,301788 1,0535654 chr13q22.3 X
kera[n 15 KRT15 ‐6,145492 1,1357817 chr17q21.2 X
baculoviral IAP repeat‐containing 3 BIRC3 ‐6,133067 1,274101 chr11q22 X X
podoplanin PDPN ‐6,117213 1,3051181 chr1p36.21 X X
[ssue factor pathway inhibitor 2 TFPI2 ‐6,02203 1,3868429 chr7q22 X X X
chemokine (C‐X‐C mo[f) ligand 3 CXCL3 ‐5,685529 0,6806859 chr4q21 X X X
interleukin 7 IL7 ‐5,619633 0,9712535 chr8q12‐q13 X X X
Supplementary  Table 3: Genes downregulated by Twist1 by ≥1.5 fold
phospha[dylinositol 3,4,5‐trisphosphate‐
dependent RAC exchanger 1 PREX1 ‐5,467587 1,1150486 chr20q13.13 X
epithelial membrane protein 1 EMP1 ‐5,466603 1,7039171 chr12p12.3 X X
sorbin and SH3 domain containing 1 SORBS1 ‐5,363524 1,274101
chr10q23.3‐
q24.1 X
neurotrimin HNT ‐5,311195 1,0115994 chr11q25 X
absent in melanoma 1 AIM1 ‐5,183018 1,0785793 chr6q21 X
signal‐regulatory protein beta 1 SIRPB1 ‐5,174008 1,2489996 chr20p13 X
thrombomodulin THBD ‐5,131474 0,3785939 chr20p11.2 X X
Rho GDP dissocia[on inhibitor (GDI) beta ARHGDIB ‐4,985514 1,1532563 chr12p12.3 X X
G0/G1switch 2 G0S2 ‐4,87667 1,1846237 chr1q32.2‐q41 X
solute carrier family 7 (ca[onic amino 
acid transporter, y+ system), member 7 SLC7A7 ‐4,806772 0,8504901 chr14q11.2 X
carbohydrate (keratan sulfate Gal‐6) 
sulfotransferase 1 CHST1 ‐4,765183 1,2897028
chr11p11.2‐
p11.1 X
metastasis suppressor 1 MTSS1 ‐4,70774 0,6027714 chr8p22 X
olfactomedin‐like 2B OLFML2B ‐4,608608 0,4041452 chr1q23.3 X
lysosomal associated mul[spanning 
membrane protein 5 LAPTM5 ‐4,54608 1,1846237 chr1p34 X
ChaC, ca[on transport regulator homolog 
1 (E. coli) CHAC1 ‐4,488007 0,9539392 chr15q15.1 X
WD repeat domain 16 WDR16 ‐4,46431 0,5291503 chr17p13.1 X
N‐deacetylase/N‐sulfotransferase 
(heparan glucosaminyl) 2 NDST2 ‐4,447715 1,1150486 chr10q22 X
potassium channel tetramerisa[on 
domain containing 12 KCTD12 ‐4,345765 0,9291573 chr13q22.3 X
WD repeat domain 66 WDR66 ‐4,310515 1,1135529 chr12q24.31 X
frizzled homolog 8 (Drosophila) FZD8 ‐4,264583 0,9451631 chr10p11.21 X
Friend leukemia virus integra[on 1 FLI1 ‐4,181213 0,9539392
chr11q24.1‐
q24.3 X X
stanniocalcin 1 STC1 ‐4,119437 1,0016653 chr8p21‐p11.2 X X X
neuromedin U NMU ‐4,040515 0,4932883 chr4q12 X
sine oculis binding protein homolog 
(Drosophila) SOBP ‐4,039766 0,7937254 chr6q21 X
secretory leukocyte pep[dase inhibitor SLPI ‐4,039766 0,7937254 chr20q12 X X X
FOS‐like an[gen 1 FOSL1 ‐4,025425 0,6658328 chr11q13 X X X
HOP homeobox HOPX ‐4,000069 0,7549834 chr4q11‐q12 X
roundabout homolog 4, magic 
roundabout (Drosophila) ROBO4 ‐3,998551 0,6027714 chr11q24.2 X
interleukin 27 receptor, alpha IL27RA ‐3,976065 0,7 chr19p13.11 X X X
protein tyrosine phosphatase, receptor 
type, N polypep[de 2 PTPRN2 ‐3,940634 0,6557439 chr7q36 X
interleukin 7 receptor IL7R ‐3,93157 0,8504901 chr5p13 X X
coronin, ac[n binding protein, 2B CORO2B ‐3,902654 1,0692677 chr15q23 X
sprouty homolog 4 (Drosophila) SPRY4 ‐3,8868 0,8386497 chr5q31.3 X
pentraxin‐related gene, rapidly induced 
by IL‐1 beta PTX3 ‐3,847034 0,6429101 chr3q25 X X
sema domain, immunoglobulin domain 
(Ig), transmembrane domain (TM) and 
short cytoplasmic domain, (semaphorin) 
4B SEMA4B ‐3,83427 0,7767453 chr15q25 X
glycine dehydrogenase (decarboxyla[ng) GLDC ‐3,818011 0,6027714 chr9p22 X
cys[n 1 CYS1 ‐3,805593 0,5686241 chr2p25.1 X
cortac[n CTTN ‐3,765608 1,040833 chr11q13 X X
leucine rich repeat neuronal 3 LRRN3 ‐3,624993 0,321455 chr7q31.1 X
spen homolog, transcrip[onal regulator 
(Drosophila) SPEN ‐3,612935 0,9643651
chr1p36.33‐
p36.11 X
v‐maf musculoaponeuro[c ﬁbrosarcoma 
oncogene homolog F (avian) MAFF ‐3,608241 0,9539392 chr22q13.1 X
methylenetetrahydrofolate 
dehydrogenase (NADP+ dependent) 2‐
like MTHFD2L ‐3,591564 0,8504901 chr4q13.3 X
Solute carrier family 20 (phosphate 
transporter), member 1 SLC20A1 ‐3,446013 0,305505 chr2q11‐q14 X X
coiled‐coil domain containing 4 CCDC4 ‐3,436091 0,5507571 chr4p13 X
laminin, gamma 2 LAMC2 ‐3,420203 0,8326664 chr1q25‐q31 X
six transmembrane epithelial an[gen of 
the prostate 1 STEAP1 ‐3,368923 0,6 chr7q21 X
G protein‐coupled receptor 92 GPR92 ‐3,313847 0,4582576 chr12p13.31 X
nuclear receptor interac[ng protein 3 NRIP3 ‐3,299529 0,6658328 chr11p15.3 X
ATP synthase mitochondrial F1 complex 
assembly factor 2 ATPAF2 ‐3,209763 0,6110101 chr17p11.2 X
Rho GTPase ac[va[ng protein 22 ARHGAP22 ‐3,181882 0,5507571 chr10q11.22 X X
transmembrane protein 163 TMEM163 ‐3,180937 0,7211103 chr2q21.3 X
calmin (calponin‐like, transmembrane) CLMN ‐3,16568 0,4932883 chr14q32.13 X
phytoceramidase, alkaline PHCA ‐3,155785 0,8144528 chr11q13.5 X
high mobility group AT‐hook 1 HMGA1 ‐3,144861 0,6557439 chr6p21 X X X
tumor necrosis factor (TNF superfamily, 
member 2) TNF ‐3,139666 0,4163332 chr6p21.3 X X X
ca[on channel, sperm associated 1 CATSPER1 ‐3,129744 0,6082763 chr11q12.1 X
leupaxin LPXN ‐3,103904 0,5567764 chr11q12.1 X
ras‐related C3 botulinum toxin substrate 
2 (rho family, small GTP binding protein 
Rac2) RAC2 ‐3,07007 0,4582576 chr22q13.1 X X X
cysta[n F (leukocysta[n) CST7 ‐3,064678 0,4358899 chr20p11.21 X
C‐type lec[n domain family 11, member 
A CLEC11A ‐3,040406 0,3464102 chr19q13.3 X X X
CD44 molecule (Indian blood group) CD44 ‐2,954289 0,5773503 chr11p13 X X X
dedicator of cytokinesis 4 DOCK4 ‐2,925812 0,6928203 chr7q31.1 X X
cytochrome P450, family 2, subfamily J, 
polypep[de 2 CYP2J2 ‐2,922883 0,4932883 chr1p31.3‐p31.2 X X X
glycerophosphodiester 
phosphodiesterase domain containing 5 GDPD5 ‐2,892167 0,4041452
chr11q13.4‐
q13.5 X
fumarylacetoacetate hydrolase 
(fumarylacetoacetase) FAH ‐2,891815 0,6244998 chr15q23‐q25 X X
cyclin D1 CCND1 ‐2,887121 0,6082763 chr11q13 X X X
eukaryo[c transla[on ini[a[on factor 3, 
subunit M EIF3M ‐2,881357 0,3511885 chr11p13 X
coiled‐coil and C2 domain containing 2A CC2D2A ‐2,862656 0,2516611 chr4p15.33 X
kynureninase (L‐kynurenine hydrolase) KYNU ‐2,86091 0,7234178 chr2q22.2 X
interleukin‐1 receptor‐associated kinase 2 IRAK2 ‐2,831444 0,4582576 chr3p25.3 X
arres[n, beta 1 ARRB1 ‐2,831444 0,4582576 chr11q13 X X X
EH‐domain containing 1 EHD1 ‐2,831444 0,4582576 chr11q13 X X
SPC24, NDC80 kinetochore complex 
component, homolog (S. cerevisiae) SPC24 ‐2,829027 0,6658328 chr19p13.2 X
axin 2 (conduc[n, axil) AXIN2 ‐2,814189 0,4 chr17q23‐q24 X X
UDP‐N‐acetyl‐alpha‐D‐
galactosamine:polypep[de N‐
acetylgalactosaminyltransferase 12 
(GalNAc‐T12) GALNT12 ‐2,804475 0,7767453 chr9q22.33 X
Protocadherin alpha cluster PCDHA ‐2,80387 0,3605551 chr5q31 X
serine/threonine kinase 17b STK17B ‐2,80387 0,3605551 chr2q32.3 X X
microtubule associated serine/threonine 
kinase family member 4 MAST4 ‐2,798123 0,7571878 chr5q12.3 X
Tetraspanin 18 TSPAN18 ‐2,79306 0,3 chr11p11.2 X
tumor necrosis factor (ligand) 
superfamily, member 9 TNFSF9 ‐2,766542 0,5033223 chr19p13.3 X X X
FERM domain containing 4A FRMD4A ‐2,759245 0,4725816 chr10p13 X
EGF, latrophilin and seven 
transmembrane domain containing 1 ELTD1 ‐2,755052 0,6658328 chr1p33‐p32 X
sor[ng nexin 8 SNX8 ‐2,739201 0,4041452 chr7p22.2 X
tribbles homolog 3 (Drosophila) TRIB3 ‐2,733221 0,781025 chr20p13‐p12.2 X
an[gen p97 (melanoma associated) 
iden[ﬁed by monoclonal an[bodies 
133.2 and 96.5 MFI2 ‐2,721217 0,5859465 chr3q28‐q29 X
glucuronidase, beta pseudogene 1 GUSBP1 ‐2,694067 0,1154701 chr5q13.2 X
unc‐5 homolog B (C. elegans) UNC5B ‐2,689649 0,4932883 chr10q22.1 X X X
cytochrome P450, family 2, subfamily R, 
polypep[de 1 CYP2R1 ‐2,667002 0,4163332 chr11p15.2 X
AHNAK nucleoprotein AHNAK ‐2,645873 0,321455 chr11q12.2 X
proges[n and adipoQ receptor family 
member VIII PAQR8 ‐2,621869 0,1527525 chr6p12.1 X
adaptor‐related protein complex 1, sigma 
2 subunit AP1S2 ‐2,602101 0,4582576 chrXp22.2 X
oligonucleo[de/oligosaccharide‐binding 
fold containing 1 OBFC1 ‐2,597406 0,4358899 chr10q24.33 X
UDP‐GlcNAc:betaGal beta‐1,3‐N‐
acetylglucosaminyltransferase‐like 1 B3GNTL1 ‐2,576374 0,3605551 chr17q25.3 X
zinc ﬁnger CCCH‐type containing 12C ZC3H12C ‐2,576277 0,3464102 chr11q22.3 X
SH3‐domain binding protein 5 (BTK‐
associated) SH3BP5 ‐2,557579 0,5507571 chr3p24.3 X
abhydrolase domain containing 2 ABHD2 ‐2,557579 0,5507571 chr15q26.1 X
adenylate kinase 5 AK5 ‐2,54967 0,1732051 chr1p31 X
glycine‐N‐acyltransferase‐like 1 GLYATL1 ‐2,543891 0,1 chr11q12.1 X
Rho GTPase ac[va[ng protein 18 ARHGAP18 ‐2,513586 0,4041452 chr6q22.33 X
OTU domain, ubiqui[n aldehyde binding 
2 OTUB2 ‐2,509109 0,4163332 chr14q32.13 X
RAB38, member RAS oncogene family RAB38 ‐2,444207 0,3785939 chr11q14 X
ventricular zone expressed PH domain 
homolog 1 (zebraﬁsh) VEPH1 ‐2,420203 0,305505 chr3q24‐q25 X
dysbindin (dystrobrevin binding protein 
1) domain containing 2 /// SYS1‐DBNDD2
DBNDD2 /// SYS1‐
DBNDD2 ‐2,407127 0,2081666 chr20q13.12 X
carbonyl reductase 4 CBR4 ‐2,377039 0,4358899 chr4q32.3 X
pleckstrin homology‐like domain, family 
A, member 1 PHLDA1 ‐2,377039 0,4358899 chr12q15 X X
dihydropyrimidinase‐like 3 DPYSL3 ‐2,377039 0,4358899 chr5q32 X X
popeye domain containing 3 POPDC3 ‐2,366399 0,4 chr6q21 X
oxysterol binding protein‐like 6 OSBPL6 ‐2,35959 0,3605551 chr2q31‐q32.1 X
UV radia[on resistance associated gene UVRAG ‐2,348004 0,3 chr11q13.5 X
serpin pep[dase inhibitor, clade A (alpha‐
1 an[proteinase, an[trypsin), member 1 SERPINA1 ‐2,342225 0,2645751 chr14q32.1 X X X
osteoclast associated, immunoglobulin‐
like receptor OSCAR ‐2,334928 0,2 chr19q13.42 X
reelin RELN ‐2,327107 0,1 chr7q22 X
rho/rac guanine nucleo[de exchange 
factor (GEF) 2 ARHGEF2 ‐2,314252 0,4725816 chr1q21‐q22 X
CDC42 eﬀector protein (Rho GTPase 
binding) 4 CDC42EP4 ‐2,292423 0,3785939 chr17q24‐q25 X
ERO1‐like beta (S. cerevisiae) ERO1LB ‐2,278408 0,305505 chr1q42.2‐q43 X
diﬀeren[ally expressed in FDCP 6 
homolog (mouse) DEF6 ‐2,265332 0,2081666
chr6p21.33‐
p21.1 X X
proteasome (prosome, macropain) 
subunit, beta type, 9 (large 
mul[func[onal pep[dase 2) PSMB9 ‐2,25994 0,1527525 chr6p21.3 X
CD82 molecule CD82 ‐2,24935 0,4932883 chr11p11.2 X X X
protein kinase (cAMP‐dependent, 
cataly[c) inhibitor alpha PKIA ‐2,229635 0,4163332 chr8q21.12 X
family with sequence similarity 131, 
member A FAM131A ‐2,229635 0,4163332 chr3q27.1 X
centaurin, delta 2 CENTD2 ‐2,21562 0,3511885 chr11q13.4 X
citron (rho‐interac[ng, serine/threonine 
kinase 21) CIT ‐2,21124 0,321455 chr12q24 X X X
jun dimeriza[on protein 2 JDP2 ‐2,207238 0,305505 chr14q24.3 X X
HIV‐1 Tat interac[ve protein 2, 30kDa HTATIP2 ‐2,204449 0,2886751 chr11p15.1 X X
integrin‐linked kinase ILK ‐2,20043 0,2516611
chr11p15.5‐
p15.4 X X X
nuclear factor of kappa light polypep[de 
gene enhancer in B‐cells inhibitor, alpha NFKBIA ‐2,20043 0,2516611 chr14q13 X X X
endothelin conver[ng enzyme 1 ECE1 ‐2,20043 0,2516611 chr1p36.1 X
t‐complex 11 (mouse)‐like 1 TCP11L1 ‐2,195038 0,2081666 chr11p13 X
transforming growth factor beta regulator 
1 TBRG1 ‐2,195038 0,2081666 chr11q24.2 X
zinc ﬁnger protein 91 homolog (mouse) ZFP91 ‐2,148453 0,3605551 chr11q12 X
ﬁbrillin 2 (congenital contractural 
arachnodactyly) FBN2 ‐2,148453 0,3605551 chr5q23‐q31 X X
extra spindle pole bodies homolog 1 (S. 
cerevisiae) ESPL1 ‐2,137642 0,3 chr12q X X
tumor necrosis factor receptor 
superfamily, member 11a, NFKB ac[vator TNFRSF11A ‐2,137642 0,3 chr18q22.1 X X
family with sequence similarity 149, 
member A FAM149A ‐2,133262 0,2645751 chr4q35.2 X
famy acid desaturase 1 FADS1 ‐2,13225 0,2645751
chr11q12.2‐
q13.1 X
amyloid beta (A4) precursor‐like protein 2 APLP2 ‐2,13225 0,2645751
chr11q23‐
q25|11q24 X
hydroxymethylbilane synthase HMBS ‐2,125442 0,2 chr11q23.3 X
CD40 molecule, TNF receptor superfamily 
member 5 CD40 ‐2,122839 0,1732051 chr20q12‐q13.2 X X X
moesin MSN ‐2,076827 0,1732051 chrXq11.2‐q12 X X
deformed epidermal autoregulatory 
factor 1 (Drosophila) DEAF1 ‐2,070475 0,305505 chr11p15.5 X
LysM, puta[ve pep[doglycan‐binding, 
domain containing 2 LYSMD2 ‐2,070475 0,305505 chr15q21.2 X
cysteinyl‐tRNA synthetase CARS ‐2,022735 0,4163332 chr11p15.5 X
solute carrier family 39 (zinc transporter), 
member 8 SLC39A8 ‐2,020763 0,4041452 chr4q22‐q24 X
6‐pyruvoyltetrahydropterin synthase PTS ‐2,001839 0,305505
chr11q22.3‐
q23.3 X
CHK1 checkpoint homolog (S. pombe) CHEK1 ‐1,999236 0,2886751 chr11q24‐q24 X X
transmembrane protein 41B TMEM41B ‐1,995486 0,2516611 chr11p15.4 X
Cas‐Br‐M (murine) ecotropic retroviral 
transforming sequence CBL ‐1,995486 0,2516611 chr11q23.3 X X X
ring ﬁnger and FYVE‐like domain 
containing 1 RFFL ‐1,995486 0,2516611 chr17q12 X
ring ﬁnger protein 26 RNF26 ‐1,993372 0,2309401 chr11q23 X
transmembrane protein 179B TMEM179B ‐1,993372 0,2309401 chr11q12.3 X
TRAF‐interac[ng protein with a forkhead‐
associated domain TIFA ‐1,993372 0,2309401 chr4q25 X
interferon induced transmembrane 
protein 2 (1‐8D) IFITM2 ‐1,990455 0,2081666 chr11p15.5 X
HIRA interac[ng protein 3 HIRIP3 ‐1,990455 0,2081666 chr16p11.2 X
proteasome (prosome, macropain) 26S 
subunit, non‐ATPase, 13 PSMD13 ‐1,990455 0,2081666 chr11p15.5 X
apolipoprotein B mRNA edi[ng enzyme, 
cataly[c polypep[de‐like 3B APOBEC3B ‐1,986075 0,1527525
chr22q13.1‐
q13.2 X
ribosomal protein S6 kinase, 90kDa, 
polypep[de 5 RPS6KA5 ‐1,986075 0,1527525 chr14q31‐q32.1 X X X
centaurin, delta 3 CENTD3 ‐1,986075 0,1527525 chr5q31.3 X X
myosin phosphatase‐Rho interac[ng 
protein M‐RIP ‐1,986075 0,1527525 chr17p11.2 X
paired‐like homeodomain 1 PITX1 ‐1,981381 0,057735 chr5q31 X
mul[ple C2 domains, transmembrane 2 MCTP2 ‐1,981381 0,057735 chr15q26.2 X
mitogen‐ac[vated protein kinase kinase 
kinase kinase 4 MAP4K4 ‐1,930584 0,2645751 chr2q11.2‐q12 X X
Rho GTPase ac[va[ng protein 5 ARHGAP5 ‐1,930584 0,2645751 chr14q12 X X
transmembrane emp24‐like traﬃcking 
protein 10 (yeast) TMED10 ‐1,930584 0,2645751 chr14q24.3 X
TMEM9 domain family, member B TMEM9B ‐1,923288 0,2 chr11p15.3 X
ﬁbroblast growth factor (acidic) 
intracellular binding protein FIBP ‐1,921174 0,1732051 chr11q13.1 X
WD repeat domain 33 WDR33 ‐1,921174 0,1732051 chr2q14.3 X
mediator complex subunit 19 MED19 ‐1,920859 0,1732051 chr11q12.1 X
DIX domain containing 1 DIXDC1 ‐1,916479 0,1 ‐‐‐ X
coiled‐coil domain containing 15 CCDC15 ‐1,916479 0,1 chr11q24.2 X
dehydrogenase/reductase (SDR family) 
member 1 DHRS1 ‐1,916479 0,1 chr14q12 X
ATP binding domain 4 ATPBD4 ‐1,914214 0 chr15q14 X
cannabinoid receptor interac[ng protein 
1 CNRIP1 ‐1,862472 0,2516611 chr2p14 X
CD59 molecule, complement regulatory 
protein CD59 ‐1,862472 0,2516611 chr11p13 X X X
ribonucleo[de reductase M1 polypep[de RRM1 ‐1,862472 0,2516611 chr11p15.5 X X
CDK2‐associated protein 2 CDK2AP2 ‐1,853692 0,1527525 chr11q13 X
twinﬁlin, ac[n‐binding protein, homolog 
2 (Drosophila) TWF2 ‐1,851577 0,1154701 chr3p21.1 X
ataxia telangiectasia mutated ATM ‐1,849312 0,057735 chr11q22‐q23 X X X
Sin3A‐associated protein, 30kDa SAP30 ‐1,792876 0,2081666 chr4q34.1 X
poly(A) polymerase alpha PAPOLA ‐1,78879 0,1527525 chr14q32.31 X
calcium/calmodulin‐dependent protein 
kinase IV CAMK4 ‐1,78879 0,1527525 chr5q21.3 X X X
peroxiredoxin 5 PRDX5 ‐1,78879 0,1527525 chr11q13 X
glucosidase, alpha; neutral AB GANAB ‐1,786524 0,1154701 chr11q12.3 X
traﬃcking protein par[cle complex 4 TRAPPC4 ‐1,725708 0,1732051 chr11q23.3 X
protein phosphatase 2 (formerly 2A), 
regulatory subunit B'', gamma PPP2R3C ‐1,721622 0,1 chr14q13.2 X
growth arrest‐speciﬁc 2 like 1 GAS2L1 ‐1,721622 0,1 chr22q12.2 X
coﬁlin 1 (non‐muscle) CFL1 ‐1,665186 0,2081666 chr11q13 X X X
microsomal glutathione S‐transferase 2 MGST2 ‐1,658834 0,1154701 chr4q28.3 X
metastasis associated lung 
adenocarcinoma transcript 1 (non‐
protein coding) MALAT1 ‐1,65672 0,057735 chr11q13.1 X
cyclic AMP phosphoprotein, 19 kD ARPP‐19 ‐1,533117 0,1 chr15q21.2 X
calmodulin 1 (phosphorylase kinase, 
delta) CALM1 ‐1,533117 0,1 chr14q24‐q31 X X
epithelial membrane protein 3 EMP3 ‐1,533117 0,1 chr19q13.3 X X
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Supplemental Table 4: List of top 16 up-regulated genes. 
 
Gene Fold Change Molecular and Cellular Bio Function 
HS6ST2 10.28 Cellular Growth and Proliferation 
COL1A1 7.22 Cellular growth and Proliferation/ Cell Death and Survival/ 
Cellular Movement 
GFRA1 6.91 Cellular growth and Proliferation/ Cell Death and Survival/ 
Cellular Movement 
KRT7 5.56 Cellular growth and Proliferation/ Cellular Movement 
VANGL2 5.48 Cellular Assembly and Organization/ Cellular Function and 
Maintenance 
MXRA8 5.41 Cancer 
PKP2 5.33 Cellular Assembly and Organization 
F2RL1 5.31 Cellular growth and Proliferation/ Cell Death and Survival/ 
Cellular Movement 
LEPREL1 4.99 Cellular Growth and Proliferation 
THRB 4.88 Cellular growth and Proliferation/ Cellular Movement 
ZBED2 4.59 Not Classified 
ADAMTS5 4.36 Cancer 
ID4 4.33 Cellular growth and Proliferation/ Cell Death and Survival 
RHOB 4.13 Cellular Growth and Proliferation/ Cell Death and Survival/ 
Cellular Movement 
PDZK1 3.99 Cellular Growth and Proliferation/ Cell Death and Survival 
PDZK1IP1 2.90 Cellular Growth and Proliferation 
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Supplemental Table 5: List of the primers used in the Q-RT-PCR. 
 
Gene Forward Primer Reverse Primer 
HS6ST2 5’-tgcgatcttctccaagattttc-3’ 5’-cgatcacggcaaataggaag-3’ 
COL1A1 5’-atgttcagctttgtggacctc-3’ 5’-ctgtacgcaggtgattggtg-3’ 
KRT7 5’-caggctgagatcgacaacatc-3’ 5’-cttggcacgagcatcctt-3’ 
VANGL2 5’-gccagccgcttctacaac-3’ 5’-tctccaggatccacactgc-3’ 
PKP2 5’-tgtcagaggaaccattgcag-3’ 5’-ggttatgaagaatgcacacacaa-3’ 
F2RL1 5’-tgctagcagcctctctctcc-3’ 5’-aggcttcttcctttagaggatctatt-3’ 
LEPREL1 5’-tgcagattgcttaattccttga-3’ 5’-ctcagggttagccacgaaaa-3’ 
THRB 5’-gggcactggtaatttggcta-3’ 5’-cagaaggaaatcgcagatcc-3’ 
ZBED2 5’-gagagaagtccagagccttgc-3’ 5’-aagcagctcaccatactccac-3’ 
ADAMTS5 5’-taagccctggtccaaatgc-3’ 5’-aggtccagcaaacagttacca-3’ 
ID4 5’-tgcagtgcgatatgaacgac-3’ 5’-gcaggatctccactttgctg-3’ 
RHOB 5’-tatgtggccgacattgagg-3’ 5’-gcggtcgtagtcctcctg-3’ 
PDZK1 5’-ccggctctgctatctcgt-3’ 5’-tcatgtacaccccctttttacc-3’ 
PDZK1IP1 5’-gcagtcaaccacttctggtg-3’ 5’-gacggtcaggatcatgtgtg-3’ 
RNApol 5’-gcgatgagaacaagatgcaa-3’ 5’-cgcaggaagacatcatcatc-3’ 
Twist1 5’-gctcagctacgccttctc-3’ 5’-ccttctctggaaacaatgacattct-3’ 
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Supplemental Table 6: LEPREL1 expression by immunohistochemistry in thyroid samples 
(n=86). 
Tissue* LEPREL1 positivity 
Percentage of positive samples (positive/total samples) 
  
NT 0% (0/27) 
  
 
PTC 
 
26% (5/19) 
+ a 0% (0/19) 
++ b 26% (5/19) 
+++ c 0% (0/19) 
    
ATC 
 
67% (27/40) 
+ a 12.5% (5/40) 
++ b 12.5% (5/40) 
+++ c 42% (17/40) 
 
* NT= normal thyroid, PTC= papillary thyroid carcinoma, ATC= anaplastic thyroid carcinoma. 
 
a +:  >10–≤30% of positive cells. 
b ++:  >30–≤60% of positive cells. 
c +++: >60% of positive cells. 
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Supplementary Figure S1. Summary of Ingenuity Pathway Analysis. List of Top Bio Functions 
is divided in three different categories: Disease and Disorders, Molecular and Cellular Function, 
Physiological System Development and Function. The number of genes in each category and p-
values corresponding to each single function are indicated on the right side.  
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Supplementary Figure S2. Graphic representation of Ingenuity Pathway Analysis classification. 
The number of the genes for each category is reported on y axis. 
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Supplementary Figure S3. Expression levels of Twist1 targets in TPC transfected cells. Q-RT-
PCR of the indicated genes in TPC-Twist1 cells in comparison to vector control cells (pcDNA 
mp). Values represent the average of triplicate experiments ± standard deviations. Asterisks 
indicate p < 0.001 (***).  13 
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Supplementary Figure S4. Expression levels of Twist1 targets in CAL62 transfected cells. Q-
RT-PCR of Twist1 in CAL62 shTwist1 mp cells in comparison to vector control cells (shLUC 
mp). Values represent the average of triplicate experiments ± standard deviations. Asterisks 
indicate p < 0.001 (***). 
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Supplementary Figure S5. Twist1 affects the ability of TPC and CAL62 cells to migrate in 
Collagen I matrix. A-C. TPC (A) and CAL62 (C) transfected cells were seeded onto the insert 
and incubated for 24h and 48h respectively. Then cells were stained and photographed. B-D. 
Migration ability was expressed as absorbance at OD 570 nm. Values represent the average of 
triplicate experiments ± standard deviations. Asterisks indicate p < 0.001 (***). 
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Supplementary Figure S6. Twist1 affects the ability of TPC and CAL62 cells to invade the 
Collagen I matrix. A-C. TPC (A) and CAL62 (C) transfected cells were seeded on insert and 
allowed to invade for 24h and 48h respectively. B-D. Invasive ability was expressed as 
absorbance at OD 570 nm. Values represent the average of triplicate experiments ± standard 
deviations. Asterisks indicate p < 0.001 (***). 
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Supplementary Figure S7. Twist1 affects the ability of TPC and CAL62 cells to migrate 
through endothelium cells. A-C. TPC and CAL62 transfected cells were seeded on confluent 
monolayer of endothelial HUVEC cells and incubated for 24h and 48h respectively. Then cells 
were stained and photographed. HUVEC only was used as negative control. B-D. Quantification 
of the assay, migration ability was expressed as absorbance at OD 570 nm. Values represent the 
average of triplicate experiments ± standard deviations. Asterisks indicate p < 0.001 (***). 
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Supplementary Fig. S8: Twist1 directly binds the promoter of the indicated genes. Schematic 
representation of the E-box consensus sequences (CANNTG) in the promoter regions of the top 
ten up-regulated genes. In black are reported the E-box amplified in ChIP assay. 
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Supplementary Fig. S9 Immunohistochemical analysis of LEPREL1 protein expression in 
normal and malignant thyroid tissues. A. Representative histological sections from normal 
thyroid (NT; 20X magnification) and anaplastic thyroid carcinoma (B) (ATC; 20X 
magnifications) stained with anti LEPREL1 antibody are shown.  
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http://www.molecular-cancer.com/content/13/1/160RESEARCH Open AccessAnterior gradient protein 2 promotes survival,
migration and invasion of papillary thyroid
carcinoma cells
Gennaro Di Maro1, Paolo Salerno1, Kristian Unger2, Francesca Maria Orlandella1, Mario Monaco3,
Gennaro Chiappetta3, Gerry Thomas2, Malgorzata Oczko-Wojciechowska4, Mariorosario Masullo5, Barbara Jarzab4,
Massimo Santoro1 and Giuliana Salvatore5*Abstract
Background: Through a transcriptome microarray analysis, we have isolated Anterior gradient protein 2 (AGR2) as a
gene up-regulated in papillary thyroid carcinoma (PTC). AGR2 is a disulfide isomerase over-expressed in several
human carcinomas and recently linked to endoplasmic reticulum (ER) stress. Here, we analyzed the expression of
AGR2 in PTC and its functional role.
Methods: Expression of AGR2 was studied by immunohistochemistry and real time PCR in normal thyroids
and in PTC samples. The function of AGR2 was studied by knockdown in PTC cells and by ectopic expression
in non-transformed thyroid cells. The role of AGR2 in the ER stress was analyzed upon treatment of cells,
expressing or not AGR2, with Bortezomib and analyzing by Western blot the expression levels of GADD153.
Results: PTC over-expressed AGR2 at mRNA and protein levels. Knockdown of AGR2 in PTC cells induced
apoptosis and decreased migration and invasion. Ectopic expression of AGR2 in non-transformed human thyroid cells
increased migration and invasion and protected cells from ER stress induced by Bortezomib.
Conclusions: AGR2 is a novel marker of PTC and plays a role in thyroid cancer cell survival, migration, invasion and
protection from ER stress.
Keywords: Thyroid cancer, AGR2, Endoplasmic reticulum stress, Survival, Migration and invasionBackground
Thyroid carcinomas arising from thyroid follicular cells
include papillary thyroid carcinoma (PTC), follicular thy-
roid carcinoma as well as the less common anaplastic
thyroid carcinoma [1-3]. PTC is a well-differentiated,
slow growing and treatable tumor. The tumor is usually
removed by surgery and treated by iodine 131-radiation
therapy, however a few PTC carriers develop recurrences
and distant metastases [4,5].
To look for genes potentially involved in the neoplastic
transformation of the thyroid gland, we conducted a
transcriptome microarray screening [6]. Among the genes
highly up-regulated in PTC, we focused on Anterior* Correspondence: giuliana.salvatore@uniparthenope.it
5Dipartimento di Scienze Motorie e del Benessere, Universita’ “Parthenope”,
Via Medina 40, Naples 80133, Italy
Full list of author information is available at the end of the article
© 2014 Di Maro et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orgradient protein 2 (AGR2). AGR2, also known as hAG-2
or Gob-4, is the human orthologue of the Xenopus laevis
protein XAG-2. In the frog embryo XAG-2 induces ce-
ment gland differentiation [7,8]. Several studies have
shown a significant function for AGR2 in biological path-
ways including cell migration and transformation [9,10].
AGR2 protein is up-regulated in several human carcin-
omas, including breast, pancreatic, ovarian, lung and pros-
tate ones, and is associated with a metastatic phenotype
and poor prognosis [11-16].
AGR2 was found up-regulated in several published
PTC microarrays [17-21]. Delys and colleagues produced
a list of genes modulated in PTC, by comparing their
data sets with two independent PTC microarray data
sets, and AGR2 scored as one of the genes commonly
up-regulated in PTC [19].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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cancer model systems, affects cell proliferation, invasion,
survival and metastasis [9,10].
Recently, AGR2 has been shown to have structural char-
acteristics of the protein disulfide isomerase (PDI) family,
including a carboxyl-terminal endoplasmic reticulum (ER)
retention signal (KTEL) and a single thioredoxin-like do-
main with a CXXS motif [22]. PDI proteins catalyze for-
mation, reduction, and isomerization of disulfide bonds,
thereby facilitating the maturation of proteins in the ER
and ensure correct folding and multimerization of pro-
teins [23,24].
During tumorigenesis, the high proliferation rate of
cancer cells requires increased ER protein folding, assem-
bly, and transport, a condition that can induce ER stress
[25,26]. Importantly, AGR2 knock out mice showed ele-
vated ER stress [27]. AGR2 expression is induced by ER
stress, and siRNA-mediated knockdown of AGR2 in-
creased ER stress response [27,28]. It has been shown that
AGR2 exists in monomer/dimer equilibrium and that
intermolecular salt bridges involving glutamic acid 60 or
cysteine 81 (in the thioredoxin domain of AGR2) stabilize
the dimer [29-31]. Importantly, it was demonstrated that
dimerization of AGR2 is crucial in mediating the ER stress
signaling pathway [29]. AGR2 localizes in the ER of nor-
mal intestinal epithelial cells and is essential for in vivo
production of mucus [32,33]. Indeed, AGR2 mediates pro-
cessing of the intestinal MUC2 through formation of
mixed disulfide bonds [33].
In this work, we analyzed the expression of AGR2 in
PTC and its functional role.
Results
AGR2 is up-regulated in human PTC samples
We measured AGR2 expression by immunohistochemis-
try with an anti-AGR2 monoclonal antibody in 64 samples
including 25 normal thyroid (NT) samples and 39 PTC
samples. Representative immunohistochemical staining is
shown in Figure 1A, and the entire dataset is reported in
Table 1. AGR2 was expressed at low levels in normal thy-
roid glands (Figure 1A, inset 1). In contrast, several PTC
samples (PTC classical variant: 23 out of 28 samples;
PTC follicular variant: 5 out of 11 samples) were strongly
positive for AGR2 expression, and positivity was confined
to tumor cells (Table 1 and Figure 1A, inset 2). No stain-
ing was observed in the absence of the primary antibody
(Figure 1A, inset 3). Normal colon mucosa was used as
positive control (Figure 1A, inset 4).
To determine whether up-regulation occurred also at
RNA level, we verified AGR2 expression levels in a DNA
array dataset of 15 normal human thyroid (NT) and 43
PTC samples. As shown in Figure 1B, PTC samples
showed significantly increased AGR2 levels compared to
normal thyroid tissues (P < 0.0001). These findings werefurther confirmed by quantitative RT-PCR analysis of an
independent set of PTC samples (Figure 1C).
Knockdown of AGR2 induces apoptosis of TPC-1 cells
We evaluated the expression level of AGR2 in the papil-
lary thyroid cancer cell line TPC-1 in comparison to
non-transformed thyroid cells Nthy-ori 3–1. As shown
in Figure 2A, AGR2 is over-expressed in TPC-1 cells.
We evaluated the effects of AGR2 ablation in TPC-1
cells by RNA interference. TPC-1 cells were transfected
with AGR2 siRNA or with scrambled siRNA, counted and
lysed at different time points. Forty-eight hours after
transfection TPC-1 cells transfected with scrambled
siRNA numbered 192 × 103, whereas those transfected
with AGR2 siRNA numbered 146 × 103 (P = 0.0492). Sev-
enty–two hours after transfection, TPC-1 cells transfected
with scrambled siRNA numbered 413 × 103, whereas
those transfected with AGR2 siRNA numbered 279 × 103
(P = 0.0045) (Figure 2B). Accordingly, the fraction of try-
pan blue excluding (viable) cells of TPC-1 transfected with
AGR2 siRNA, was reduced with respect to scrambled
control, at 48 and 72 hours post transfection (P < 0.0001)
(Figure 2C).
Knockdown of AGR2 reduces migration and invasion of
TPC-1 cells
We evaluated migration (by a wound-closure assay) and
invasion (by a Matrigel invasion assay) ability of AGR2
siRNA-transfected cells. A scraped wound was introduced
on a confluent monolayer of TPC-1 cells transfected with
AGR2 siRNA or scrambled siRNA. Figure 2D and E show
that TPC-1 transfected with the scrambled control effi-
ciently migrated into the wound; in contrast, cells trans-
fected with AGR2 siRNA had a reduced migrating ability
both at 12 and 24 hours (P < 0.0001). Moreover, cells
transfected with AGR2 siRNA showed a reduced ability to
invade Matrigel compared to control cells (P < 0.0001)
(Figure 2F and G). The efficiency of AGR2 knockdown at
the different time points examined is shown in Figure 2H.
Ectopic AGR2 promotes migration and invasion of
Nthy-ori 3–1 cells
We transfected the non-transformed thyroid cells, Nthy-
ori 3–1, with the empty vector (pcDNA), AGR2 wild type,
AGR2-carrying the cysteine 81 to serine mutation AGR2
(C→ S), or AGR2 carrying the glutamic acid 60 to alanine
mutation AGR2 (E→A) (Figure 3A). Wild type AGR2,
after treatment with disuccinimidyl suberate (DSS), is di-
meric (Additional file 1: Figure S1). The C81S mutation
targets the thioredoxin domain of AGR2 and impairs its
catalytic activity and dimer formation, while the E60A
mutation impairs AGR2 dimer formation [29-31]. Nthy-
ori 3–1 AGR2, AGR2 (C→ S), AGR2 (E→A) and
pcDNA cells showed comparable growth rates (Figure 3B).
Figure 1 AGR2 expression in human thyroid tissue samples. A) Representative images (at 200x magnification) of normal thyroid (NT) (inset 1),
papillary thyroid carcinoma (PTC) (inset 2), normal colon sample (inset 4) (used as positive control) stained with a mouse monoclonal anti-AGR2
antibody. PTC shows a strong immunoreactivity for AGR2, whereas NT is negative. Inset 3, shows a PTC sample incubated only with secondary
antibody as negative control. B) Expression of AGR2 in DNA array of 15 normal thyroid (NT) samples and 43 PTC. The box plot of AGR2 shows
a significant up-regulation of this gene in tumor tissues. C) Quantitative RT-PCR showing increased levels of AGR2 in PTC samples (n = 10) in
comparison to normal thyroid controls (n = 10). The level of AGR2 expression in each sample was measured by comparing its fluorescence
threshold with the average fluorescence threshold of the NT samples.
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layer and cell migration into the wound was monitored
after 12 hours. As shown in Figure 3C and D, migrationrate was larger in AGR2-transfected cells compared to con-
trol vector (pcDNA), AGR2 (C→ S) and AGR2 (E→A)
cells. Then we seeded AGR2, AGR2 (C→ S) and vector
Table 1 AGR2 expression in thyroid samples (n = 64)
Tissue* Number of
samples**
AGR2 (score***)
Negative Positive
0 1+ 2+ 3+
NT 25 4 21
PTC 28 (PTC CV) 1 2 2 23
11 (PTC FV) 2 1 3 5
*NT = normal thyroid; PTC = papillary thyroid carcinoma.
**PTC CV = papillary thyroid carcinoma, classical variant; PTC FV = papillary
thyroid carcinoma, follicular variant.
***0 = < 10% of positive cells; 1 = 10-50% of positive cells; 2 = 51-75% of
positive cells; 3 = 76-100% of positive cells.
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and evaluated their ability to invade Matrigel. AGR2 over-
expression increased the invasive ability of Nthy-ori 3–1
cells in comparison to vector control (P < 0.0001) and
AGR2 (C→ S) cells (P < 0.0001) (Figure 3E and F).
Ectopic AGR2 promotes cell migration and invasion of
TPC-1 cells
To confirm these findings, we over-expressed AGR2
in TPC-1 cells. Cells were transfected with AGR2,
AGR2 (C→ S), AGR2 (E→A) or with the empty vec-
tor (pcDNA). Mass populations were selected in G418
(Additional file 1: Figure S2A). Growth rates of TPC-1
AGR2, AGR2 (C→ S), AGR2 (E→A) and control (pcDNA)
cell lines were similar (Additional file 1: Figure S2B). We
studied cell migration using the wound closure assay. As
shown in Additional file 1: Figure S2C, migration rate was
larger in TPC-1 AGR2 cells compared to AGR2 (C→ S),
AGR2 (E→A) cells and to vector control (pcDNA) cells.
We next seeded TPC-1 AGR2, AGR2 (C→ S), and
pcDNA control cells into the top chamber of transwells
and evaluated their ability to invade Matrigel. AGR2 over-
expression increased TPC-1 invasiveness in comparison
to AGR2 (C→ S) cells and control vector (Additional
file 1: Figure S2D).
Nthy-ori 3–1 AGR2 cells have an increased disulfide
isomerase activity
AGR2 has been identified as a protein disulfide isomerase,
playing a role in the endoplasmic reticulum (ER) stress re-
sponse [22-33]. Protein disulfide isomerases catalyze the
formation (oxidation), breakage (reduction) and rearrange-
ment (isomerization) of disulfide bonds between cysteine
residues within proteins during their folding process.
To determine whether AGR2 had a disulfide isomer-
ase activity in thyroid cells we performed an insulin-
reduction assay. In this assay, insulin reduction catalyzed
by protein disulfide isomerases in the presence of dithio-
threitol (DTT) results in the aggregation of its β chains
that can be spectrophotometrically revealed at 650 nm
[34]. As shown in Figure 4A, Nthy-ori 3–1 AGR2 cellsshowed an increased rate of insulin reduction compared
to AGR2 (C→ S) or vector control cells.
To confirm these findings, we measured the levels of
oxidized (GSSG) and of reduced (GSH) glutathione in
Nthy-ori 3–1 AGR2, AGR2 (C→ S) and vector control
cells. As shown in Figure 4B and C, levels of GSSG and
GSH were increased in Nthy-ori 3–1 AGR2 cells com-
pared to AGR2 (C→ S) and to vector control cells. Fi-
nally, as shown in Figure 4D Nthy-ori 3–1 AGR2 cells
displayed a decreased level of H2O2 compared to vector
control and to AGR2 (C→ S) cells (P < 0.001).
AGR2 protects non-transformed thyroid Nthy-ori 3–1 cells
from endoplasmic reticulum stress
It was shown that AGR2 has a role in the endoplasmic
reticulum (ER) stress response [27-30]. Thus, we studied
the effects of ectopic AGR2 expression in the ER stress
pathway upon treatment with Bortezomib. Bortezomib is
a potent and selective inhibitor of the proteasome that
causes an accumulation of unfolded proteins in the ER
[35-37]. Nthy-ori 3–1 cells transfected with AGR2, AGR2
(C→ S), or vector (pcDNA) were treated for 24 hours
with 100 nM Bortezomib. After treatment, cells were
counted. As shown in Figure 5A, AGR2 protected Nthy-
ori 3–1 cells from reduced viability caused by Bortezomib
in comparison to AGR2 (C→ S) and to control (pcDNA)
cells.
Then, we determined by Western blot the expression
level of GADD153 (also named Chop), a well-characterized
biomarker of ER stress [37], in Nthy-ori 3–1 AGR2,
AGR2 (C→ S) or empty vector (pcDNA) cells treated
with Bortezomib (100 nM) for 24 hours. As shown in
Figure 5B, Nthy-ori 3–1 AGR2 cells presented a blunted
increase of GADD153 upon Bortezomib treatment
compared to pcDNA and to AGR2 (C→ S) cells. These
data suggest that ectopic AGR2 expression protects
non-transformed thyroid cells from ER stress induced
by Bortezomib.
Discussion
AGR2 is a protein disulfide isomerase that is over-
expressed in several human carcinomas and stimulates
cancer cell proliferation, survival, invasion, and metasta-
sis [9,10]. In the present study, we demonstrated that
AGR2 is over-expressed in PTC. Our data are in agree-
ment with thyroid carcinoma microarray screenings that
isolated AGR2 as a gene up-regulated in PTC [17-21].
We investigated the functional role of AGR2 using
gain and loss-of-function approaches. Knockdown of
AGR2 in PTC cells decreased cell survival, migration
and invasion. On the other hand, forced AGR2 expres-
sion in non-transformed thyroid Nthy-ori 3–1 cells, re-
sulted in increased cell migration and invasion and
protection from ER stress.
Figure 2 Effects of AGR2 knockdown on TPC-1 cell growth, migration and invasion. A) Expression levels of AGR2 in Nthy-ori 3–1 and TPC-1
cells. Cells were lysed and analyzed by Western blotting with the indicated antibodies. B) TPC-1 cells were transfected with AGR2 siRNA or with
scrambled siRNA and counted at different time points. Values represent the average of triplicate experiments ± standard deviations. C) TPC-1 cells
were transfected with AGR2 siRNA or with scrambled siRNA; after 48 and 72 hours cells were collected by trypsinization, stained for 10 minutes
with trypan-blue and counted in triplicate. The percentage of trypan blue excluding cells compared to cells transfected with scrambled siRNA is
reported ± standard deviations. D) TPC-1 cells were transfected with AGR2 siRNA or with scrambled siRNA; after 48 hours a wound was introduced
and cell migration into the wound was monitored at 12 and 24 hours. E) Wound closure was measured by calculating pixel densities in the wound
area and expressed as percentage of wound closure of triplicate areas ± standard deviations. F) TPC-1 (1 × 105) cells were transfected with AGR2 siRNA
or with scrambled siRNA; 48 hours after transfection, cells were seeded in the upper chamber of transwells and incubated for 24 hours; the upper
surface of the filter was wiped clean and cells on the lower surface were stained, photographed and counted. This figure is representative of three
independent experiments. G) Invasive ability is expressed as number of invaded cells. Values represent the average of triplicate experiments ± standard
deviations. H) TPC-1 cells were transfected with AGR2 siRNA or with scrambled siRNA. Cells were harvested at different time points and protein lysates
were subjected to immunoblotting with the indicated antibodies. Asterisks indicate P < 0.05 (*), P <0.01 (**) and P < 0.001 (***).
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the ER and their accumulation may constitute a form
of stress to the cell. Several signaling pathways, col-
lectively known as unfolded protein response (UPR),
have evolved to detect the accumulation of misfolded
proteins in the ER and activate a cellular response tomaintain homeostasis [25,26]. As a member of the
protein disulfide isomerase family, AGR2 aids protein
folding and assembly by catalyzing the formation, re-
duction, and isomerization of disulfide bonds, thereby
stabilizing intermediate conformations during protein
maturation in the ER.
Figure 3 Effects of AGR2 ectopic expression on Nthy-ori 3–1 cell growth, migration and invasion. A) Expression levels of AGR2, AGR2
(C→ S) and AGR2 (E→ A) in transfected Nthy-ori 3–1 cells: after G418 selection, cells were lysed and analyzed by Western blotting with the
indicated antibodies. B) Nthy-ori 3–1 cells transfected with AGR2, AGR2 (C→ S), AGR2 (E→ A) or empty vector (pcDNA) were plated and counted
at different time points. Values represent the average of triplicate experiments ± standard deviations. C) A wound was introduced on confluent
monolayer of Nthy-ori 3–1 cells transfected with AGR2, AGR2 (C→ S), AGR2 (E→ A) and vector control (pcDNA) and wound closure was
monitored at 12 hours time points. D) Wound closure was measured by calculating pixel densities in the wound area and expressed as
percentage of wound closure of triplicate areas ± standard deviations. E) Nthy-ori 3–1 cells transfected with AGR2, AGR2 (C→ S) or the empty
vector (pcDNA) were seeded in the upper chamber of transwells and incubated for 24 hours; the upper surface of the filter was wiped clean and
cells on the lower surface were stained and counted. F) Invasive ability was expressed as number of invaded cells. Values represent the average
of triplicate experiments ± standard deviations. Asterisks indicate P < 0.001 (***).
Di Maro et al. Molecular Cancer 2014, 13:160 Page 6 of 11
http://www.molecular-cancer.com/content/13/1/160Accordingly, here we demonstrated in vitro that AGR2
acts as a disulfide isomerase in Nthy-ori 3–1 cells. By evalu-
ating the aggregation of insulin as a result of reduc-
tion of disulfide bonds catalyzed by protein disulfide
isomerase, we demonstrated that AGR2 over-expressing
cells have an increased disulfide isomerase activity com-
pared to control cells, an increased levels of GSSG and
GSH and a decreased level of H2O2.
Further, we showed that wild type AGR2 is dimeric in
transfected Nthy-ori 3–1 cells treated with DSS. Interest-
ingly, it was recently demonstrated that dimerization ofAGR2 attenuates ER stress-induced cell death through the
association with BiP/GRP78 [29-31].
Increased expression of the UPR components, includ-
ing GADD153 has been detected in breast, lung, gastric,
and esophageal carcinomas [38-40]. In this context, our
hypothesis is that AGR2 is up-regulated by PTC cells to
cope with the ER stress. Thus, as shown for other ER
resident proteins [25,26], increased AGR2 expression in
PTC could enhance ER folding capacity and allow cancer
cells to cope with increased protein production and se-
cretion [41,42].
Figure 5 Effects of Bortezomib in Nthy-ori 3–1 cells ectopically expressing AGR2. A) Nthy-ori 3–1 cells transfected with AGR2, AGR2 (C→ S)
or with the empty vector (pcDNA) were treated for 24 hours with Bortezomib 100 nM. After treatment, cells were collected by trypsinization and
counted in triplicate. The percentage of total cell number respect to untreated cells is reported ± standard deviations. B) Nthy-ori 3–1 cells
transfected with AGR2, AGR2 (C→ S) or with the empty vector (pcDNA) were treated for 24 hours with Bortezomib 100 nM. After treatment,
cells were lysed, and protein lysates were subjected to immunoblotting with the indicated antibodies. Asterisks indicate P < 0.001 (***).
Figure 4 Disulfide isomerase activity of AGR2 and intracellular redox state. A) The disulfide isomerase activity of AGR2 was assayed with
the insulin precipitation method. The absorbance at 650 nm was plotted against time (minutes). Only dithiothreitol was used as blank.
B-C) Levels of GSSG and GSH in Nthy-ori 3–1 AGR2, AGR2 (C→ S) and vector control cells were determined using GSH and GSSG assay
kit. Values represent the average of duplicate experiments ± standard deviations. D) Nthy-ori 3–1 AGR2, AGR2 (C→ S) and vector control
cells were incubated H2DCFDA (100 μM) and levels of H2O2 were measured as described in Methods. Asterisks indicate P < 0.001 (***).
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Here, we demonstrated that AGR2 plays a key role in thy-
roid cancer cell survival, migration, invasion and protec-
tion from ER stress. AGR2 may be one of the pro-survival
factors used by cancer cells to overcome stress due to ex-
cess protein production and to assist protein folding, deg-
radation or both. These findings suggest that AGR2 could
be exploited as a molecular marker of PTC.
Methods
Tissue samples
Tumor (n = 39) and normal (n = 25) thyroid tissue sam-
ples for immunohistochemical analysis were retrieved
from the Pathology Department of the Istituto Pascale,
Naples, Italy. In addition, RNA from frozen tissues of 10
PTC cases and 10 normal matched thyroid controls was
obtained from the Chernobyl Tissue Bank (http://www.
chernobyltissuebank.com) [43]. A set of 43 PTC and 15
normal thyroid tissues, also obtained from Chernobyl Tis-
sue Bank, was used in the DNA array study (HG-U133
Plus 2.0, Handkiewicz Junak et al., manuscript submitted
for publication) carried out in MSC Memorial Cancer
Center and Institute of Oncology, Gliwice, Poland. In
all cases, the respective Institutional review boards ap-
proved the study. The samples were classified according
to the diagnostic criteria required for the identification of
PTC [44].
Immunohistochemical staining
Sections of paraffin-embedded samples were stained
with hematoxylin and eosin for histological examination
[44]. For immunohistochemistry, 2 μm paraffin sections
were deparaffinized and placed in a solution of 0.3%
hydrogen peroxide in absolute methanol for 30 minutes
and then washed in phosphate buffered saline (PBS) be-
fore immunoperoxidase staining. The slides were then
incubated overnight at 4°C in a humidified chamber with
mouse monoclonal antibody against AGR2 (PO1, Abnova,
Taipei City, Taiwan) diluted 1:100 in PBS. The slides were
subsequently incubated with biotinylated goat anti-mouse
IgG for 20 minutes (Vectostain ABC kits, Vector Labora-
tories) and then with premixed reagent ABC (Vector) for
20 minutes. The immunostaining was performed by incu-
bating the slides in diaminobenzidine (DAB, DAKO) solu-
tion containing 0.06 mM DAB and 2 mM hydrogen
peroxide in 0.05% PBS, pH 7.6, for 5 minutes, and after
chromogen development, the slides were washed, dehy-
drated with alcohol and xylene and mounted with cover-
slips using a permanent mounting medium (Permount).
Micrographs were taken on Kodak Ektachrome film with
a Zeiss system. Negative controls were performed in each
case by incubating tissue slides with secondary antibody
only. The expression of AGR2 was categorized as positive
(staining of ≥10% of the tumor cells) or negative (stainingof < 10% of the tumor cells). The staining intensity was
further graded in: score 1 (10-50% of positive cells), score
2 (51-75% of positive cells) and score 3 (76-100% of posi-
tive cells). Score values were independently assigned by
two blinded investigators (G.C. and M.M.) and a consen-
sus was reached on all scores used for computation.
Cell cultures
Human papillary thyroid cancer cell line TPC-1 was ob-
tained from M. Nagao (Carcinogenesis Division, National
Cancer Center Research Institute, Tokyo, Japan) and iden-
tified based on the presence of the RET/PTC1 rearrange-
ment. TPC-1 cell line was grown Dulbecco’s modified
Eagle’s medium (DMEM) (Invitrogen) supplemented with
10% fetal bovine serum (FBS), L-glutamine and penicillin/
streptomycin (Invitrogen). Nthy-ori 3–1 cells are non-
transformed human thyrocytes immortalized by the Large
T of SV40 and were obtained from the European Tissue
Culture collection (Sigma Aldrich, St. Louis, MO, USA).
Nthy-ori 3–1 cell line was grown in Roswell Park Memorial
Institute (RPMI) 1640 medium supplemented with
10% fetal bovine serum (FBS), L-glutamine and penicillin/
streptomycin (Invitrogen, Carlsbad, California, USA).
Reagents
Bortezomib was obtained from Millenium (Cambridge,
MA, USA). Human insulin, disuccinimidyl suberate
(DSS) and dithiothreitol (DTT) were from Sigma Aldrich
(St. Louis, MO, USA). Glutathione reduced and oxidized
assay kit was obtained from Bioassay Systems (Hayward,
CA, USA).
Cell viability
For cell viability determination, cells were collected by
trypsinization stained for 10 minutes with 0.4% trypan-
blue (Sigma Aldrich) according to manufacturer’s in-
structions, and counted in triplicate.
Chemoinvasion
Cell invasion was examined using a reconstituted extra-
cellular matrix (Matrigel, BD Biosciences, San Jose, CA).
The cell suspension (1 × 105 cells per well) was added to
the upper chamber of transwell cell culture chambers on
a prehydrated polycarbonate membrane filter of 8 μm
pore size (Costar, Cambridge, MA) coated with 35 μg of
Matrigel (BD Biosciences). The lower chamber was filled
with 10% medium. After incubation at 37°C, non-migrating
cells on the upper side of the filter were wiped-off. Invading
cells were mounted on glass slides using mounting medium
and stained with Hoechst (Sigma Aldrich). Cell migration
was quantified by counting the number of stained nuclei in
three individual fields in each transwell membrane, by
fluorescence microscopy, in duplicate.
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A wound was introduced on the confluent monolayer
cells using a micropipette tip. Photographs were taken
at 40 X magnification using phase-contrast microscopy
immediately after wound incision and at selected time-
points. Wound closure was measured by calculating
pixel densities in the wound area by Cella software
(Olympus Biosystem Gmb, Hamburg, Germany) and
expressed as percentage of wound closure of triplicate
areas ± SD.
RNA silencing
A pool of 4 small inhibitor duplex RNAs (ON-TARGETplus
siRNA SMARTpool) targeting human AGR2 (#L-0036
26-00), and a non-targeting pool (ON-TARGETplus Non-
Targeting Pool) control (#D 001810-10-20) were purchased
from Dharmacon RNAi Technologies (Dharmacon Inc.,
Chicago, IL, USA). Cells were grown under standard con-
ditions. TPC-1 cells were plated in 60-mm dishes in
complete medium without antibiotics and electroporated
using MicroPorator (MP-100, Digital Bio, Euroclone,
Milan, Italy) according to the manufacturer’s instructions.
Cells were harvested at different time points after trans-
fection, counted and analyzed for protein expression.
Protein studies
Immunoblotting was carried out according to standard
procedures. Anti-AGR2 (PO1) monoclonal antibody was
from Abnova (Taipei City, Taiwan); anti-GADD153 (B-3,
sc-7351) and anti-α-tubulin monoclonal antibody was
from Sigma-Aldrich. Secondary anti-mouse and anti-
rabbit antibodies coupled to horseradish peroxidase were
from Santa Cruz Biotechnology.
Generation of stable AGR2 transfectants
cDNA containing the complete coding sequence of hu-
man AGR2 was produced by reverse transcription of
RNA from HT29 colon adenocarcinoma cells (American
Type Culture Collection, Rockville, MD, USA) using the
following primers:
AGR2 Cl For: 5′-ATCCTCGAGCGATCATGGAGA
AAATTCCA-3′;
AGR2 Cl Rev: 5′-ATCGGATCCCAATTCAGTCTTC
AGCAA-3′ (annealing temperature: 60°C).
AGR2 cDNA was cloned into pcDNA3.1 (named
pcDNA) (Invitrogen) by using BamHI and XhoI restric-
tion enzymes and verified by sequencing.
Point mutations in AGR2 that changed the cysteine at
position 81 to serine (C→ S) and glutamic acid at pos-
ition 60 to alanine (E→A) were introduced in the
pcDNA-AGR2 plasmid by the Stratagene QuikChange
site-directed mutagenesis kit (Agilent Technologies, Inc.
Life Sciences and Chemical Analysis Group, Santa Clara,
CA, USA).The following oligonucleotides were used:
AGR2 C81S For: 5′- CATCACTTGGATGAGTCCCC
ACACAGTCAAGC-3′;
AGR2 C81S Rev: 5′-GCTTGACTGTGTGGGGACT
CATCCAAGTGATG-3′ (annealing temperature: 55°C).
AGR2 E60A For: 5′- CTGGACTCAGACATATGAA
GCAGCTCTATATAAATCCAAGAC-3′;
AGR2 E60A Rev: 5′-GTCTTGGATTTATATAGAGCT
GCTTCTTCATATGTGTCCAG-3′ (annealing temperature:
55°C).
The Nthy-ori 3–1 and the TPC-1 cells were transfected
with pcDNA-AGR2, AGR2 (C→ S), AGR2 (E→A) or the
empty vector (pcDNA) using the Lipofectamine Reagent
(Invitrogen) according to the instructions of the manufac-
turer. Two days later, G418 (Invitrogen) was added at con-
centration of 0.3 mg/ml (Nthy-ori 3–1) or of 1.2 mg/ml
(TPC-1). Several clones and mass populations of transfec-
tants were isolated, expanded and screened for AGR2 ex-
pression by Western blotting.
Chemical crosslinking
Nthy-ori 3–1 AGR2 transfected cells were treated with
1 mM disuccinimidyl suberate (DSS). Cells were har-
vested and washed 3 times with ice-cold PBS. The cross-
linked cells were incubated for 60 minutes with mild
shaking at room temperature, and then quenched by
quenching buffer (1 M Tris, pH 7.5) to a final concen-
tration of 10 mM for 15 min at room temperature to
stop the chemical reaction. The chemically cross-linked
cells were subjected to Western blotting analysis.
Evaluation of GSSG, GSH and H2O2 levels
To measure the oxidized glutathione (GSSG) and reduced
glutathione (GSH), the EnzyChrom™ GSH and GSSG Assay
Kit (EGTT-100) (Bioassay Systems, Hayward, CA, USA)
was used according to manufacturer’s instructions. Intracel-
lular hydrogen peroxide levels were determined using the
cell-permeable probe 2′,7′-dichlorodihydrofluorescein dia-
cetate (H2DCFDA) that upon cleavage of the acetate groups
by intracellular esterases and oxidation is converted to
2′,7′-dichlorofluorescein (DCF) (Invitrogen, Carlsbad, CA).
DCF is a highly fluorescent compound that can be detected
by fluorescence spectroscopy using excitation and emission
wavelength of 485 nm and 538 nm, respectively. Cells were
incubated with H2DCFDA (100 μM) in complete media for
1 hour at 37°C. After that, cells were washed twice in PBS
and fluorescence intensity was quantified by microplate
reader (Perkin-Elmer Envision 2103 multilabel reader).
Insulin reduction assay
The disulfide isomerase activity was measured by the re-
duction of disulfide bonds in human insulin in the pres-
ence of DTT, giving rise to the aggregation of its β chain,
a process that can be followed by turbidimetry [32]. The
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60 μl of insulin (10 mg/ml) to cell lysates in a buffer con-
taining 100 mM sodium EDTA pH7 and 100 mM sodium
phosphate pH 7 to give a final volume of 500 μl. The reac-
tion started with the addition of 2 mM DTT and was
followed kinetically by the increase of absorbance at
650 nm, due to insulin β chain precipitation. The absorb-
ance at 650 nm was plotted.
RNA extraction and expression studies
Total RNA was isolated with the RNeasy Kit (Qiagen,
Crawley, West Sussex, UK). The quality of the RNAs was
verified by the 2100 Bioanalyzer (Agilent Technologies,
Waldbronn, Germany); only samples with RNA integrity
number (RIN) value > 7 were used for further analysis.
One μg of RNA from each sample was reverse-transcribed
with the QuantiTect® Reverse Transcription (Qiagen).
Quantitative RT-PCR
Quantitative RT-PCR was applied to study AGR2 expres-
sion in PTC samples (n = 10) and normal thyroid control
(n = 10). RNA from each sample was reverse-transcribed
with the QuantiTect® Reverse Transcription (Qiagen). For
quantitative RT-PCR, we used the Human ProbeLibray™
system (Roche). AGR2 and RNA polymerase 2 primers se-
quences were:
AGR2 For: 5′-CTG GCC AGA GATACC ACA GTC-3′;
AGR2 Rev: 5′-AGT TGG TCA CCC CAA CCT C-3′;
RNA pol-For: 5′-GCGATGAGAACAAGATGCAA-3′;
RNA pol-Rev: 5′-CGCAGGAAGACATCATCATC-3′.
PCR reactions were performed in triplicate and fold
changes were calculated with the formula: 2-(sample 1 ΔCt -
sample 2 ΔCt), where ΔCt is the difference between the amp-
lification fluorescent thresholds of the mRNA of interest
and the mRNA of RNA polymerase 2 used as an internal
reference. Sample 1 represented each single PTC sample,
and sample 2 was the average of all (n = 10) normal thy-
roid samples.
Statistical analysis
Data are presented as mean ± standard deviations. Two-
tailed unpaired Student’s t test was used for all statistical
analysis. Mann–Whitney U test was used only for DNA
array data analysis. P < 0.05 was considered statistically
significant. Statistical analyses were carried out using the
Graph Pad InStat (version 3.1a, La Jolla, CA, USA).Additional file
Additional file 1: Figure S1. The chemical crosslinker DSS was added
to Nthy-ori 3-1 AGR2 cell suspension at final concentration of 1 mM.
Monomeric and dimeric AGR2 were detected by Western blotting with
AGR2 antibody. Tubulin levels were used for normalization. Figure S2.
Effects of AGR2 ectopic expression on TPC-1 cell growth, migration andinvasion. A) Expression levels of transfected AGR2, AGR2 (C→S) and AGR2
(E→A) in TPC-1 cells: after G418 selection, cells were lysed and blotted
with the indicated antibodies. Levels of exogenous AGR2 are shown.
B) TPC-1 cells transfected with AGR2, AGR2 (C→S), AGR2 (E→A) or empty
vector (pcDNA) were plated and counted at different time points. Values
represent the average of triplicate experiments ± standard deviations.
C) A wound was introduced on confluent monolayer of TPC-1 cells
transfected with AGR2, AGR2 (C→S), AGR2 (E→A) or vector control
(pcDNA) and wound closure was monitored at 24 hours time point.
D) TPC-1 cells transfected with AGR2, AGR2 (C→S) or the empty vector
(pcDNA) were seeded in the upper chamber of transwells and incubated
for 24 hours; the upper surface of the filter was wiped clean and cells on
the lower surface were stained.
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Supplemental Figure 1: The chemical crosslinker DSS was added to Nthy-ori 3-1 AGR2 cell 
suspension at final concentration of 1 mM. Monomeric and dimeric AGR2 were detected by 
Western blotting with AGR2 antibody. Tubulin levels were used for normalization. 
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Supplemental Figure 2: Effects of AGR2 ectopic expression on TPC-1 cell growth, 
migration and invasion. 
A) Expression levels of transfected AGR2, AGR2 (C→S) and AGR2 (E→A) in TPC-1 cells: 
after G418 selection, cells were lysed and blotted with the indicated antibodies. Levels of 
exogenous AGR2 are shown. B) TPC-1 cells transfected with AGR2, AGR2 (C→S), AGR2 
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(E→A) or empty vector (pcDNA) were plated and counted at different time points. Values 
represent the average of triplicate experiments ± standard deviations. C) A wound was introduced 
on confluent monolayer of TPC-1 cells transfected with AGR2, AGR2 (C→S), AGR2 (E→A) or 
vector control (pcDNA) and wound closure was monitored at 24 hours time point. D) TPC-1 cells 
transfected with AGR2, AGR2 (C→S) or the empty vector (pcDNA) were seeded in the upper 
chamber of transwells and incubated for 24 hours; the upper surface of the filter was wiped clean 
and cells on the lower surface were stained. 
